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ABSTRACT 
Solute carrier transporters belonging to the major facilitator family of 
membrane transporter are increasingly being recognized as a possible 
mechanism to explain inter-individual variation in drug efficacy and response. 
Genetic factors are estimated to be responsible for approximately 15-30% of 
inter-individual variation in drug disposition and response. The aims of this 
study were to determine the minor allele frequencies of 78 previously 
identified single nucleotide polymorphisms in the pharmacogenomically 
relevant SLC22A1-3 and SLCO1B1 genes in the Admixed population of South 
Africa. Thereafter, to determine whether allele and genotype frequencies for 
these SNP were different from that reported for other African, Caucasian, and 
Asian populations. The inferred haplotypes from the genetic information 
possessed the potential to subsequently be used in future to design and interpret 
results of pharmacogenomic association studies involving these genes and their 
substrate drugs. Furthermore, to determine whether the Cape Admixed 
population harbour novel SNPs in the proximal promoter regions of SLC22A1-
3 and SLCO1B1-3 genes, that encodes hOCT1-3 and hOATP1 and hOATP3, 
respectively. SNaPshot™ multiplex single base mini-sequencing systems were 
developed and optimized for each of SLC22A1, SLC22A2, SLC22A3, and 
SLCO1B1 genes covering the previously identified 78 SNPs. These systems 
were then used to genotype the alleles of 130 healthy Cape Admixed subjects 
residing in Cape Town, South Africa. In addition, the proximal promoter 
regions of the SLC22A1-3 and SLCO1B1-3 genes of 96 of the participants were 
screened for novel SNPs by direct sequencing. The Cape Admixed subjects 
investigated displayed a lack of variation and were monomorphic for 78% of 
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the SNPs screened. None of the SLC22A3 SNPs investigated was observed in 
this study. Sequencing of the proximal promoter regions of the SLC22 and 
SLCO genes did not reveal any novel SNPs in the 96 Cape Admixed subjects 
that were screened. This study highlights the fact that African populations do 
not have the same allele frequencies for SNPs in pharmacogenomically 
relevant genes. Furthermore, the Cape Admixed and other African populations 
do not share all reduced-function variants of the SLC22A1-3 and SLCO1B1-3 
genes with Caucasian and Asian populations. In addition, previously identified 
novel regulatory variants in SLC22A2 did not exhibit a significant effect on the 
ability of the promoter to drive transcription. However, it must be noted that 
these results were observed at 95% confidence interval, and that a 99% 
confidence interval the significance may increase theoretically. Additionally, it 
should be noted that more intensive studies are required to determine the 
potential effect these novel variants may well cause. This study lays the 
foundation for the design and interpretation of future pharmacogenomic 
association studies between the variant alleles of the SLC22A and SLCO genes 
in the Cape Admixed population, as well as optimizations for future 
expression, and more importantly, drug transport assays with respect to drug 
disposition and efficacy. 
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 1 
1. LITERATURE REVIEW 
1.1. Introduction 
Inter-individual differences in the clinical efficacy and the toxicity of medication 
are common amongst patients (Kalow, 2006, Shastry, 2005). These inter-
individual differences in drug response could be due to age, sex, body weight, 
nutrition, organ function, infections, co-medication, environmental factors, and 
genetic variation (Sadee and Dai, 2005, Shastry, 2005). In general, genetic factors 
are estimated to account for 15-20% of inter-individual variations in drug 
disposition and responses (Choi and Song, 2008a). 
Adverse drug reactions (ADRs) are side effects experienced during drug therapy 
within the approved dosage and labelling recommendations for the specific drug 
(Daly, 2012). Severe ADRs are a significant clinical problem which may result in 
disabilities or permanent damage, congenital abnormalities or birth defects, 
hospitalizations, life-threatening events, and death (Daly, 2013). ADRs are 
amongst the leading causes of hospitalizations in the developed world, and the 
incidence of severe ADRs has been estimated at 6.2-6.7% in hospitalized patients 
(Bachtiar and Lee, 2013). However, in developing countries like South Africa 
ADRs are estimated to occur in 14% of hospitalized patients (Mehta et al., 2008, 
Warnich et al., 2011).  Moreover, the incidence of fatal ADRs is estimated at 
between 0.15-0.3% in developed countries and may be five to ten times higher in 
developing countries (Bachtiar and Lee, 2013, Mehta et al., 2008). The economic 
impact of ADR-related hospitalizations has been estimated at $136 billion in the 
USA alone (Becquemont, 2009, Bond and Raehl, 2006). 
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It has long been recognized that genetic variations in drug metabolizing enzymes 
underlie the inter-individual differences in drug response. However, 
polymorphisms in solute carrier transporters (SLCs) are increasingly being 
recognized as a factor accounting for inter-individual variation in drug response 
and being involved in the toxicity of drug treatment or predisposition to ADRs. 
These polymorphisms are attracting interest because SLCs are widely distributed 
in the epithelial membrane of the liver, kidney, and intestine and play an 
important role in the gastrointestinal absorption, biliary and renal uptake and 
excretion, and distribution to target sites of their substrate drugs. 
Approximately 40% of therapeutic drugs are organic cations or weak bases at 
physiological pH and are substrates of organic cation transporters (OCTs) and 
multidrug and toxin extrusion (MATEs) transporters (Neuhoff et al., 2003). The 
transport of OCs is mediated by OCTs in an electrogenic, and independently of a 
sodium gradient, and by MATEs through an oppositely directed proton gradient 
(Koepsell et al., 2007b, Otsuka et al., 2005). Examples of clinically important 
drugs transported by OCTs and MATEs include the antidiabetic drugs metformin 
and phenformin, the antineoplastic drugs cisplatin and oxaliplatin, the anti-HIV 
drugs lamivudine and zalcitabine, and the histamine receptor antagonist 
cimetidine (Barendt and Wright, 2002, Busch et al., 1998, Ciarimboli et al., 
2005b, Dresser et al., 2002, Kimura et al., 2005b, Jung et al., 2008). 
Previous studies have shown that human OCTs and MATEs are highly 
polymorphic in ethnically diverse populations (Sakata et al., 2004, Shu et al., 
2003, Kang et al., 2007a). A number of these variants have been associated with 
reduced effect of therapeutic drugs, example the antidiabetic metformin and the 
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antineoplastic imatinib. However, these aforementioned reduced-function genetic 
variants were however primarily found in studies with European participants and 
have not been consistently replicated for other ethnic groups (Chen et al., 2010b, 
Leabman et al., 2003a). 
Although Africa and South Africa harbour a significant proportion of genomic 
diversity and have a significant disease burden, the impact of this genomic 
diversity on the inter-individual differences in drug response is however 
understudied (Coovadia et al., 2009, Hardy et al., 2008, Tishkoff et al., 2009). 
Furthermore, pharmcogenomic and pharmacogenetic research in Africa is in its 
infancy and has primarily focused on drug metabolizing enzymes (Hardy et al., 
2008, Warnich et al., 2011). Thus, this review summarizes our current 
understanding about the structure, distribution, substrate specificity, physiological 
roles of OCTs and MATEs and to discuss the importance of these transporters in 
the pharmacokinetics and pharmacodynamics of clinically important cationic 
drugs. 
1.2. Human genetic variation and its contribution to complex traits 
Human genetic variants are typically referred to as either common or rare, to 
denote the frequency of the minor allele in the human population. These variants 
are classified as single nucleotide polymorphisms (SNPs), insertions-deletions, 
varying number of tandem repeats (VNTRs), inversions, and copy number 
variants (Brockmöller and Tzvetkov, 2008). SNPs are the most prevalent class of 
variants amongst individuals.  
Currently, it is estimated that the human genome contains at least between 11 and 
12 million SNPs (Brockmöller and Tzvetkov, 2008). Moreover, approximately 7 
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million of these SNPs occur at a minor allele frequency (MAF) greater than 5% 
and the remaining at a MAF between 1 and 5%. The current opinion is that 
African populations harbour more genetic variation than other populations (Hardy 
et al., 2008, Tishkoff et al., 2009). This view is supported when considering the 
fact that the Yoruban genome has 1.25 fold more single base variants than the 
Caucasian genomes and that a greater percentage is novel, which is reflective of 
the overall increased amount of genome diversity in individuals of African origin 
(Frazer et al., 2009). 
Variation in the human genome has a wide variety of medical and health 
implications. The current belief is that the knowledge acquired through human 
genetic studies will have a major impact on medical sciences, and that initially our 
increased understanding of the molecular pathways/mechanisms involved in 
disease will provide new potential drug targets (Frazer et al., 2009, Séguin et al., 
2008, Daar and Singer, 2005a). Subsequently, the expectation is that this 
increased understanding will equip us to predict disease susceptibility, to classify 
diseases in sub-phenotypes from genotypic information, and to improve treatment 
and expand the use of pharmacogenomics (Frazer et al., 2009).  
1.3. Pharmacogenomics and Personalized Drug Therapy 
Pharmacogenetics is not a new discipline itself but has been around for 
approximately 50 years (Kalow, 2006). However, advances in genomics, 
especially in methodology, have given rise to pharmacogenomics, improving our 
ability to identify the genetic causes of specific diseases, search for novel drug 
targets, and to improve drug development (Daar and Singer, 2005a). 
 
 
 
 
CHAPTER 1 
 5 
Pharmacogenetics is defined as the discipline which uses the patient‘s genetic 
information of drug metabolizing enzymes, drug receptors, and drug transporters 
in order to develop and individualized drug therapy that will result in optimal 
choice and dose of the drugs in question (Holm, 2008). The science of 
pharmacogenetics originated from the analysis of a few rare and sometimes 
unexpectedly found extreme reactions (phenotypes) observed in some humans. 
These phenotypes were either inherited diseases or abnormal reactions to drugs or 
other environmental factors (Brockmöller and Tzvetkov, 2008). An important 
milestone in pharmacogenetics occurred when it became clear that drug effects 
tended to differ not only between individuals, but also between human 
populations (Kalow, 2006). 
Pharmacogenomics, on the other hand, is defined as ‗The study of variations of 
DNA and RNA characteristics as related to drug response‘ (Bhathena and Spear, 
2008). Moreover, pharmacogenomics is an approach that has evolved from 
pharmacogenetics and has become a new scope for the pharmaceutical and 
biomedical fields (Khoury et al., 2008). It is widely expected that 
pharmacogenomics will facilitate a trend toward improved patient outcomes by 
increasing our understanding at the molecular level of both the disease and 
treatment response (Bhathena and Spear, 2008, Eichelbaum et al., 2006). 
Moreover, the pharmacogenomics approach has already supplied researchers with 
a number of candidate genes and their translational ramifications on drug response 
in many complex states (McCarthy and Zeggini, 2007). 
Inter-individual difference in the efficacy and the toxicity of medication is 
common amongst patients (Shastry, 2005). This difference in drug response could 
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be due to age, sex, body weight, nutrition, organ function, infections, co-
medication, environmental factors, the dose-response curve of a drug 
(pharmacokinetics and pharmacodynamics), and genetic variation (Sadee and Dai, 
2005, Shastry, 2005). 
However, when treating individual patients, the focus must be shifted from 
populations, ethnicities or races to the inherent genetic individuality that results 
from mosaics of variable haplotypes (Suarez-Kurtz, 2008b). Knowledge of an 
individual‘s genetic variability in drug response is, therefore, clinically and 
economically important. This type of genetic profiling provides benefits for future 
medical care by predicting drug response or assisting in the development of DNA-
based tests. Thus, pharmacogenetics and pharmacogenomics are two recent 
developments to investigate inter-individual variations in drug response (Shastry, 
2005). 
While the initial focus of pharmacogenetics was on drug metabolizing pathways 
(pharmacokinetics), the focus of pharmacogenomics is on the genetic basis of the 
individual variation in drug efficacy and toxicity (pharmacodynamics) (Kalow, 
2006, Urban, 2010). The assumption or expectation of both pharmacogenetics and 
pharmacogenomics is the ability to deliver ―personalized medicine‖, a broad and 
rapidly advancing field of healthcare that is informed by each patient‘s unique, 
clinical, genetic, genomic, and environmental information (Holm, 2008, Limdi 
and Veenstra, 2010). That is, personalized medicine can be used to refine the 
definition of disease, identify disease subtypes, and ultimately define biomarkers 
capable of discriminating between the patients most likely to benefit from a 
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specific treatment and those unlikely to respond or likely to experience adverse 
events (Reitman and Schadt, 2007). 
There are many challenges that must be overcome to apply rapidly accumulating 
genomic information to understand variable drug responses. These include, 
defining candidate genes and pathways; relating disease genes to drug response 
genes; precisely defining drug response phenotypes; and addressing analytic, 
ethical, and technological issues involved in the generation and management of 
large drug response sets (Roden et al., 2006). One of the impediments to the use 
of pharmacogenomics testing is the fact that some prescribing decisions must be 
made emergently, necessitating the availability of pre-emptive genotype results 
(Relling et al., 2010). Furthermore, various pharmacogenomic associated studies 
have not been reproduced and confirmed. In addition, the Genome Wide 
Association Studies (GWAS) that have been performed have been restricted 
primarily to populations of European descent, mostly because biomedical research 
funding is highest in the United States and Western Europe, where European 
ancestral populations make up the majority (Urban, 2010). Furthermore, a great 
deal of education for the public and healthcare professionals in the area is 
necessary before gaining overall acceptance (Avery et al, 2009). 
1.4. Adverse Drug Reactions 
Adverse drug reactions (ADRs) is defined as a response to a drug which is 
noxious and unintended, and occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function (WHO, 2004). The undesirable effects of the drug may 
lead to any of the following: death or a life-threatening event, hospitalization, 
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disability or permanent damage, congenital abnormality or birth defect (FDA, 
2011). 
From a clinical perspective, ADRs can be broadly classified as either Type A, 
which are dose-dependent, or Type B (idiosyncratic), where the reaction is not 
predictable from normal drug pharmacology and is generally dose-independent 
(Daly, 2013). Although Type A ADRs are more common, they are frequently 
mild and often self-limited. On the other hand, Type B ADRs are less common, 
but are often more severe and are more likely to result in serious morbidity or 
even mortality. 
ADRs are implicated in a notable number of hospitalizations, and fatal ADRs are 
amongst the leading causes of death in developed nations (Sim and Ingelman-
Sundberg, 2011, Wester et al., 2008). The incidence of severe ADRs, in the 
United States, has been estimated at between 6.2-6.7% in hospitalized patients and 
the incidence of fatal ADRs is estimated to be between 0.15-0.3%. In South 
Africa, on the other hand, ADRs are reported to occur in 14% of hospitalized 
patients with a five to ten times higher fatality rate (Mehta et al., 2008). In recent 
years, the economic cost of ADR-related hospitalizations has reached $136 billion 
in the USA alone (Becquemont, 2009, Bond and Raehl, 2006). 
Genetic susceptibility is an important feature of serious ADRs and there is 
considerable interest in the possibility that development of genetic tests to identify 
all those at risk of adverse events prior to prescription might lead to valuable 
drugs being retained (Daly, 2013). In order to achieve this goal consideration must 
be given to the fact that population differences exist in drug response, including 
susceptibility to ADRs, and that these differences are in part due to genetic 
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polymorphisms (Bachtiar and Lee, 2013). Genetic variation frequencies differ 
among different ethnicities, which may be associated with variation of 
susceptibility to ADRs among different populations. 
1.5. Race, Ethnicity and Genetic Ancestry in Biomedical Research 
The problem of race in scientific research is not a new one, and the issue seems to 
perpetually reappear and remain fundamentally unresolved (Caulfield et al., 
2009). However, it is a known fact that specific monogenic diseases such as sickle 
cell anaemia, Tay-Sachs, and cystic fibrosis for example, differ between 
populations (Via et al., 2009b). In order to use genomic knowledge to develop 
drugs and to improve health, we need to consider ethnical differences in different 
populations (Shastry, 2005). There exist inter-ethnical differences in 
polymorphisms of genes encoding drug metabolizing enzymes, transporters and 
disease-associated proteins (Bachtiar and Lee, 2013). Many gene variants differ in 
frequency between populations or subpopulations, but this is often merely due to 
random fluctuations (called genetic drift) and has no true biological meaning 
(Urban, 2010). With the availability of genetic ancestry estimates it is believed 
that admixed populations represent a valuable opportunity to study complex 
disease and drug response (Via et al., 2009b). Since admixed populations share 
varying proportions of different ancestral populations their genetic complexity can 
potentially complicate biomedical research. On the other hand, precisely because 
of this complexity, admixed populations can also provide unique opportunity to 
disentangle the clinical, social, environmental, and genetic underpinnings of 
population differences in health outcomes (Suarez-Kurtz, 2008b). 
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The accumulated data reveal that allele, genotype and haplotype frequency of 
polymorphisms of pharmacological relevant genes (pharmaco-genes) may differ 
significantly among populations categorized by race, ethnicity, or continental 
origin (Suarez-Kurtz, 2008b). It is widely accepted that population based 
pharmacogenetics studies can help in establishing baseline frequency distributions 
of SNPs of genes important in drug metabolism and/or transport. Therefore, 
recognition of interethnic differences in drug response might be useful in the 
establishment of public health policies, the design and interpretation of clinical 
drug trials, and possibly to guide clinicians to prospectively evaluate those 
patients with the greatest possibility of expressing a variant genotype which may 
be associated with inter-individual variation in drug response, efficacy and 
toxicity (Matimba et al., 2008, Suarez-Kurtz, 2008b). 
1.6. Single Nucleotide Polymorphisms and Variability in Drug Response and 
Toxicity 
Inter-individual variability in drug response and toxicity is a significant clinical 
and public health problem. This variation can be due to genetic, environmental, 
physiological, and pathophysiological factors (Choi and Song, 2008a, Giacomini 
et al., 2010).  
A considerable body of evidence currently exists that suggests that single 
nucleotide polymorphisms (SNPs) in genes encoding drug metabolizing  enzymes, 
enzymes involved in DNA biosynthesis and repair, and drug transporters might 
determine drug efficacy and toxicity (Shastry, 2005). Many drug metabolizing  
enzymes and drug transport proteins have consistently replicated associations 
between genetic variants and the clinical pharmacokinetics of at least one drug 
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(Bhathena and Spear, 2008). Genetic polymorphisms in membrane transporter 
genes are increasingly been recognized as a possible mechanism for explaining 
variation in drug response (Leabman et al., 2003a, Shu et al., 2007). 
1.7. Membrane Transporters 
Membrane transporters are specialized integral proteins that span cell membrane 
bilayers and play a critical role in the translocation of chemicals into and out of 
cells using active and passive mechanisms (Klaassen and Aleksunes, 2010). They 
are responsible for maintaining cellular and organismal homeostasis by importing 
nutrients essential for cellular respiration and exporting metabolic waste products 
and xenobiotics (Leabman et al., 2003a). These transporters are located in the 
epithelial membrane of the liver, kidney, intestine, and target organs and are now 
widely acknowledged as important determinants governing drug absorption, 
excretion, and, in many cases, extent of drug entry into target organs (Choi and 
Song, 2008a, DeGorter et al., 2012). 
Inter-individual variation in transporter activity can arise from numerous factors, 
including genetic heterogeneity, certain disease processes, concomitant 
medications, and herbal and dietary constituents that may inhibit or induce 
transporter expression or activity (DeGorter et al., 2012, Giacomini et al., 2010). 
Numerous studies have suggested that membrane transporters play a part in vivo 
in drug disposition, therapeutic efficacy, and adverse drug reactions. Moreover, 
genetic polymorphisms in membrane transporter genes have increasingly been 
recognized as a possible mechanism accounting for variation in drug response 
(Leabman et al., 2003a, Shu et al., 2007). In general, genetic factors are estimated 
to account for 15-30% of inter-individual variations in drug disposition and 
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responses, however for certain drugs, this estimate can be as high as 95% (Choi 
and Song, 2008a, Eichelbaum et al., 2006, Evans and Relling, 2004). 
During the last decade, a greater focus has been given to impact of genetic 
variations in membrane transporters on the pharmacokinetics and toxicity of 
numerous therapeutic drugs (Hediger et al., 2004). However, while the majority of 
transporter-related pharmacogenomic research has been in regards to classic genes 
encoding the outward-directed ATP-binding cassette (ABC) transporters, more 
studies have been conducted in recent years evaluating genes encoding solute 
carrier (SLC) transporters that mediate the cellular uptake, distribution and 
elimination of clinically important drugs (Franke et al., 2010). 
1.8. Solute Carrier Transporters 
The solute carrier transporter (SLC) superfamily is a large family of membrane-
bound proteins that share 2025% of sequence homology (Hediger et al., 2004). 
This major facilitator family consists of more than 300 members grouped into 51 
classes. SLC transporters typically use secondary and tertiary active transport to 
move chemicals over biological membranes (Klaassen and Aleksunes, 2010). 
They are transmembrane proteins which typically have a predicted membrane 
topology that consists of 12 αhelical transmembrane helices (TMHs), an 
intracellular N-terminus, a large glycosylated extracellular loop between TMHs 1 
and 2, a large intracellular loop with phosphorylation sites between TMHs 6 and 
7, and an intracellular C-terminus (Koepsell et al., 2007b). SLCs are expressed in 
most tissues. However, these proteins are expressed most abundantly in the liver, 
kidney, and intestine where they are either located at the basolateral or apical 
plasma membranes of polarized cells (Wojtal et al., 2009). Today it is known that 
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members of the SLC family are involved in the facilitated transport of a variety of 
substances including drugs, environmental toxins, xenobiotics, and endogenous 
metabolites across plasma membranes (Hediger et al., 2004, Koepsell et al., 
2007b). Moreover, these SLC transporters play a critical role in the absorption and 
excretion of drugs in the kidneys, liver, and intestine, thus, influencing the 
pharmacodynamic and pharmacokinetic characteristics of these drugs (Meier et 
al., 2007b). 
The SLC family can be divided into three subgroups based on substrate specificity 
and function: organic cation transporters (OCTs), the organic cation/zwitterion 
transporters (OCTNs), and the organic anion transporters (OATs) (Koepsell et al., 
2007b). The OCT subgroup contains three subtypes of facilitated transporters 
called hOCT1 (encoded by the SLC22A1 gene), OCT2 (SLC22A2), and OCT3 
(SLC22A3). The genes encoding the three OCT isoforms are clustered together on 
the long arm of chromosome 6 (Tzvetkov et al., 2009, Koehler et al., 1997a). 
Based on their substrate properties and tissue distributions, hOCT1, hOCT2, and 
hOCT3 are thought to play important roles in the biliary and renal excretion of 
their substrates and the distribution of organic cationic drugs in the liver, kidney, 
heart, and brain (Jonker and Schinkel, 2004, Koepsell et al., 2007b). Moreover, 
there are several members of the SLC family for which the substrate specificity 
and/or function have not been elucidated yet. 
1.8.1. Organic Cation Transporters 
1.8.1.1. Structure 
Members of the OCT family are highly conserved among species and generally 
550-560 amino acids in length and share common structural features, including a 
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characteristic membrane topology, depicted in Figures 1.1 and 1.2, of 12 putative 
transmembrane spanning αhelices (TMHs), intracellular COOH and NH2 termini, 
an intracellular loop with phosphorylation sites between the sixth and the seventh 
TMHs and a large extracellular loop between the first and second TMHs 
containing glycosylation sites (Burckhardt and Wolff, 2000, Ciarimboli, 2008, 
Koepsell et al., 2007b). 
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Figure 1.1. Multiple protein sequence alignment of OCTs from four animal 
species showing a high degree of evolutionary conservation. 
 
10 20 30 40 50 60 70 80 90 100
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 MP-TVDDILEQVGESGWFQKQAFLILCLLSAAFAPICVGIVFLGFTPDHH-CQSPGVAELSQRCGWSPAEELNYTVPGLGPAGEA-FLGQCRRYEVDWNQ
rabbit OCT1 MP-TVDDVLEQVGEFGWFQKRTFLFLCLISAILAPIYLGIVFLGFTPDHR-CRSPGVDELSQRCGWSPEEELNYTVPGLG-ATDGAFVRQCMRYEVDWNQ
mouse  OCT1 MP-TVDDVLEHVGEFGWFQKQAFLLLCLISASLAPIYVGIVFLGFTPDHH-CRSPGVAELSQRCGWSPAEELNYTVPGLGSAGEASFLSQCMKYEVDWNQ
rat    OCT1 MP-TVDDVLEQVGEFGWFQKQAFLLLCLISASLAPIYVGIVFLGFTPGHY-CQNPGVAELSQRCGWSQAEELNYTVPGLGPSDEASFLSQCMRYEVDWNQ
human  OCT2 MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHR-CRSPGVAELSLRCGWSPAEELNYTVPGPGPAGEAS-PRQCRRYEVDWNQ
rabbit OCT2 MP-TVDDILEQVGHFHFFQKQTFFLLALISAAFTPIYVGIVFLGFTPDHR-CRSPGVAELSQRCGWSPGEELNYTVPGLG-AADGAFARQCMRYEVDWNQ
mouse  OCT2 MP-TVDDILEHIGEFHLFQKQTFFLLALLSGAFTPIYVGIVFLGFTPNHH-CRSPGVAELSQRCGWSPAEELNYTVPGLGSAGEVSFLSQCMRYEVDWNQ
rat    OCT2 MS-TVDDILEHIGEFHLFQKQTFFLLALLSGAFTPIYVGIVFLGFTPDHH-CWSPGAAKLSQRCGWSQAEELNYTVPGLGPSDEASFLSQCMRYEVDWNQ
human  OCT3 MP-SFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYWCRGPSAAALAERCGWSPEEEWNRTAPASRGPEPPERRGRCQRYLLEAAN
rabbit OCT3 ----------------------------------------------------------------------------------------------------
mouse  OCT3 MP-TFDQALRKAGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGSQPDYYWCRGPRATALAERCAWSPEEEWNLTTPELHVPAERRGQGHCHRYLLEATN
rat    OCT3 MP-TFDQALRKAGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGSQPDYYWCRGPRATALAERCAWSPEEEWNLTTPELHVPAERRGQGHCHRYLLEDTN
110 120 130 140 150 160 170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 SA------LSCVDPLASLATNRSHLPLGPCQDGWVYDTPGSSIVTEFNLVCADSWKLDLFQSCLNAGFLFGSLGVGYFADRFGRKLCLLGTVLVNAVSGV
rabbit OCT1 SS------LGCVDPLASLAPNRSHLPLGPCQHGWVYDTPGSSIVTEFNLVCADAWKVDLFQSCVNLGFFLGSLGVGYIADRFGRKLCLLLTTLINAVSGV
mouse  OCT1 ST------LDCVDPLSSLAANRSHLPLSPCEHGWVYDTPGSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIADRFGRKLCLLVTTLVTSLSGV
rat    OCT1 ST------LDCVDPLSSLVANRSQLPLGPCEHGWVYDTPGSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIADRFGRKLCLLVTTLVTSVSGV
human  OCT2 ST------FDCVDPLASLDTNRSRLPLGPCRDGWVYETPGSSIVTEFNLVCANSWMLDLFQSSVNVGFFIGSMSIGYIADRFGRKLCLLTTVLINAAAGV
rabbit OCT2 SS------PGCVDPLASLAPNRSHLPLGPCQHGWVYDTPGSSIVTEFNLVCARSWMLDLFQSAVNIGFFIGSVGIGYLADRFGRKLCLLVTILINAAAGV
mouse  OCT2 ST------LDCVDPLSSLAANRSHLPLSPCEHGWVYDTPGSSIVTEFNLVCAHSWMLDLFQSLVNVGFFIGAVGIGYLADRFGRKFCLLVTILINAISGV
rat    OCT2 ST------LDCVDPLSSLAADRNQLPLGPCEHGWVYNTPGSSIVTEFNLVCAHSWMLDLFQSVVNVGFFIGAMMIGYLADRFGRKFCLLVTILINAISGA
human  OCT3 DSASATSALSCADPLAAFP-NRS-APLVPCRGGWRYAQAHSTIVSEFDLVCVNAWMLDLTQAILNLGFLTGAFTLGYAADRYGRIVIYLLSCLGVGVTGV
rabbit OCT3 -------------------------------------------------------MLDLTQAILNLGFLAGAFTLGYAVDRYGRRVTYLISCLGVGITGV
mouse  OCT3 TSSELS-----CDPLTAFP-NRS-APLVSCSGDWRYVETHSTIVSQFDLVCSNAWMLDLTQAILNLGFLAGAFTLGYAADRYGRLIIYLISCFGVGITGV
rat    OCT3 TSSELS-----CDPLAAFP-NRS-APLVPCSGDWRYVETHSTIVSQFDLVCGNAWMLDLTQAILNLGFLAGAFTLGYAADRYGRLIVYLISCFGVGITGV
210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 LMAFSPNYMSMLLFRLLQGLVSKGNWMAGYTLITEFVGSGSRRTVAIMYQMAFTVGLVALTGLAYALPHWRWLQLAVSLPTFLFLLYYWCVPESPRWLLS
rabbit OCT1 LTAVAPDYTSMLLFRLLQGLVSKGSWMSGYTLITEFVGSGYRRTVAILYQVAFSVGLVALSGVAYAIPNWRWLQLTVSLPTFLCLFYYWCVPESPRWLLS
mouse  OCT1 LTAVAPDYTSMLLFRLLQGMVSKGSWVSGYTLITEFVGSGYRRTTAILYQVAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLS
rat    OCT1 LTAVAPDYTSMLLFRLLQGMVSKGSWVSGYTLITEFVGSGYRRTTAILYQMAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLS
human  OCT2 LMAISPTYTWMLIFRLIQGLVSKAGWLIGYILITEFVGRRYRRTVGIFYQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLLYYWCIPESPRWLIS
rabbit OCT2 LMAVSPNYTWMLIFRLIQGLVSKAGWLIGYILITEFVGLNYRRTVGILYQVAFTVGLLVLAGVAYALPRWRWLQLTVTLPYFCFLLYYWCIPESPRWLIS
mouse  OCT2 LMAISPNYAWMLVFRFLQGLVSKAGWLIGYILITEFVGLGYRRTVGICYQIAFTVGLLILAGVAYALPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLIS
rat    OCT2 LMAISPNYAWMLVFRFLQGLVSKAGWLIGYILITEFVGLGYRRMVGICYQIAFTVGLLILAGVAYVIPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLIS
human  OCT3 VVAFAPNFPVFVIFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPNWQGIQLAITLPSFLFLLYYWVVPESPRWLIT
rabbit OCT3 VVAFAPNFPVFAVFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPSWQGIQLAVTLPNFLFLLYYWVVPESPRWLIT
mouse  OCT3 VVAFAPNFSVFVIFRFLQGVFGKGAWMTCFVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFTPSWQGIQLAISLPSFLFLLYYWVVPESPRWLIT
rat    OCT3 VVAFAPNFSVFVIFRFLQGVFGKGAWMTCFVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFTPSWQGIQLAISLPSFLFLLYYWVVPESPRWLIT
310 320 330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 QKRNTEAIKIMDHIAQKNGKLPPADLKMLSLEEDVTEKLSPSFADLFRTPRLRKRTFILMYLWFTDSVLYQGLILHMGATSGNLYLDFLYSALVEIPGAF
rabbit OCT1 QKRNTDAVKIMDNIAQKNGKLPPADLKMLSLDEDVTEKLSPSLADLFRTPNLRKHTFILMFLWFTCSVLYQGLILHMGATGGNVYLDFFYSSLVEFPAAF
mouse  OCT1 QKRTTQAVRIMEQIAQKNRKVPPADLKMMCLEEDASERRSPSFADLFRTPSLRKHTLILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAF
rat    OCT1 QKRTTRAVRIMEQIAQKNGKVPPADLKMLCLEEDASEKRSPSFADLFRTPNLRKHTVILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAF
human  OCT2 QNKNAEAMRIIKHIAKKNGKSLPASLQRLRLEEETGKKLNPSFLDLVRTPQIRKHTMILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
rabbit OCT2 QNKNAKAMRIMEHIAKKNGKSLPVSLQSLRAAEDVGEKLNPSFLDLVRTPQIRKHTCILMYNWFTSSVLYQGLIMHLGLAGGDIYLDFFYSALVEFPAAF
mouse  OCT2 QNKNAKAMKIIKHIAKKNGKSVPVSLQSLTADEDTGMKLNPSFLDLVRTPQIRKHTLILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
rat    OCT2 QNKIVKAMKIIKHIAKKNGKSVPVSLQNLTPDEDAGKKLKPSILDLVRTPQIRKHTLILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
human  OCT3 RKKGDKALQILRRIAKCNGKYLSSNYSEITVTDEEVS--NPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGAL
rabbit OCT3 RKEGDEALKILRKIAKCNGKYLSPNYSEITVTDEEVS--NPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGAL
mouse  OCT3 RKQGEKALQILRRVAKCNGKHLSSNYSEITVTDEEVS--NPSCLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGLIGGNLYIDFFISGLVELPGAL
rat    OCT3 RKQGEKALQILRRVAKCNGKHLSSNYSEITVTDEEVS--NPSCLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGLIGGNLYMDFFISGLVELPGAL
410 420 430 440 450 460 470 480 490 500
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 IALITIDRVGRIYPMAMSNLLAGAACLVMIFISPDLHWLNIIIMCVGRMGITIAIQMICLVNAELYPTFVRNLGVMVCSSLCDIGGIITPFIVFRLREVW
rabbit OCT1 VILVTIDRVGRIYPMAASNLAAGVASVILIFVPQDLHWLTIVLSCVGRMGATIVLQMICLVNAELYPTFVRNLGVMVCSALCDVGGIITPFMVFRLMEVW
mouse  OCT1 IILVTIDRIGRIYPIAASNLVAGAACLLMIFIPHELHWLNVTLACLGRMGATIVLQMVCLVNAELYPTFIRNLGMMVCSALCDLGGIFTPFMVFRLMEVW
rat    OCT1 IILVTIDRIGRIYPIAASNLVTGAACLLMIFIPHELHWLNVTLACLGRMGATIVLQMVCLVNAELYPTFIRNLGMMVCSALCDLGGIFTPFMVFRLMEVW
human  OCT2 MIILTIDRIGRRYPWAASNMVAGAACLASVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIGGIITPFLVYRLTNIW
rabbit OCT2 LIIATIDRVGRRYPWAVSNMVAGAACLASVFVPDDLQGLRITVACLGRMGITMAYEMVCLVNAELYPTFIRNLGVLVCSSLCDVGGIVTPFLVYRLTAIW
mouse  OCT2 IIILTIDRIGRRYPWAVSNMVAGAACLASVFIPDDLQWLKITVACLGRMGITIAYEMVCLVNAELYPTYIRNLAVLVCSSMCDIGGIVTPFLVYRLTDIW
rat    OCT2 IIILTIDRVGRRYPWAVSNMVAGAACLASVFIPDDLQWLKITIACLGRMGITMAYEMVCLVNAELYPTYIRNLGVLVCSSMCDIGGIITPFLVYRLTDIW
human  OCT3 LILLTIERLGRRLPFAASNIVAGVACLVTAFLPEGIAWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVW
rabbit OCT3 LILLTIERLGRRLPFAASNMMAGVACLVTAFLPEGVPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVW
mouse  OCT3 LILLTIERLGRRLPFAASNIVAGVSCLVTAFLPEGIPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAIW
rat    OCT3 LILLTIERLGRRLPFAASNIVAGVSCLVTAFLPEGIPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAIW
510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 QALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENL-GRKAKPKE--------NTIYLKVQTSE----------------PSGT------------
rabbit OCT1 QPLPLIVFGVLGLLAGGMTLLLPETKGVALPETIEDAENL-RRKAKPKE--------SKIYLQVQTSE----------------LKGP------------
mouse  OCT1 QALPLILFGVLGLSAGAVTLLLPETKGVALPETIEEAENLGRRKSKAKE--------NTIYLQVQTGK----------------SPHT------------
rat    OCT1 QALPLILFGVLGLTAGAMTLLLPETKGVALPETIEEAENLGRRKSKAKE--------NTIYLQVQTGK----------------SSST------------
human  OCT2 LELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPRKNKEK---------MIYLQVQKLD----------------IPLN------------
rabbit OCT2 LQLPLVVFAVVGLVAGGLVLMLPETKGRTLPETIEEAENLQRPRKNREK---------VIYVHVRKAD----------------GPLT------------
mouse  OCT2 LEFPLVVFAVVGLVAGGLVLLLPETKGKALPETIEDAEKMQRPRKKKEK---------RIYLQVKK------------------AELS------------
rat    OCT2 MEFPLVVFAVVGLVAGALVLLLPETKGKALPETIEDAENMQRPRKKERKENLPPSQASRPSAKLKRKGIIAAGADFALSEARDGASLSPPPKPTQTNLTY
human  OCT3 LELPLIIFGILASICGGLVMLLPETKGIALPETVDDVEKLGSPHSCKCG--------RNKKTPVSRSHL-------------------------------
rabbit OCT3 LELPLIIFGVLASVCGGLVMLLPETKGIALPETVDDVENLGSPHSFRCR--------RKKKSPVCSSHL-------------------------------
mouse  OCT3 LELPLIIFGILASVCGGLVMLLPETKGIALPETVEDVEKLGSSQLHQCG--------RKKKTQVSTSDV-------------------------------
rat    OCT3 LELPLIIFGILASVCGGLVMLLPETKGIALPETVEDVEKLGSSQLHQCG--------RKKKTQVSTSNV-------------------------------
.
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rabbit OCT1 -
mouse  OCT1 -
rat    OCT1 -
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mouse  OCT2 -
rat    OCT2 P
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Figure 1.2.  Predicted membrane topology of OCTs as represented by human 
OCT1 (UCSF Protein Membrane Transporter database, 2015) 
1.8.1.2. Substrate Specificity 
OCTs are defined as polyspecific transporters and function as uniporters that play 
a role in facilitated diffusion in either direction and are involved in translocation 
of organic cations, endogenous amines, therapeutic drugs and cationic xenobiotics 
with different molecular structures (Jonker and Schinkel, 2004, Koepsell et al., 
2007b). There is extensive overlap of substrate and inhibitor specificities among 
hOCT13 from different species. Oct1/hOCT1 orthologs from four species (rat, 
mouse, rabbit, and human) all transport tetraethylammonium. However, the 
affinity and transport rates differ between the four species. Oct1/hOCT1 substrates 
include pharmaceuticals such as the antidiabetic drug metformin (Kimura et al., 
2005a, Wang et al., 2002), the antiviral drugs acyclovir and zalcitabine (Jung et 
al., 2008, Takeda et al., 2002), the antineoplastic cisplatin (Ciarimboli et al., 
2005b, Ciarimboli et al., 2010), the N-methyl-D-aspartate-receptor antagonist 
memantine, and the histamine H2 receptor antagonist ranitidine. In addition, OCTs 
are also responsible for the transport of biogenic amine neurotransmitters (Figure 
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1.3) such as dopamine, epinephrine, norepinephrine, and histamine (Klaassen and 
Aleksunes, 2010). 
 
Figure 1.3.  Chemical structures of 4 platinum agents which are substrates of 
hOCTs and hMATEs (Yokoo et al., 2007). 
 
1.8.1.3. Tissue Distribution and Localization 
The tissue distribution of the OCT subgroup is quite distinctive, with hOCT1 
being primarily expressed in the basolateral or sinusoidal membrane of 
hepatocytes and also being present in the epithelial membrane of the intestine at 
low levels (Gorboulev et al., 1997a, Zhang et al., 1997). Thus, hOCT1 is thought 
to play a fundamental role in the uptake of substrates into the hepatocytes. On the 
other hand, hOCT2 is predominantly expressed at the basolateral membrane of the 
proximal renal tubules and facilitates uptake of substrates from the circulation into 
renal epithelial cells (Gorboulev et al., 1997a, Motohashi et al., 2002). hOCT3, on 
the other hand, shows a widespread tissue distribution, including the brain, heart, 
skeletal muscle, blood vessels, placenta, and liver (Koepsell et al., 2007b). 
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Figure 1.4.  Chemical structures of selected bio-amine substrates of hOCTs (Chen 
et al., 2010a). 
 
1.8.1.4. Expression and Regulation of OCTs 
The regulation of OCTs has great physiological and even clinical importance 
because they can ultimately change the mRNA or protein levels of OCTs, and as a 
result, alter the absorption, secretion and tissue distribution of endogenous 
metabolites, drugs, and xenobiotics (Choi and Song, 2008a, Ciarimboli et al., 
2005a). These regulatory mechanisms are important because stimulation of OCT 
expression can accelerate detoxification, whereas inhibition can prolong exposure 
of the body to dangerous substances. However, the regulation of OCTS is 
complex and may occur at the transcription, message stability, translation, and 
various posttranslational modification levels (Koepsell et al., 2007). 
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Figure 1.5.  Schematic representation of transcriptional and posttranslational 
regulation of hOCT1 (A) and hOCT2 (B) (Choi and Song, 2008a). 
 
1.8.1.4.1.  Short-Term Regulation 
Mechanisms of posttranslational activation of hOCT1 by its phosphorylation 
status have been proposed (Ciarimboli et al., 2004, Ciarimboli and Schlatter, 
2005).  There are multiple potential phosphorylation sites that are conserved 
among OCTs, which provide target sequences for functional regulation by kinases 
and phosphatases. hOCT1 and hOCT2 share common regulatory mechanisms 
involving protein kinase A (PKA) and calmodulin (CAM). hOCT1 is activated by 
Src-like p53
lck
 tyrosine kinase (Ciarimboli et al., 2004). However, PKC activation 
decreases the affinity of hOCT1 for prototypical substrates (Ciarimboli and 
Schlatter, 2005). Expression levels of hOCT1 were unchanged by a PKA 
activator, whereas OCT2 was downregulated by the PKC activator 
1,2diocanoylsnglycerol (DOG). 
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Çetinkaya et al. (2003) demonstrated that hOCT2 is inhibited by PKA and 
phosphatidylinositol 3kinase (PI3K) and activated by a CAM-dependent 
signalling pathway, probably through a change in substrate affinity (Cetinkaya et 
al., 2003). Furthermore, in a subsequent study Biermann et al. (2006) showed that 
inhibition of the Ca
2+
/CAM complex by calmidazolium causes changes in 
transport capacity due to reduced hOCT2 trafficking/localization to the plasma 
membrane (Biermann et al., 2006). 
1.8.1.4.2. Long-Term Regulation 
Transcription factors may be responsible for the constitutive expression of 
SLC22A1. In a study by Saborowski et al. (2006) it was demonstrated that 
transcriptional activation of SLC22A1 can be mediated by the binding of  
hepatocyte nuclear factor 4α (HNF4α) to DNA response elements (DR2) adjacent 
to the gene and suppressed by bile acids via the bile acid-inducible transcriptional 
repressor, small heterodimer partner (SHP) (Saborowski et al., 2006). 
Furthermore, Rulcova et al. (2013) in a recent study showed that SLC22A1 
expression is indirectly induced by glucocorticoid activation through the 
upregulation of HNF4α in primary hepatocytes (Rulcova et al., 2013). Moreover, 
Asaka et al. (2007) demonstrated that basal transcription of SLC22A2 was 
stimulated by binding of the ubiquitously expressed and constitutively active 
upstream stimulating factor (USF) 1 to the proximal promoter region (Asaka et 
al., 2007). In a recent study O‘Brien et al showed through electrophoretic mobility 
shift and chromatin immunoprecipitation assays that the expression of hOCT1 is 
regulated by HNF1 through binding to an evolutionary conserved region in intron 
1 of SLC22A1 (O‘Brien et al., 2013).Epigenetic gene silencing may also provide a 
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mechanism of organic cation transporter gene regulation. Recent studies have 
shown that DNA methylation of SLC22A1 in hepatocellular carcinoma (HCC) 
(Schaeffeler et al., 2011) and SLC22A3 in prostate cancer (Chen et al., 2013) is 
associated with reduced expression of these genes. 
 
10 20 30 40 50 60 70 80 90 100
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 MEAPEE-PAPVRGGPEATLEVRGS-RCLRL-------SAFREELRALLVLAGPAFLVQLMVFLISFISSVFCGHLGKLELDAVTLAIAVINVTGVSVGFG
rabbit MATE1 MEAPVE-LGP--GGRQASPERRHWLRCLVL-------SDFREELRALLVLACPAFLAQLMVFLISFVSSVFCGHLSKLELNAVTLAIAVINVMGVSVGFG
mouse  MATE1 MERTEE-SAPGPGGADAASERRGL-RCLLL-------PGFLEELRALLVLAGPAFLAQLMMFLISFISSVFCGHLGKLELDAVTLAIAVINVTGISVGHG
rat    MATE1 MEVLEE-PAPGPGGADAA-ERRGL-RRLLL-------SGFQEELRALLVLAGPAFLAQLMMFLISFISSVFCGHLGKLELDAVTLAIAVINVTGISVGHG
human  MATE2 isoform 1 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
human  MATE2 isoform 3 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
human  MATE2 isoform 2 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
rabbit MATE2 MDSQQDVVNLDQGGCCPALRKLLP-------------RGFWDEARALFVLSGPLFLFQVLNFLTYVVGTVFCGHLGKVELASVTLGVAFVNVCGVSVGAG
mouse  MATE2 MEPAEDSLGATIQPPELVRVPRGRSLRILLGLRGALSPDVRREAAALVALAGPVFLAQLMIFLISIVSSIFCGHLGKVELDAVTLAVSVVNVTGISVGTG
110 120 130 140 150 160 170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 LSSACDTLISQTYGSQNLKHVGVILQRSALVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLNQ----------
rabbit MATE1 LSSACDTLISQTYGSRNLKHVGVILQRGSLILLLCCLPCWALFLNTQHILLLFRQDPAVSRLTQTYVTIFIPALPATFLYTLQVKYLLNQ----------
mouse  MATE1 LSSACDTLISQTYGSQNLKHVGVILQRGTLILLLCCFPCWALFINTEQILLLFRQDPDVSRLTQTYVMIFIPALPAAFLYTLQVKYLLNQ----------
rat    MATE1 LSSACDTLISQTYGSQNLKHVGVILQRGTLILLLCCFPCWALFINTEQILLLFRQDPDVSRLTQTYVMVFIPALPAAFLYTLQVKYLLNQ----------
human  MATE2 isoform 1 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWLKGQEEES
human  MATE2 isoform 3 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQ----------
human  MATE2 isoform 2 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQ----------
rabbit MATE2 LSSACDTLMSQSFGSPNKKHVGVILQRGSLILLLCCLPCWALFLNTQHILLLFRQDPAVSRLTQDYAMIFIPGLPAIFLYSLLAKYLQNQ----------
mouse  MATE2 LASACDTLMSQSFGGKNLKRVGVILQRGILILLLCCFPCWAIFLNTERLLLLLRQDPDVARLAQVYVMICIPALPAAFLFQLQTRYLQSQ----------
210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 --------------------------GIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKLHQATWGGWSLECLQD
rabbit MATE1 --------------------------GIVLPQVVTGVAANLVNALANYLFVYQLHLGVMGSALANTVAQFTLALLLFLYILRSKVYQATWGGWSLECLQD
mouse  MATE1 --------------------------GIVLPQIMTGIAANLVNALANYVFLYHLHLGVMGSALANTISQFALAIFLFLYILWRRLHQATWGGWSWECLQD
rat    MATE1 --------------------------GIVLPQVITGIAANLVNALANYLFLHQLHLGVMGSALANTISQFALAIFLFLYILWRKLHHATWGGWSWECLQD
human  MATE2 isoform 1 PFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
human  MATE2 isoform 3 --------------------------KITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
human  MATE2 isoform 2 --------------------------KITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
rabbit MATE2 --------------------------GIVWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANTISQFVQAAFLFLHIVLKKLHLETWEGWSSQCLRD
mouse  MATE2 --------------------------GIIMPQVIVGIAANVVNVGMNAFLLYALDLGVVGSAWANTTSQFFLSALLFLYVWWKRIHIHTWGGWTRECFQE
310 320 330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 WASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYELAIIVYM--------------VPAGFSVAASVRVGNALGAGDMEQARKSSTVSLL
rabbit MATE1 WASFFRLAIPSMLMLCMEWWAYEIGSFLSGILGMVELGAQSVTYELAVIVYM--------------IPMGLSVAVNVRVGNALGAGNIEQAKKSSAVALL
mouse  MATE1 WASFLRLAIPSMLMLCIEWWAYEVGSFLSGILGMVELGAQSITYELAIIVYM--------------IPSGFSVAANVRVGNALGAGNIDQAKKSSAISLI
rat    MATE1 WASFLQLAIPSMLMLCIEWWAYEVGSFLSGILGMVELGAQSITYELAIIVYM--------------IPAGFSVAANVRVGNALGAGNIDQAKKSSAISLI
human  MATE2 isoform 1 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYM--------------IPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
human  MATE2 isoform 3 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMRHSHRLAYAAHVTRIPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
human  MATE2 isoform 2 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYM--------------IPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
rabbit MATE2 WGPFLSLAIPSMLMMCVEWWAYEIGSFLMGLLGVVDLSGQAIIYEVATVVYM--------------IPMGLGMAVCVRVGTALGAADTLQAKRSAVSGLL
mouse  MATE2 WSSYTRLAIPSMFMVCIEWWTFEIGTFLAGLVNVTELGAQAVIYELASVAYM--------------VPFGFGVAASVRVGNALGAGNADQARCSCTTVLL
410 420 430 440 450 460 470 480 490 500
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 ITVLFAVAFSVLLLSCKDHVGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVGLPIGIALMFATTLGVMGLWSG
rabbit MATE1 VTELIAVVFCVMLLSCKDLVGYIFTSDRDIIALVAQVTPIYAVSHLFESLAGTSGGILRGSGNQKFGAIVNAIGYYVVGLPIGIALMFAAKLGVIGLWLG
mouse  MATE1 VTELFAVTFCVLLLGCKDLVGYIFTTDRDIVALVAQVIPIYAVSHLFEGLACTCGGILRGTGNQKVGAIVNAIGYYVIGLPIGIALMFAAKLGVIGLWSG
rat    MATE1 VTELFAVTFCVLLLGCKDLVGYIFTTDWDIVALVAQVVPIYAVSHLFEALACTCGGVLRGTGNQKVGAIVNAIGYYVIGLPIGISLMFVAKLGVIGLWSG
human  MATE2 isoform 1 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
human  MATE2 isoform 3 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
human  MATE2 isoform 2 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
rabbit MATE2 CTAGTSLVVGTLLGLLNSQLGYIFTSDEEVIALVNQVLPIYIVFQLVEAVCCVFGGVLRGTGKQAFGAIVNAIMYYIVGLPLGIVLTFVVGMRIMGLWLG
mouse  MATE2 CAGVCALLVGILLAALKDVVAYIFTNDKDIISLVSQVMPIFAPFHLFDALAGTCGGVLRGTGKQKIGAVLNTIGYYGFGFPIGVSLMFAAKLGIIGLWAG
510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 IIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNV-------PRSGNSALPQDPLHPGCP-ENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQD
rabbit MATE1 IVVCAVSQAVCFLGFIARLNWTKACQQARVHANLTVN-T-------ASNGNSAVLPDQPHPVGP-DSHGGIVLRDADRKEGAELNEQVHPELPLPVRPED
mouse  MATE1 IIICTTCQTTCFLAFIARLNWKRACQQAQVHANLKVN----------VALNSAVSHEPAHPVCP-ESHGEIMMTDLEKKDETQLDQPMNQQQALPIRPKD
rat    MATE1 IIICSVCQTSCFLVFIARLNWKLACQQAQVHANLKVN----------VALNSAVSQEPAHPVGP-ESHGEIMMTDLEKKDEIQLDQQMNQQQALPVHPKD
human  MATE2 isoform 1 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
human  MATE2 isoform 3 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
human  MATE2 isoform 2 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
rabbit MATE2 MLTCIFLAAVTFVVYAVQLDWKLAAEEAQKHAGLQQQQQQQQQQGAECTAPSPGPDKAVVSSVATGCNPGIALTMYSRP-GCHVDFYGRPEAAPAPAAPA
mouse  MATE2 LIVCVSFQAFSYLIYILRTNWSRVAEQAQVRAGLKST-------------KELIPTPADLPILEREVMDGVILPDIIRP-ESQTGQLVVEENSQCAVPTV
610 620 630
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
human  MATE1 GAKLSRKQLVLRRGLLLLGVFLILLVGILVRFYVRIQ
rabbit MATE1 SAHLSGKQLALRRGLLLLGVILVLLAGILVKVYVRTQ
mouse  MATE1 SNKLSGKQLALRRGLLLLGVVLVLVGGILVRVYIRIE
rat    MATE1 SNKLSGKQLALRRGLLFLGVVLVLVGGILVRVYIRTE
human  MATE2 isoform 1 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
human  MATE2 isoform 3 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
human  MATE2 isoform 2 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
rabbit MATE2 S-RLSVRQLLFRRGAALAASVAVLMAGLLVRVLTTGY
mouse  MATE2 GEVLTGRQLVFYRGMALTVSVAVLIAGIVVRVFNDRG
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Figure 1.6. Multiple protein sequence alignment of MATE protein sequences 
from four different animal species. 
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1.8.2. Multidrug and Toxin Extrusion 1 (MATE1) 
1.8.2.1.  Structure 
hMATE1 and the kidney-specific hMATE2K are orthologs of the multidrug and 
toxin extrusion (MATE) family of bacteria. hMATE1 is encoded by the SLC47A1 
gene located at 17p11.2 with gene organization as depicted in Figure 1.7 (Otsuka 
et al., 2005, Terada and Inui, 2008). MATEs are highly conserved among species 
as shown in Figure 1.6 with human, mouse, rat, and rabbit MATE1 being 570, 
532, 566, and 568 amino acid residues in length, respectively (Otsuka et al., 2005, 
Terada et al., 2006). While the prokaryotic, fungal, and plant MATE family 
members share a predicted membrane topology of 12 TMHs, Zhang and Wright‘s 
study has shown that hMATE1and hMATE2K appear to have an additional 
COOH-terminal helix (Zhang and Wright, 2009). 
Initial studies using rat renal brush-border membranes vesicles have indicated that 
cysteine and histidine residues are critical for H+/organic cation antiporter activity 
(Hori et al., 1987, Hori et al., 1989). Subsequently, Matsumoto et al. (2009) 
showed that when the conserved Glu273, Glu278, Glu300, and Glu389 residues of 
hMATE1 were substituted with alanine or aspartate transport activity was 
reduced, suggesting an important role in the transport function of the MATE 
family (Matsumoto et al., 2008). 
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Figure 1.7. A schematic representation of the gene organization and the primary 
protein structure of human (A) SLC47A1 (hMATE1) and (B) SLC47A2 
(hMATE2K). The diagram depicts exons (numbered 117) and introns of both 
genes together with the arrangement of transmembrane helices (TMHs) 
(numbered 113) of encoded proteins (Staud et al., 2013). 
1.8.2.2. Tissue Distribution, Membrane Localization and Substrate 
Specificity 
hMATE1 is predominantly expressed at the luminal membranes of the renal 
proximal tubules (kidney) and the bile canaliculi (liver) and mediates the secretion 
of organic cations by using an oppositely directed H
+
 gradient as a driving force 
(Masuda et al., 2006, Otsuka et al., 2005, Tsuda et al., 2009). On the hand, 
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hMATE2K is primarily expressed in the brush-border membrane of renal 
proximal tubules (Masuda et al., 2006). 
hMATE1 and hMATE2K mediates the H
+
-coupled electroneutral exchange of 
tetraethylammonium (TEA) and 1methyl4phenylpyridinium (MMP
+
), two 
prototypical organic cation substrates of renal and hepatic H
+
-coupled organic 
cation antiporters (Koepsell et al., 2007b, Tanihara et al., 2007). In addition, 
MATEs are also involved in the transport of clinically important drugs such as 
metformin, cimetidine, and procainamide (Tanihara et al., 2007). Km values of 
cationic drugs for hMATE1 and hMATE2K are similar and higher than the 
plasma concentrations in clinical use. As a key element in the renal (and hepatic) 
secretion of cationic drugs, the human MATEs are likely targets for unwanted 
drug-drug interactions, as well as principal arbiters of the pharmacodynamics and 
pharmacokinetics of many clinically important agents (Zhang et al., 2012). 
Although MATEs recognize substrates similar to the OCT family, MATEs can 
transport zwitterions and anionic compounds in addition to cationic drugs.  In 
spite of having overlapping substrate spectra, MATE1 and MATE2-K do differ in 
substrate specificity and affinity. 
1.8.2.3. Regulation of MATEs 
In contrast to OCTs, little information is available on the regulation of MATEs. 
The proximal promoter region of human, murine, and rat SLC47A1 genes lacked a 
canonical TATA-box but contained two conserved Sp1binding consensus 
sequences. Moreover, disruption of Sp1 binding through mutagenesis affected 
hMATE1 activity that lead to an approximate 50% reduction relative to the 
control. 
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In a study by Lickteig et al (2008) the pharmacological induction of MATEs in 
the liver by the activation of known transcription factors was investigated 
(Lickteig et al., 2008). Their study suggested that none of Aryl hydrocarbon 
receptor (AhR), constitutive androstane receptor (CAR), pregnane x receptor 
(PXR), peroxisome proliferator-activated receptor α (PPARα), and NFE2related 
factor 2 (NrF2) were able to alter hMATE1 or hMATE2 function. 
1.8.3. Organic Anion Transporters 
Oatp1a1 was first member of OATP/SLCO superfamily to be isolated from rats 
(Jacquemin et al., 1994). Subsequently, Oatp2a1 was isolated by Kinai et al 
(1995). The first human superfamily member (OATP1A2) was isolated and 
described by (Kullak-Ublick et al., 1995). Subsequently, further OATPs have 
been identified and characterized from various species using homology screening 
by either hybridization experiments or in silico techniques. OATPs have been 
identified in the intestine, liver, kidney, lung, testis, placenta and blood-brain 
barrier. Their substrates include endogenous substances such as bile salts, steroid 
conjugates and thyroid hormones, as well as several xenobiotics such as statins 
(Seithel et al., 2008). 
1.8.3.1. Structure and Function of the OATPs 
OATPs are comprised of 12 transmembrane domain (TMD) proteins with 
common structural features. This includes a large extracellular loop between TMD 
9 and 10,  N-glycosylation sites in extracellular loops 2, 3 and 5, and the 
consensus superfamily signature; DXRW(I,V0GAWWXG9F,L)L at the border 
between extracellular loop 3 and TMD 6 (Hagenbuch and Meier, 2003). 
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OATPs are sodium-independent uptake transporters that mediate the influx of a 
variety of amphipathic compounds. Their transport mechanism is electroneutral 
exchange, coupling the cellular uptake of organic compounds with the efflux of 
neutralizing anions such as bicarbonate, glutathione and glutathione-S-conjugates 
(Li et al., 1998, Satlin et al., 1997). The majority of OATPs transport a wide 
assortment of amphipathic organic compounds (Bossuyt et al., 1996). Oatp1a1 
was initially isolated in rat liver as a sodium-independent bromosulfophthalein 
and taurocholate uptake system (Jacquemin et al., 1994).  
Thereafter, comprehensive functional characterization, in different experimental 
systems, indicated that it can facilitate the transport of a wide variety of 
amphipathic organic compounds including bile salts, steroid hormones, thyroid 
hormones, organic cations including N-(4,4azonpentyl)21deoxyajmalinium and 
numerous drug compounds. The included drugs are BQ123, CRC220, [D-
penicillamine 2,5] (DPDPE) & deltorphin II, ACE inhibitors enalapril & 
temocaprilat, the HMG-CoA reductase inhibitor pravastatin and fexofenadine, an 
antihistamine (Hagenbuch and Meier, 2003, Hagenbuch and Meier, 2004, Meier 
et al., 2007a). The majority of member of the OATP1A and OATP1B subfamilies 
have been shown to exhibit similar broad, as well as partially overlapping, 
substrate specificities. This indicates that they may play a vital role, in 
conjunction with P-glycoproteins and multidrug resistance proteins, in drug 
absorption and disposition (Hagenbuch and Meier, 2004).  
1.8.3.2. OATP1B 
OATP1B is subdivided into two human members, OATP1B1 and OATP1B3. 
OATP1B1 cloned from human liver cells (Abe et al., 2001) encodes a 691 amino 
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acid glycoprotein which share 80% sequence homology with OATP1B3. 
However, it shares only 65% sequence homology with rat Oatp1b2 (Hagenbuch 
and Meier, 2003). OATP1B1 is expressed at the basolateral plasma membrane of 
hepatocytes (Tamai et al. 2000; Abe et al. 1999) and has a total mass of 84kDa, 
which is reduced to 54kDa after de-glycosylation (Konig et al., 2000). Since it is 
primarily expressed in the human liver it is suggested that OATP1B1 plays a 
critical role in the hepatic clearance of albumin-bound amphipathic compounds 
(Hagenbuch and Meier, 2004). This includes bile salts, conjugated and 
unconjugated bilirubin, BSP, steroid conjugates, thyroid hormones T4 and T3, 
eicosanoids, cyclic peptides, drugs including benzyl-penicillin, methotrexate, 
pravastatin and rifampicin as well as natural toxins such as mircosystin and 
phalloidin  (Hagenbuch and Meier, 2003).  
OATP1B3 was cloned from human liver and encodes a 702 amino acid 
glycoprotein with a molecular mass of 120kDa, which is reduced to 65kDa after 
de-glycosylation (Konig et al., 2000). OATP1B3 is exclusively expressed at the 
basolateral plasma membrane of hepatocytes. However, it has been shown to be 
expressed in several human cancer tissues, but the significance of this has yet to 
be investigated (Hagenbuch and Meier, 2004, Konig et al., 2000). OATP1B3 has 
similar broad substrate specificities as OATP1B1 transports bile salts, mono-
glucuronosyl bilirubin, BSP, steroid conjugates, thyroid hormones T3 and T4, 
leukotriene C4, linear and cyclic peptide, cardiac glycosides such as digoxin and 
ouabain, methotrexate, rifampicin and natural toxins such microcystin and 
phalloidin (Hagenbuch and Meier, 2003). However, OATP1B3 also exhibits 
unique transport capabilities, mediating transport of cholecystokinin 8 (CCK8), 
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deltorphin II and cardiac glycosides digoxin and ouabain (Konig et al., 2000, 
Kullak-Ublick et al., 2001).  
1.8.3.3. Pharmacogenetics of OATP1B1 
OATP1B1 is encoded by the SLCO1B1 gene, located on chromosome 12 
(12p12). Numerous synonymous and nonsynonymous SNPs have been discovered 
on the SLCO1B1 gene. Many of these variants have been shown to affect 
transport function, both in vitro and in vivo (Iwai et al., 2004, Tirona et al., 2001). 
Furthermore, it has been recognized that most of these SNPs span the 
transmembrane domain or extracellular loop 5 of OATP1B1 (Iwai et al., 2004, 
Tirona et al., 2001). However, it is important to note that the effects of certain 
SLCO1B1 SNPs on transport function are substrate-specific (Tirona et al., 2001). 
Within SLCO1B1 numerous nonsynonymous SNPs are prevalent. This includes 
RS4149056 and RS2306283, two of the most characterized SNPs in this gene, 
which produce amino acid changes Val174Ala and Asn130Asp respectively. 
However, when the effects of particular SNPs are evaluated it is important to take 
into account the underlying haplotype these SNPs are found in (Mwinyi et al., 
2008). For example, the abovementioned SNPs are in linkage equilibrium and 
exist in varying haplotypes together. However, when the nucleotide Adenine (A) 
is present at RS2306283 and Thymine (T) is present at RS4149056 it is referred to 
as haplotype *1A or the reference haplotype (Table 1). Furthermore, SNPs in the 
promoter region of this gene can further sub-classify its haplotype into two 
distinct functional haplotypes (table 1) (Niemi et al., 2004).  
Haplotypes *5 and *15 have been associated with a strikingly reduced uptake of 
multiple OATP1B1 substrates including oestrone3sulphate, oestradiol17βD-
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glucuronide, atorvastatin, cerivastatin, pravastatin and rifampicin (Iwai et al., 
2004, Kameyama et al., 2005, Nozawa et al., 2005, Tirona and Kim, 2005, Tirona 
et al., 2001). Additionally, RS4149056>C has been associated with increased 
plasma concentrations of many statins as well as fexofenadine and repaglinide 
(Chung et al., 2005, Lee et al., 2005, Mwinyi et al., 2008, Niemi et al., 2005a, 
Niemi et al., 2005b, Niemi et al., 2004, Nishizato et al., 2003).   
It is important to note that these haplotype designations only refer to the SNPs in 
linkage disequilibrium. Other, less studied SNPs also occur in the SLCO1B1 gene 
which are potentially functional variants.  
1.9. Diseases influenced by OCT, OAT and MATE regulation 
1.9.1. Cholesterol homeostasis 
Cholesterol is a major component of mammalian cell membranes. It is involved in 
controlling fluidity and maintaining the barrier between the cell and its 
environment. Furthermore, tissue growth, bile acid synthesis in the liver, vitamin 
D production in the skin and steroid hormone synthesis in the adrenal glands, 
ovaries and testes is also mediated by cholesterol (Brown and Goldstein, 1986). 
Cholesterol is transported in the circulatory system by lipoproteins, which are 
spherical particles with a hydrophobic core of esterified cholesterol and 
triglycerides surrounded by a hydrophilic shell of apolipoproteins (apos), 
phospholipids and unesterified cholesterol. Plasma lipoproteins can be 
characterised by their density into very low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL). Lipoprotein receptors, specifically LDL receptors 
located on the surface of cells, bind LDL and transport cholesterol into cells via 
 
 
 
 
CHAPTER 1 
 31 
receptor-mediated endocytosis where it will either be used immediately or stored 
as cytoplasmic cholesteryl ester droplets (Brown and Goldstein, 1983, Brown and 
Goldstein, 1986).  
1.9.2. Cholesterol and Cancer 
Recent discovery indicates that elevated glycolytic activity in various cancer types 
(Warburg effect) is a crucial feature of the cancer (Christofk et al., 2008, Fantin et 
al., 2006, Weinberg et al., 2010). Correspondingly, an increased cholesterol level 
in malignant cell transformation has long been debated. This phenomenon was 
first suggested in the early 20
th
 century where xenografts were shown to have 
accelerated tumour growth rates following injection with cholesterol (Robertson 
and Burnett, 1913). However, research into this area has been lacking. Abnormal 
regulation of cholesterol homeostasis has been associated with numerous types of 
cancer. Several studies have established increased cholesterol levels in tumours as 
compared with normal tissues (Dessi et al., 1992, Kolanjiappan et al., 2003, 
Rudling and Collins, 1996, Schaffner, 1981, Yoshioka et al., 2000). Furthermore, 
low serum cholesterol levels have been associated with the presence of tumours in 
cancer patients. This suggests that cholesterol is accumulated in the tumour tissue) 
(Benn et al., 2011, Jacobs et al., 1992, Strasak et al., 2009). Multiple paths exist in 
cancer cells which result in increased intracellular cholesterol. This includes 
upregulation of 3hydroxy3methylglutayl CoA reductase (HGM-CoA) activity, 
loss of feedback inhibition of HMG-CoA by cholesterol, increased uptake of 
extracellular cholesterol via LDL receptor and decreased expression of the ATP-
binding cassette transporter A1 (ABCA1) (Basso et al., 2005, Caruso et al., 2002, 
Graziani et al., 2002, Gregg et al., 1986, Hentosh et al., 2001, Ki et al., 2007, 
Moustafa et al., 2004, Notarnicola et al., 2004, Schimanski et al., 2010, Siperstein, 
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1995, Tatidis et al., 2002). Moreover, recent studies have shown that various 
statins, which block HMG-CoA activity and thereby inhibit cholesterol synthesis, 
reduce tumour growth in xenograft models (Huang et al., 2010, Kochuparambil et 
al., 2011). 
1.9.3. Hyperlipidaemia and Diabetes 
Diabetic patients suffer and increased risk of morbidity and mortality from 
cardiovascular disease (CVD) (Beckman et al. 2002). Patients with Type2 
diabetes have an approximated two to fourfold increased risk of coronary artery 
disease (CAD). This is further compounded by the presence of such complications 
as diabetic nephropathy (Stephenson et al., 1995). Notably, the short term and 
longer term consequences for diabetic patients following myocardial infarction or 
stroke are generally higher than those of non-diabetic patients. Therefore, 
prevention of CAD in these high-risk patients is of vital importance (Yudkin, 
1998). (Turner et al., 1998), showed that increased concentrations of LDL 
cholesterol, low levels of HDL cholesterol, hyperglycaemia, systolic hypertension 
and smoking are potentially modifiable risk factor for CAD in diabetic patients. 
Moreover, it has been established that low HDL cholesterol levels are more 
pathogenic in the presence of Type-2 diabetes. This is thought to be a result of the 
presence of small, dense LDL cholesterol particle and oxidation of glycated LDL 
cholesterol particles. Glycated LDL cholesterol particles are formed by the non-
enzymatic reaction of glucose with apoproteins (Haffner, 1998). However, 
regardless of the importance of elevated LDL levels, the dyslipidaemia 
encountered in diabetic patients is more complex, interacting with numerous 
components in insulin resistance syndrome to enhance the risk of CVD through 
quantitative and qualitative changes (Krentz, 2003). 
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1.9.4. Hyperlipidaemia and Hypertension 
It is estimated that up to 40% of hypertensive patients have high cholesterol levels 
(Hyperlipidaemia) and over 40% are obese (Criqui et al., 1980, Ostrander and 
Lamphiear, 1976). Hypertension and hyperlipidaemia are thought to be related as 
insulin resistance and saturate fat intake are common features in the pathogenesis 
of these diseases, as shown by epidemiological studies (Goode et al., 1995, 
Hopkins et al., 1996, Kannel et al., 1991). This suggests that hypertension and 
hyperlipidaemia act synergistically as cardiovascular risk factors.   
1.10. Clinical association between OCT, OAT and MATE variant alleles 
and drug disposition, response and toxicity 
1.10.1 Oral Anti-Diabetic Drugs 
Type-2 diabetes mellitus is carbohydrate metabolism disorder. It manifests as 
hyperglycaemia as a result of defects in insulin secretion and insulin resistance. It 
is often related to symptoms of metabolic syndrome such as obesity, 
hyperlipidaemia, hypertension and endothelial dysfunction (Ryden et al., 2007). 
Oral antidiabetic therapies include metformin, sulfonylureas, thiazolidinediones, 
meglitinides, insulin, exenatide and dipeptidylpeptidase4 inhibitors (Edwards et 
al., 2008, Ryden et al., 2007). Patients with type-2 diabetes are often also treated 
with statins or fibrates, anti-hypertensives and acetylsalicylic acid (Ryden et al., 
2007). However, since SLCO1B1 directly influences the meglitinide class of oral 
antidiabetic drugs, repaglinide will be focused on. Repaglinide is a short-acting 
meglitinide analogue that enhances glucose-stimulated insulin secretion from 
pancreatic beta cells, thereby reducing blood glucose concentrations (Dornhorst, 
2001). Its mechanism of action is binding and closing the ATP-sensitive K
+
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channels. Binding and closing the K
+
 channel serves to depolarize the beta cell, 
allowing for the opening of voltage-gated Ca
++
 channels (Hatorp, 2002). This 
results in the influx of Ca
++
 ions which triggers the release of insulin by 
exocytosis. However, insulin release is dependent on the beta cell secretory 
capacity (Hatorp, 2002). The SLCO1B1 RS4149056C polymorphism has been 
shown to directly affect repaglinide plasma levels (Kajosaari et al., 2005). This is 
particularly evident when atorvastatin is used in combination with repaglinide. It 
is suggested that the atorvastatin acts as an inhibitor, thus inhibiting 
OATP1B1mediated hepatic repaglinide uptake (Chung et al., 2005, Lee et al., 
2005, Mwinyi et al., 2008, Niemi et al., 2004, Nishizato et al., 2003).   
Metformin is a biguanide organic cationic (pKa 12.4) drug that is routinely 
prescribed as the preferred first-line therapeutic drug in the treatment of type-2 
diabetes mellitus (Kirpichnikov et al., 2002, Nathan et al., 2009). It improves 
insulin sensitivity and thus decreases the insulin resistance that is prevalent in 
type-2 diabetes mellitus. Metformin is not metabolized and is excreted unchanged 
by active tubular secretion and glomerular filtration into the urine. 
Although, the exact mechanistic pathway for metformin action is currently only 
partially understood, it is widely believed to activate adenosine monophosphate 
(AMP) activated protein kinase (AMPK) by inhibition of the mitochondrial 
respiratory chain (Owen et al., 2000, Zhou et al., 2001). Moreover, this activation 
of AMPK by metformin requires the phosphorylation of AMPK by a serine-
threonine kinase, LKB1 (Shaw et al., 2005). This results in an increase in cellular 
AMP levels which in turn lead to insulin suppression of glucose production via 
gluconeogenesis and increased peripheral glucose uptake (Hawley et al., 2010, 
Hundal et al., 2000, Zhou et al., 2001). However, evidence exists which suggests 
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that metformin also exerts its metabolic effects via AMPK-independent 
mechanisms. 
In addition to its favourable effect on hyperglycaemia, metformin also has other 
beneficial effects. Firstly, metformin is able to exert its glucose-lowering actions 
with a low risk of hypoglycaemia. Secondly, it reduces the likelihood of 
developing macrovascular (hypertension and atherosclerosis) and microvascular 
(neuropathy, retinopathy, and nephropathy) complications. Thirdly, it is weight 
neutral, that is, it does not affect body mass index (BMI) or decrease body weight 
in obese patients with or without diabetes. 
However, approximately 30-40% of patients using metformin as an antidiabetic 
therapeutic experience adverse events such as diarrhoea and nausea; or a more 
serious but rare side effect, lactic acidosis (Reitman and Schadt, 2007, Takane et 
al., 2008, Wang et al., 2002). Moreover, approximately 38% of metformin users 
did not achieve acceptable control of fasting glucose levels and showed a variable 
glycaemic response (Reitman and Schadt, 2007). This variation in glycaemic 
response to metformin was attributed to the uptake of the drug either at the hepatic 
level or the elimination of the drug at the renal level. Furthermore, it was 
established that genetic variations in solute carrier transporter (SLC) genes, 
specifically hOCT1 (hepatic level) and hOCT2 (renal level), are involved in this 
varied response to the drug (Figure 1.8) (Kimura et al., 2005a, Wang et al., 2002). 
In addition, genetic variation in another SLC, hMATE1 transporter protein was 
also implicated in the glucose lowering effect of metformin (Becker et al., 2009b). 
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Figure 1.8.  Pharmacokinetics pathway of metformin (Gong et al., 2012). 
1.10.2. OCT and OAT SNPs as predictors of response to Anti-Cancer Drugs 
OCTs may play an important role in the treatment of malignant tumours. For 
example, hOCT1 is responsible for the active uptake of the charged hydrophilic 
anticancer agents imatinib, cisplatin, oxaliplatin, picoplatin, irinotecan, and 
paclitaxel, thus contributing to the susceptibility of cancer cells to these 
antineoplastic drugs (Gupta et al., 2012). hOCT1 activity was reported to correlate 
well with the sensitivity of tyrosine kinase inhibitors (TKIs) such as imatinib in 
patients with chronic myeloid leukaemia (CML). 
Yokoo et al. (2008) investigated whether hOCT3 was significantly involved in the 
oxaliplatin-induced cytotoxicity and accumulation of platinum in colorectal 
cancer (Yokoo et al., 2008). They found that SLC22A3 expression was higher in 
colon and rectal cancerous tissues compared to normal tissues in Caucasian 
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patients. Moreover, they found that the cytotoxicity and accumulation of platinum 
caused by the treatment of oxaliplatin but not cisplatin depended on SLC22A3 
expression. Li et al. (2012) in a recent study investigated whether drug 
transporters played a role in determination of cisplatin resistance in cervical 
cancer cells (Li et al., 2012). They found that hOCT3 partially contributed to the 
sensitivity of adenocarcinoma cells to cisplatin cytotoxicity. Based on their data 
they suggested that downregulation of SLC22A3 as a mechanism responsible for 
cisplatin accumulation in cervical adenocarcinoma cells. Expression of hOCT3 in 
kidney carcinoma cell lines increases chemo-sensitivity to the anti-neoplastics 
melphalan, irinotecan, and vincristine (Shnitsar et al., 2009). 
In a recent study, Heise et al. (2012) investigated the impact of OCT expression 
on hepatocellular carcinoma (HCC) and patient survival (Heise et al., 2012). They 
found that downregulation of SLC22A1 expression in HCC is associated with 
advance tumour stages and a worse patient survival rate. Downregulation of 
SLC22A1 expression was also associated with tumour progression and reduced 
patient survival in human cholangiocellular carcinoma (CCA) (Lautem et al., 
2013). Moreover, the downregulation of SLC22A1 was significantly associated 
with advanced CCA stages. These findings could be important in future treatment 
strategies for these diseases. 
Mohelnikova-Duchonova et al. (2013) investigated the association between the 
expression of solute carrier transporters and the prognosis of pancreatic cancer 
(Mohelnikova-Duchonova et al., 2013). They found that expression of some SLCs 
predicted the outcome of PDAC patients regardless of chemotherapy and that 
there is considerable variability in the expression in SLC transporters between 
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tumour and normal human pancreas tissues which may modify the outcomes of 
patients treated with nucleoside analogues and platinum containing regimens. 
A common variant in 6q26q27 is associated with distal colon cancer in a Japanese 
population (Cui et al., 2011).  However, Zhu et al. (2013) found that the genetic 
variant rs7758229 in 6q2627 was not associated with colorectal cancer risk in a 
Chinese population (Zhu et al., 2013). Genetic and functional analysis have 
implicate the SLC22A3 gene together with 2 other genes in prostate cancer 
pathogenesis (Grisanzio et al., 2012). 
Chronic myeloid leukaemia (CML) is a hematopoietic stem cell disorder, 
characterized by the presence of the Philadelphia (Ph) chromosome that results 
from a balanced reciprocal translocation between chromosomes 9 and 22 (Singh et 
al., 2012). Functionally, this translocation results in the formation of the BCRABL 
gene which is then translated into the BCRABL a protein with intrinsic tyrosine 
kinase activity that is critical to the development of CML (Rowly, 1973). Imatinib 
mesylate, a tyrosine kinase inhibitor (TKI), is now the first-line therapeutic for the 
treatment of chronic phase CML (White et al., 2010). However, 30-40% of 
patients with CML are resistant to imatinib treatment and do not achieve a 
complete cytogenic response (CCR) (Druker et al., 2006, Hochhaus et al., 2009). 
This heterogeneity in imatinib response could be attributed to the presence of 
SNPs in the SLC22A1 gene which codes for the hOCT1 transporter protein 
(Giannoudis et al., 2013). hOCT1 is an influx organic cation transporter that 
mediates the uptake of imatinib, a selective inhibitor of the oncogenic protein 
Bcr/Abl, into CML cells (Crossman et al., 2005, Thomas et al., 2004). In a recent 
study by Giannoudis et al. (2013), the effect of polymorphisms rs628031 
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(M408V) and rs35191146 (M420del) on imatinib uptake and clinical efficacy was 
investigated (Giannoudis et al., 2013). In CML cell lines transfected with the 
M420del variant and/or M408V variant, M420del significantly decreased imatinib 
uptake. However, this effect was countered if the M408V SNP was also present. 
Giannoudis et al. (2013) concluded that the only SNP associated with imatinib 
treatment outcome was M420del (rs35191146), with patients with the M420del 
genotype demonstrating an increased probability of imatinib treatment failure 
(Giannoudis et al., 2013). 
However, the role of hOCT1 in the uptake of imatinib is controversial. In a recent 
study, Nies et al. (2014) challenged the role of hOCT1 in imatinib uptake, and 
showed through transport and inhibition studies that overexpression of functional 
hOCT1 did not lead to increased accumulation of imatinib (Nies et al., 2014). 
They concluded that cellular uptake of imatinib is independent of hOCT1 and as 
such hOCT1 is not a valid biomarker for imatinib resistance. 
(Faber et al., 2003) first showed that anti-folate aminopterin could produce 
remissions in children with acute leukaemia. Thereafter, folate-dependant 
enzymes became a major target for chemotherapy as they play an essential role in 
the synthesis of DNA precursors(Chu et al., 1996, Huennekens, 1994). 
Methotrexate is the most commonly used anti-folate for the treatment of 
leukaemia, lymphoma, chorio-carcinoma, head and neck cancer and osteogenic 
sarcoma. It is additionally used in the treatment of numerous autoimmune 
diseases, including rheumatoid arthritis, psoriasis and the prevention of graft-host 
diseases after transplantations (Gorlick et al., 1996). Methotrexate and its 
polyglutamates bind tightly to dihydrofolate reductase, inhibiting the enzyme. 
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This results in the depletion of N
5
N
10
 methylene tetrahydrofolate and N
10
 formyl 
tetrahydrofolate, essential cofactors for the biosynthesis of thymidylate and purine 
respectively (Chu et al., 1996). The depletion of these cofactors results in the 
inhibition of DNA replication and ultimately cell death. Furthermore, 
methotrexate polyglutamates also inhibit the enzymes involved in the de novo 
synthesis of purines, glycinamide ribonucleotide (GAR) transformylase and 
aminoimidazole carbozamide (AICAR) transformylase. Additionally, 
methotrexate competes with reduced folates for transport and polyglutamates 
(Chu et al., 1996). However, the genetic origins of inter-individual 
pharmacokinetic and pharmacodynamic variability of methotrexate remain poorly 
understood, with conflicting results on candidate pharmacogenetic predictors for 
methotrexate (de Jonge et al., 2005, Laverdiere et al., 2002). SLCO1B1 has been 
shown to transport methotrexate in vitro (Abe et al., 2001, Tirona et al., 2001). 
Previous studies have confirmed the functional consequences of nonsynonymous 
polymorphisms in SLCO1B1 (Kameyama et al., 2005, Tirona et al., 2001).  
Trevino et al. (2009) concluded that for RS 4149056C, as well as other less 
studied SNPs, a lower methotrexate clearance was observed. This is consistent 
with numerous preceding studies which demonstrated greater plasma exposure to 
several SLCO1B1 substrates in those carrying the RS4149056C polymorphism 
(Ho et al., 2007, Niemi, 2007, Pasanen et al., 2007). 
1.10.3. HMG-CoA Reductase inhibitors (Statins) 
Statins are the most commonly prescribed lipid-modifying therapy for 
hyperlipidaemia (Downton and Clark, 2003). Numerous largescale studies have 
proven the advantageous effects of statins in primary and secondary prevention of 
CVD (Law et al., 2003, Sacks et al., 1996, Shepherd et al., 1995, Strandberg et al., 
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2001). Statins are reversible competitive inhibitors of the HMG-CoA reductase 
enzyme. Inhibition of this enzyme results in a reduction of cholesterol synthesis in 
hepatocytes, which leads to a reduction in intracellular cholesterol concentrations 
and therefore an increase in LDL-receptor expression on the hepatocyte cell 
surface (Law et al., 2003). The result is an increase in extraction of LDL 
cholesterol from the blood and therefore a decrease in the total cholesterol 
concentration in the circulatory system (Law et al., 2003).  Additionally, statins 
also moderately reduce triglyceride concentrations and increase HDL cholesterol 
concentrations. However, the biological effects, other than LDL reduction, may 
vary between statins (Bonetti et al., 2004, Chong et al., 2001, Rosenson and 
Tangney, 1998). Statins have been shown to slow the progression, or even 
promote regression, of coronary artherosclerosis and avoid plague that would 
elicit intramural haemorrhage and intraluminal thrombosis (Kreisberg and 
Oberman, 2002, Liao et al., 2002). Included in the statin class are Fluvastatin, 
Pravastatin, Simvastatin, Rosuvastatin and Atorvastatin.  
1.11. OCTs and MATEs in drug-drug interactions 
OCTs and MATEs play an important role in the uptake, distribution, and 
elimination of commonly used clinical drugs. Since more than 30% of clinically 
used drugs are organic cations, drug-drug interaction (DDI) by inhibition of OCT 
and/or MATE transporters may be clinically relevant. DDIs involving the 
inhibition of metabolism and/or excretion prolong the plasma elimination half-
lives, leading to the accumulation of victim drugs in the body, and consequently 
potentiate pharmacological/adverse effects (Ito et al., 2012). 
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Apical efflux by the MATE family is considered one of the sites of DDI in 
addition to OCTs at the basolateral membrane (Tsuda et al., 2009). The 
antihistamine cimetidine is known to cause DDIs with OCs in the kidney, and a 
previous study showed that the co-administration of cimetidine with fexofenadine 
(FEX), for example, decreases the renal clearance of the drug.  Previously hOCT2 
was implicated in DDIs which involved the antihistamine cimetidine. In a study 
by Matsushima et al. (2009) it was suggested that the DDI with cimetidine and 
FEX was mainly caused by the inhibition of hMATE1mediated efflux of FEX 
rather than the inhibition of its renal uptake process (Matsushima et al., 2009).  
Moreover, a recent study by Ito et al. (2012) supported this observation and 
showed that it is in fact the competitive inhibition of the luminal efflux by 
hMATE1, and not the basolateral uptake by hOCT2, which is the likely 
mechanism underlying the pharmacokinetic DDIs caused by cimetidine in the 
kidney (Ito et al., 2012). Inhibitors that preferentially interact with and impair the 
function of MATEs, may not only result in decreased clearance but may also lead 
to nephrotoxicity. 
Minematsu et al. (2011) investigated the inhibitory effect of 8 tyrosine kinase 
inhibitors on metformin transport activity by human hOCT1, hOCT2, hOCT3, 
hMATE1 and hMATE2K (Minematsu et al., 2010). They found that imatinib, 
nilotinib, gefitinib, and erlotinib exerted selectively potent inhibitory effects on 
hMATE1, hOCT3, hMATE2K, and hOCT1, respectively. Furthermore, they 
found that compared to the reference hOCT1, the M420del variant was more 
sensitive to drug inhibition erlotinib. 
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1.12. Genomic Diversity and Personalized Medicine: The African 
Perspective 
Although controversial, the concepts of race, ethnicity, and ancestry, have for a 
long time been recognized as having a strong influence on pharmacogenomic 
discovery, and our understanding of population differences in drug efficacy and 
toxicity (Urban, 2010). 
Most dosing regimens are recommended on the basis of clinical trials that have 
been conducted in Caucasian or Asian populations which may not be appropriate 
for African populations (Masimirembwa and Hasler, 2013). Pharmacogenomic 
applications hold the promise of using genome-based technologies to improve 
health by the prevention or effective treatment of disease. The current belief is 
that even developing nations, such as those in sub-Saharan Africa, can benefit 
from pharmacogenomics in order to inform public health policies, designing and 
interpreting clinical trials, and possibly to help guide clinicians to prospectively 
evaluate those patients with the greatest probability of expressing a variant 
genotype (Suarez-Kurtz, 2008b, Daar and Singer, 2005a). 
The South African health system, both private and public, faces a high burden of 
communicable and non-communicable diseases, high maternal and child 
mortality, as well as injury and violent related deaths (Coovadia et al., 2009, 
Mayosi et al., 2012). This high burden of infectious and chronic diseases results in 
a health system that is continuously under-resourced. Although South Africa‘s per 
capita health expenditure is the highest of any middle-income country in the world 
its health outcomes are often worse than that of lower-income countries (Coovadia 
et al., 2009, Warnich et al., 2011). The current challenge in pharmacogenomics in 
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sub-Saharan Africa, and for that matter South Africa, is to ascertain the extent of 
the genomic diversity in our understudied populations, to understand genotype-
environment interactions, and to translate this knowledge into clinical applications 
that can be utilized in public health care (Hardy et al., 2008). 
1.13. Usage of Manuscript Data 
Data from the following manuscripts was used in Chapter 2: Pearce et al (2016) 
and Du Plessis et al (2015). Data from Hoosain et al (2016) was used in Chapter 3.  
1.14. Summary and Main Objectives of the Project 
The past decade has seen remarkable progress in the field of membrane 
transporters, not only in terms of functional characterization and substrate 
specificity but also in elucidating the important role that transporters play in 
diseases such as cancer and in the disposition and efficacy of drugs in clinical use. 
To date 48 members of the ABC and over 325 members of the SLC families of 
membrane transporters have been identified. These transporters are ubiquitously 
expressed and play a critical role in maintaining cellular and organismal 
homeostasis by importing nutrients essential for cellular metabolism and 
eliminating metabolic by-products and toxic xenobiotics. Whereas most 
membrane transporters are oligo-specific (specialized for the translocation of 
specific metabolic or nutritional compounds), poly-specific transporters accept 
compounds with different sizes and molecular structures. These poly-specific 
transporters exhibit large variations in affinity and turnover for different 
compounds and may have specific physiological roles. Given the fact that 40% of 
clinically used drugs exist as organic cations at physiological pH, the poly-
specific OCT and MATE families of SLCs have attracted a significant amount of 
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interest. The genes encoding these transporters are also being investigated as 
potential risk loci for cancer, and SNPs in these genes have been associated with 
imatinib treatment failure in CML patients. Moreover, genetic variations in these 
transporters are increasingly being recognized as a possible mechanism that can 
explain the inter-individual variability in drug efficacy and toxicity. However, the 
majority of these studies were conducted in Caucasian and Asian populations and 
were based on genetic variants that are specific to these populations. The findings 
of these studies are often extrapolated for use and interpretation in other 
populations. This is in spite of the fact that the population frequency of variant 
alleles can differ markedly between populations. In addition, ethnic-specific 
variants exist in non-Caucasian and non-Asian populations which may be more 
predictive of treatment outcome or disease progression for a specific ethnic group. 
However, the allelic distribution and role of genetic variants of OCT, OAT and 
MATE transporters in drug efficacy and toxicity and disease progression in 
indigenous South African populations have not received the necessary priority. 
Inter-individual variability in drug response is a significant clinical problem which 
has attracted a fair amount of research interest. It is estimated that genetic factors 
can account for approximately 15-30% of inter-individual variability in drug 
response and efficacy. Initially the focus has been on drug metabolizing enzymes, 
however membrane transporter belonging to the SLC family are increasingly 
being recognized as a possible mechanism explaining this variability in drug 
response and efficacy. Given that 40% of therapeutic drugs exist as OCs at 
physiological pH, the OCTs, OATs and MATEs of the SLC family is receiving a 
greater amount of attention. Reduced-function variants have been identified, 
primarily in American and European Caucasians, which affect the 
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pharmacokinetics of OCT and MATE substrate drugs such as metformin for 
example. Although African populations are considered to harbour more genomic 
diversity than Caucasian populations, this diversity is however understudied. 
Thus, little or no information is available on the extent of genetic variation in 
OCT, OAT and MATE genes within African populations. Although several 
populations from West, East, and Central Africa are included in the 1000 
Genomes and Hap-Map projects, these groups cannot represent the genomic 
diversity of the entire continent. Therefore, in order to bridge the gap that exist 
with regards to information on the pharmacogenomic relevant OCT and MATE 
genes, especially in indigenous southern African populations, this study 
prioritized the genotyping of 78 SNPs in four genes, known to affect drug 
disposition and efficacy, in the Cape Admixed population of South Africa. 
The main aim of this study was to evaluate the distribution of genetic variants in 
solute carrier transporters amongst the Cape Admixed population and this aim 
was achieved through the following objectives; 
(1) Investigating the genotypic and allelic distributions of thirty-eight SNPs, 
and to infer the haplotype structure of the SLC22A1-3 genes. 
(2) Determining the baseline genotypic and allelic frequency distributions of 
20 known SLCO1B1 coding SNPs. 
(3) To determine whether the SLC genes of the Cape Admixed population 
harbours any novel SNPs, using direct sequencing of the promoter regions 
of these genes in 96 healthy individuals. Secondly to determine the 
promoter haplotype structure of the SLC genes based on the genetic 
information acquired by sequencing. 
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(4) Investigate the effect promoter haplotypes have on gene expression of 
SLC22A2.  
 
 
 
 
 
CHAPTER 2 
 48 
CHAPTER 2 
Genetic Polymorphisms and Haplotype Structure of SLC22A Genes in the Cape 
Admixed Population 
2.1. Abstract 
Human organic cation transporters are primarily expressed in hepatocytes and 
mediates the electrogenic transport of various endogenous and exogenous 
compounds, including clinically important drugs. Genetic polymorphisms in these 
genes are increasingly being recognized as a possible mechanism explaining the 
variable response to clinical drugs, which are substrates for this transporter. The 
genotypic and allelic distributions of nonsynonymous solute carrier transporter 
single nucleotide polymorphisms were determined in 130 healthy Cape Admixed 
participants from South Africa, using a SNaPshot
™
 multiplex assay. In addition, 
haplotype structure for each gene (SLC22A1, SLC22A2, SLC22A3) was inferred 
from the genotypic data. The minor allele frequencies for SLC22A1 variants S14F 
(rs34447885), P341L (rs2282143), V519F (rs78899680), and the intronic variant 
rs622342 were 1.0%, 0.5%, 1.5%, and 18.0%, respectively. The minor allele 
frequencies for the SLC22A2 variants S270A (rs316019) and R176H (rs57371881) 
were 7.1% and 4.5%, respectively. None of the participants carried the variant allele 
at any of the elected loci in SLC22A3. This study reports important genetic data that 
could be useful for future pharmacogenomic studies of drug transporters in the 
indigenous Sub-Saharan African populations.  
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2.2. Introduction 
Membrane transporters play an important role in the metabolism of clinical drugs 
and endogenous compounds. Single nucleotide polymorphisms (SNPs) in ATP-
binding cassette (ABC) and solute carrier transporter (SLC) genes have been 
increasingly recognized as a possible mechanism accounting for altered transport 
activity, which may have profound clinical implications (Leabman et al., 2003a). In 
general, genetic factors are estimated to account for 15-20% of inter-individual 
variations in drug disposition and responses (Choi and Song, 2008a, Evans and 
Relling, 1999, Eichelbaum et al., 2006). However, for certain drugs genetic factors 
can account for up to 95% of inter-individual variability in drug disposition and 
effect (Eichelbaum et al., 2006, Evans and Relling, 2004). 
Poly-specific organic cation transporters (OCTs) are involved in the sodium-
independent electrogenic transport of small organic cations (OCs) with different 
molecular structures (Koepsell et al., 2007b). These organic cations include 
clinically important drugs (metformin, cimetidine, procainamide), endogenous 
compounds (dopamine, norepinephrine, and toxic substrates (tetraethylammonium, 
haloperidol-derived pyridinium metabolite, 1methyl4phenylpyridinium) (Gorboulev 
et al., 1997a). Based on their substrate properties and tissue distributions, human 
OCT13 are thought to play important roles in the biliary and renal excretion of their 
substrates and the distribution of organic cationic drugs in the liver, kidney, heart, 
and brain (Jonker and Schinkel, 2004). 
The uptake transporter hOCT1 is encoded by the SLC22A1 gene which is located on 
chromosome 6q26, and consists of 11 exons spanning approximately 37kb 
(Gorboulev et al., 1997a, Koehler et al., 1997a, Koepsell et al., 2007b). hOCT1 is 
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primarily expressed in the sinusoidal or basolateral membrane of hepatocytes and is 
thought to play an important role in the hepatic uptake, distribution and excretion of 
clinically important drugs (Gorboulev et al., 1997a, Zhang et al., 1997). 
The role of hOCT1 in the clinical pharmacology of clinical therapeutics such as the 
antidiabetic drug metformin, the antineoplastic imatinib, the anti-HIV drug 
lamivudine, and the serotonin receptor type antagonists tropisetron and ondansetron 
has been extensively researched (Shu et al., 2007, Shu et al., 2008, Tzvetkov et al., 
2009). Moreover, a number of SLC22A1 variants have been associated with 
functional changes in protein activity, as well as drug disposition, response, and 
toxicity. For example, Bazeos et al. (2010) found that SLC22A1 transcript levels and 
SNPs can be predictive factors for response to imatinib in chronic myeloid leukemia 
(CML) (Bazeos et al., 2010). Previous studies have shown that hOCT1 is highly 
polymorphic in ethnically diverse populations (Sakata et al., 2004, Shu et al., 2003, 
Kang et al., 2007a). 
The hOCT2 gene SLC22A2, consisting of 11 exons, was first cloned in 1997 and is 
located on chromosome 6q26, adjacent to SLC22A1 which encodes for hOCT1 
(Gorboulev et al., 1997a, Koehler et al., 1997a, Koepsell et al., 2007b). The hOCT1 
paralogue hOCT2 consists of 555 amino acid residues and has been detected in the 
kidney, placenta, spleen, intestine, and neuron (Busch et al., 1998, Gorboulev et al., 
1997a, Koepsell et al., 2007b) 
Examples of clinically important drugs transported by hOCT2 include the 
antidiabetic drugs metformin and phenformin, the antineoplastic drugs cisplatin and 
oxaliplatin, the anti-HIV drugs lamivudine and zalcitabine, and the histamine 
receptor antagonist cimetidine (Barendt and Wright, 2002, Busch et al., 1998, 
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Ciarimboli et al., 2005b, Dresser et al., 2002, Kimura et al., 2005b, Jung et al., 
2008). In addition, hOCT2 is also responsible for the transport of endogenous 
compounds such as monoamine neurotransmitter 5-hydroxytryptamine (5-HT), 
agmatine, choline, dopamine, epinephrine, histamine, and norepinephrine, as well as 
compounds such as creatinine (Amphoux et al., 2006, Busch et al., 1998). 
Furthermore, this transporter is critical in the detoxification and elimination of 
xenobiotics from the systemic circulation and is also involved in the transport of 
toxic substances such as tetraethylammonium bromide (TEA), HPP+, and 
1methyl4phenylpyridinium (MPP+) (Burckhardt and Wolff, 2000, Gorboulev et al., 
1997a, Okuda et al., 1999, Otsuka et al., 2005, Zhang et al., 1997, Zhang et al., 
1998) 
The human organic cation transporter 3 (hOCT3), also known as extra-neuronal 
monoamine transporter (EMT), has a broad distribution and is found in various 
tissues, including the liver, heart, placenta, skeletal muscle, kidney, and brain 
(Gründemann et al., 1998, Wu et al., 2000). Moreover, hOCT3 is a poly-specific 
transporter that is involved in the cellular uptake and elimination of small OCs with 
different molecular structures. These OC substrates include endogenous bio-amines, 
clinically important drugs and xenobiotics. Examples of substrates transported by 
hOCT3 include the antidiabetic metformin, the biogenic amines histamine, 
dopamine, and epinephrine, and the xenobiotics tetraethylammonium bromide (TEA) 
and the neurotoxin 1methyl4pyridinium (MPP
+
) (Martel 2003). 
The gene encoding for hOCT3, SLC22A3, encodes a protein consisting of 556 
amino acid residues and is located on chromosome 6 where it is clustered together 
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with SLC22A1 and SLC22A2 the genes coding for hOCT3‘s paralogues hOCT1 and 
hOCT2, respectively (Koehler et al., 1997a, Verhaagh et al., 1999). 
These aforementioned reduced-function genetic variants were however primarily 
found in studies with European participants and have not been consistently replicated 
for other ethnic groups (Chen et al., 2010b, Leabman et al., 2003a). Recent reports 
using genome-wide polymorphisms suggested that: (i) genetic variation seen outside 
of Africa is generally a subset of the total genetic variation that exists within Africa, 
(ii) genetic diversity decreases with increased geographic distance from Africa, and 
(iii) linkage disequilibrium (LD) patterns increase proportionally to the distance from 
Africa (Jakobsson et al., 2008, Li et al., 2008, Tishkoff et al., 2009). Moreover, 
Rosenberg et al (2002) found that there is greater genetic diversity among African 
populations compared to Caucasian or Asian populations (Rosenberg et al., 2002). 
However, despite Africa harboring a significant proportion of human genomic 
diversity, this genomic diversity is unfortunately relatively understudied (Hardy et 
al., 2008, Tishkoff et al., 2009). 
South Africa is home to a large number of indigenous and immigrant population 
groups (Hardy et al., 2008, Benjeddou, 2010). Amongst these are the indigenous 
Khoisan, Xhosa, Zulu, Venda, and Sotho Pedi groups, the Afrikaners and the Cape 
Coloured, the latter being a uniquely admixed population of immigrant Europeans, 
Asians and the indigenous populations(Hardy et al., 2008). Admixed groups, such as 
Latinos, African Americans, or Cape Coloureds from South Africa, share varying 
proportions of different ancestral populations and their genetic complexity can 
potentially complicate biomedical research studies (Via et al., 2009a). This genomic 
diversity could provide a wealth of information and knowledge, which could 
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eventually be applied to aid our understanding of the impact of genetic variation on 
complex diseases such as cancer, diabetes mellitus, hypertension and the inter-
individual variability in response of patients to drugs used in the treatment of these 
diseases. Although limited, studies that have been conducted in South Africa suggest 
that South African populations have unique genetic profiles which include novel and 
rare variants, with allele frequencies differing from each other and other African 
populations (Warnich et al., 2011). 
Previous studies have shown that South African populations exhibit unique allele 
frequencies and novel genetic variations in pharmacogenomically relevant genes 
(Ikediobi et al., 2011). However, these studies have primarily focused on variants in 
drug metabolizing enzyme genes. Information on variants in drug transporter genes 
for South African populations is however limited or nonexistent. Therefore, the aim 
of this study was to investigate the genotypic and allelic distributions of thirty-eight 
SNP(s), and to infer the haplotype structure of the SLC22A1-3 genes in the CA 
population.  
2.3. Materials and Methods 
2.3.1. Subjects 
Samples were obtained from the participants with informed consent. This study was 
approved by the Senate Research Ethics Committee of the University of the Western 
Cape, South Africa. Biological samples were collected in the form of buccal swabs 
from 130 unrelated healthy volunteers from the CA population. Ethnicity of 
volunteers was determined by self-report. 
2.3.2. DNA extraction 
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Genomic DNA was isolated from buccal swab samples using a standard salt lysis 
protocol and stored frozen at 20°C until the time of genotyping (Leat et al., 2004).                                                                                                                                                
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2.3.3. SNP selection 
A total of 20 OCT1 gene SNPs (19 nonsynonymous and 1 intronic), 20 OCT2 gene 
nonsynonymous SNPs, and 18 OCT3 gene coding SNPs were selected for this study. 
SNPs were selected from the literature and the Ensembl database 
(http://www.ensebl.org) (Flicek et al., 2012). OCT1 variants A306T, A413V, 
M420V, C436F, I421F, V501E, V519F, and I542V, OCT2 variants M1V; R176H; 
C282G; L351W; R207H; T357M; M393T; R404C; G439E; R463K; R487Q R487W; 
V502E/G; and V502M, and OCT3 variants N162I; A169T; R212H; M248V; G269E; 
R293C; R310C; S337F; R348W; I381T; V388M; R403H; R407H; I431K; and 
R490Q were included in this study based on predicted effect on function, using the 
SIFT (Sorting Intolerant From Tolerant) program (Flanagan et al., 2010, Kumar et 
al., 2009, Ng and Henikoff, 2003). To our knowledge no population data exist in the 
public domain for these variants. 
2.3.4. Primer design 
Multiplex PCR primers, listed in Tables 2.3.12.3.3, were designed to have an 
annealing temperature between 55°C and 60°C using Primer3 software 
(www.genome.wi.mit.edu/cgibin/primer/primer3). To test for possible nonspecific 
amplification, primers were aligned with the NCBI sequence databases using Basic 
Local Alignment Search Tool (www.ncbi.nlm.nih.gov/blast/blastcgi). Two 
SNaPshot® Multiplex systems were specifically designed, for each gene, 
successfully optimized and used for genotyping. The single base extension primer 
sets for multiplex 1 and 2 are listed in Tables 2.3.4 (OCT1), Table 2.3.5 (OCT2) 
and Table 2.3.6 (OCT3). 
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Table 2.3.1 Multiplex PCR primers for the generation of SLC22A1 amplicons used in SNaPshot™ genotyping.  
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) 
Amplicon length 
 (bp) 
     
Exon 1 TGCTGAGCCATCATGCCCACCGTG GGACACAGCCAGACACCCACG 160121924 - 160122483 560 
Exon 2 CTCTTGCCGTGGTATGACTGGCAG CAGAGGGGCTTACCTGGACTGG 160130080 -160130240 161 
Exon 3 CCTCCATGTCTCCTTCTCTCTGAAG CTGGCCTCATCCCCATGATAATTAC 160132207 -160132411 205 
Exon 4 CCCGCATAACGTCCACACCTCCTG GTAGGCAGGAGGAAGGGCCTCAC 160133927 -160134148 222 
Exon 5 & 6 GATAGTGATGAGTGGTGTTCGCAG GCGAGCGTGCTGATTCTGCCT 160136196 -160136698 503 
Exon 7 GACTTGAAACCTCCTCTTGGCTCAG TTCCCCACACTTCGATTGCCTGGGA 160139628 -160139923 296 
Exon 8 GAAGCCCCCATCCACCACCCACACC GGCTACCCCTGTTCCATGCACTCAC 160143495-160143674 180 
Exon 9 ATTGCATGGGCAACGGATGGCT CCATGCTGAGCCCACTGCCGAGCTG 160154557-160154972 416 
Intron 9 GAGTAGGAGGGGTTAATAGAGAGAG GTAGCTGAGACTACATGCATGCACCAC 160151769-160152004 236 
Exon 10 TTCCTCTCTTTGGCTGGCTGTGA ACTCCAGCAAACCTTGCTCTCTGT 160155888-160156508 621 
Exon 11 TGCCCTTTTCTTCTTTGCTGTTTGC AGCACCAACAGCTTTCCCTAGATCG 160158364-160158823 460 
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Table 2.3.2 Multiplex PCR primers for the generation of SLC22A2 amplicons used in SNaPshot™ genotyping. 
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) 
Amplicon length 
(bp) 
     
Exon 1 TTTGGGAAGTGCAGAAGGAC CCATTTGCTTCTCCATCTGAG 160258972 - 160258303 670 
Exon 2 GGAACACTTCTCCCCTGCT CACCACAGGTGATTCAACCTAC 160256741 - 160256592 150 
Exon 3 GTGAATGGGGCTTATCATGC TCTATTTTGGCAGCGAGGTT 160250933 - 160250491 443 
Exon 4 CAGGCCTTTCATCCCATCTA GGGTCTGGAGAGTGAAAGCA 160249613 - 160249098 516 
Exon 5 GGATGGGGTAAGGAGGATTC TTTCTCCATCCCCTGATTTG 160247353 - 160247143 211 
Exon 6 TGACCCAGGGACACTAGCAT TACCGGGATGAGGTCATGTT 160245603 - 160245344 260 
Exon 7 CACAGCCAGCCACTGAAGTA GCTGGCCATATGAATTTGCT 160243961 - 160243408 554 
Exon 8 ATTCTGGGATGGGGAATTTG TCCTTTGTCTGCACTTGTGG 160242504 - 160242212 293 
Exon 9 AGGGGTGGATGGGAGATAAC ACATCCAGGAAGAACGCAAG 160241655 - 160241313 343 
Exon 10 TTCAATGGAGTTTGGAACTGG TGAATTTATCTCAGTGTATGGTGTGA 160224991 - 160224588 404 
Exon 11 AATTTCTTTCTCCCCTCTCCA TTTTAAAATCCACAAATGTTAAGACA 160217538 - 160216700 839 
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Table 2.3.3 Multiplex PCR primers for the generation of SLC22A3 amplicons used in SNaPshot™ genotyping.  
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) 
Amplicon 
length (bp) 
     
Exon 2 TGCATTCTGGCATGTCTCCATGTGT ACCGGGAACAGCCTCAGACCT 160397935 - 160398311 377 
Exon 3 GTTTAAGGTGAGCTCTTTTCCTGT TTGGCTCCCAAAGTAAGGTGG 160407004 - 160407404 401 
Exon 4 CTGCAAGTGTGGAAGCCTCCGT GCTGGGCAGCGTGATGGCTA 160408607 - 160408898 292 
Exon 5 TGCAGGAATAATCTGTATTTCAGGG ACTGAAAATGATTTCCCAGATGTT 160410569 - 160411034 466 
Exon 6 & 7 TGAAAGCCCCTAGTCACTTCAG TGGAGTGACATCACGAAAGACT 160436664 - 160437340 677 
Exon 8 CTTCAGACTGGAGGCCACTAAGCA ACGCTGGTCTACAGAGTTACTTAG 160442659 - 160442921 263 
Exon 9 GGATAACACCCTCCACCCAC ACTGAATTGGCTCTCAAAACTG 160443405 - 160443934 530 
Exon 10 TGTTTCCCTGTGATGCAGGA TGCTTCTCTCTTCACAACCACAT 160447401 - 160448051 651 
Exon 11 TGATCCTGGAGACAGATATTGTTGT GTCAGAGACCACAGGGAACA 160450844 - 160451347 504 
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2.3.5. Multiplex PCR 
The PCR reactions were performed in a 20 µl volume, containing 20 – 50 ng of 
genomic DNA, 1 x Qiagen multiplex PCR master mix (Qiagen, Courtaboeuf, 
France) and 0.2 µM of each primer. Cycling consisted of an initial 15-minute 
activation step for HotStar Taq polymerase at 95°C, followed by a total of 35 cycles 
using the following conditions: 94°C denaturation for 30 seconds, primer annealing 
at 60°C for 90 seconds, and primer extension at 72°C for 30 seconds, and 15 minutes 
of final extension at 72°C and a 4°C holding step. PCR products were purified to 
remove excess primers and unincorporated dNTPs using an Exo/SAP protocol. The 
entire 20 µl of PCR products were incubated with 0.5 µl of Exo1 and 1 µl of FastAP 
for 30 minutes at 37°C followed by 15 minutes at 80°C for enzyme inactivation. 
PCR quality and yield were checked using Nano-Drop. 
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Table 2.3.4 SLC22A1 multiplex 1 single base extension primers. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
Change 
Single Base Extension Primers 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Size bp 
Poly-GACT 
tail 
Multiplex 1       
rs34447885 S14F C/T TGACTATTCTGGAGCAGGTTGGGGAGT 160121976 40 13 
rs34104736 S189L C/T GAACTGTGCTGGTCAACGCGGTGT 160132282 45 21 
rs36103319 G220V G/T GGTCAGCAAGGGCAACTGGATGGCTG 160132375 50 24 
rs4646277 P283L C/T GATAACAGCCACCGGGGGACACC 160136228 55 32 
rs34130495 G401S G/A AGCCCTCATCACCATTGACCGCGTG 160139792 60 35 
rs72552763 M420V A/G AACTTACCAGGTGAGATAAAAATCA 160139849 65 40 
rs35956182 M440I G/A CATAATCATGTGTGTTGGCCGAAT 160143584 70 46 
rs34059508 G465R G/A CCACAGGGAGGAACACACCATCACTC 160154805 75 49 
rs78899680 V519P G/T CTACTTCTTCCAGAGACCAAGGGG 160156031 80 56 
rs137928512 I542V A/G CAGAGGTTTGGACCTTAAGGTAAA 160158541 85 61 
Multiplex 2       
rs622342 Intron A/C ATTTCTTCAAATTTGATGAAAACTTC 160151834 14 40 
rs12208357 R61C C/T TCCTGGGGTGGCTGAGCTGAGCCAG 160122116 20 45 
rs4646278 R287G C/G CAGTGTTTCTTTTTTGTGATAACAGCCACC 160136239 20 50 
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rs55918055 C88S T/A TCCAGTCCACTTCATAGCGCCTGC 160122197 31 55 
COSM164365 A306T G/A AGGAGGCAACTTCCCATTCTTTTGAG 160136296 34 60 
rs2282143 P341L C/T CTTCATTTGCAGACCTGTTCCGCACGC 160136611 38 65 
rs144322387 A413V C/T CCCCATGGCCATGTCAAATTTGTTGG 160139829 44 70 
rs151333280 I421F A/T CCAACTTACCAGGTGAGATAAAAA 160143571 51 75 
rs139512541 C436F G/T GCACTGGTTAAACATCATAATCATGT 160143571 54 80 
rs143175763 V501E T/A CACTCCCGCGGCAAGCAGGCCCAAC 160155979 60 85 
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Table 2.3.5 SLC22A2 gene multiplex 1 single base extension primers for SNaPshot™ genotyping assay of selected SNPs. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length 
(bp) 
Poly-GACT 
tail 
Multiplex 1      
rs57371881 R176H ATGAGGACTGTAGTTAGGAGGCAGAGCTTA rs57371881 30 0 
rs201919874 T199I CAGCTGGAGTTCTCATGGCCATTTCCCCAA 160250625 35 5 
rs8177508 M165V TCAGTGAATGTAGGATTCTTTATTGGCTCT 160256639 40 10 
rs144729356 C282G AGATCAGCCACCTGGGAGACTCAGGTATGC 160247297 45 15 
rs45599131 L351W GTGAAAAATATTCCTTACCAGTTGTACATC 160245451 50 20 
rs8177517 K432Q TCTTTTCCCTCTTAGATCTACAATGGCTA 160242388 55 25 
rs145450955 T201M CCTTGGATTAAGCGAAAAATTAACATCCAC 160250619 60 30 
rs316019 S270A CCTCACTGGAGGTGGTTGCAGTTCACAGTT 160249250 65 35 
rs8177516 R400C ATGCAGCCCAAGGGTAACGGCGTCCGATGC 160243653 70 40 
rs141582772 M1V GCAGCCTCGGGCCCTCCTGCCTGCAGGATC 160258757 75 45 
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Multiplex2      
rs141205337 M393T CGTCCGATGCGGTCGATGGTGAGGATGATC 160243673 30 0 
rs141405449 G439E ATCTCATAGGCCATTGTGATCCCCATTCTT 160242366 35 5 
rs3907239 R463K CCCTCGTCATTCTAAGGAAAATGCACTCAC 160242294 40 10 
rs184227446 T357M ATGATGAGGCCCTGGTAGAGCACAGAGCTC 160243781 45 15 
rs140829992 R487W GGTGGCATCATCACGCCATTCCTGGTCTAC 160241516 50 20 
rs17853948 V502E/G AGCACCAGACCTCCAGCAACCAAGCCAAGC 160224801 55 35 
rs137885730 R404C CAACCATATTTGATGCAGCCCAAGGGTAAC 160243641 60 30 
rs140033522 V502M ATGTGATATTCATCTGTTTGGCTTTCAGGC 160224802 65 25 
rs151282335 R487Q AGCGGGAGCTCAAGCCAGATGTTAGTGAGC 160241515 70 40 
rs199783132 R207H GCTGCTTTGCTGACCAGTCCTTGGATTAAGC 160250602 75 45 
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Table 2.3.6 SLC22A3 gene single base extension primers for SNaPshot™ genotyping assay of selected SNPs. 
NCBI 
(dbSNP) 
Amino 
Acid 
Change 
Nucleotide 
change 
Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length 
(bp) 
Poly-GACT 
tail 
Multiplex 1       
rs183669984 R310C C>T AAAGGAGATAAAGCATTACAGATCCTGAGA 160410799 30 0 
rs137958808 M370I G>T AAGCGCAGTGGTGTATCAAGGACTTGTCAT 160437033 35 5 
rs199688797 R212H G>A CACCAAACTTCCCTGTGTTTGTGATCTTCC 160407142 40 10 
rs150004342 A169T G>A ACCTGTCTGCTGCATAGCCTAAGGTGAATG 160398054 45 15 
rs142228053 R293C C>T TTCTTTGCCAGGGTGGTCCCTGAGTCTCCC 160410748 50 20 
rs149424049 I431K T>A AATGTAGCCACTGTGGTCCTCAACCATGCT 160442764 55 25 
rs147863404 G269E G>A AAGCTGGGCAGCGTGATGGCTAACTGGATT 160408870 60 30 
rs8187725 T400I C>T AAGGGGAGGCGTCGTCCAAGGCGCTCAATG 160437122 65 35 
rs149101094 M248V A>G CAAAGGAGGATTGTGGGAATCGTGATTCAA 160408806 70 40 
rs141104413 S337F C>T CTGTTACAGATGAGGAAGTTAGTAATCCAT 160436814 75 45 
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Multiplex 2       
rs139266499 N162I A>T GGATGCTGGACCTCACCCAAGCCATCCTGA 161081878 35 5 
rs145328121 R348W A>T TTTTTAGATCTGGTGAGAACTCCCCAAATG 160436846 45 15 
rs187750009 I381T T>C GCCTGGGAATTATAGGGGGCAACCTCTATA 160437065 50 20 
rs189883656 V388M G>A AGATCAAGAGAGCTCCTGGCAGTTCCACCA 160437085 55 25 
rs200478210 R403H G>A GAGCTCTCTTGATCTTACTAACCATTGAGC 160437131 60 30 
rs145082363 R407H G>A GCCACTATATTGCTTGCCGCAAAGGGGAGG 160437143 65 35 
rs12212246 A439V C>T CAGGAATAGCATGGTTGAGGACCACAGTGG 160442788 70 40 
rs144856002 R490Q G>A AGAGGTAGTTCTAGCCACACGGCTGCTAGC 160443701 75 45 
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2.3.6. Multiplex mini-sequencing reactions 
Multiplex mini-sequencing was performed in a 10 µl reaction volume using 3 µl of a 
1/10 dilution of purified PCR products, 0.10.2 µM of primers, and 5 µl of 
SNaPshot® (ThermoFisher Scientific, California, USA) ready reaction mix. 
Sequence cycling consisted of 25 cycles of denaturation at 96°C for 10 seconds, 
primer annealing at 50°C for 5 seconds, and primer extension at 60°C for 30 
seconds. Post-extension treatment was done by adding 1 U of FastAP to the 10 µl 
reaction volume and incubation at 37°C for 30 minutes followed by 15 minutes at 
80°C to deactivate the enzyme. 
2.3.7. Electrophoresis of the mini-sequencing products 
The purified mini-sequencing products (1 µl) were mixed with 8.7 µl of HiDi™ 
formamide and 0.3 µl of GeneScan120 Liz size standard (Also observed in the 
promoter region within the Xhosa population (Jacobs et al., 2015)) and denatured at 
95°C for 5 minutes. The fluorescently labelled fragments were separated on 36 cm 
long capillaries in POP4 polymer on an ABI Prism 3500 Genetic Analyzer (Also 
observed in the promoter region within the Xhosa population (Jacobs et al., 2015)). 
Data analyses were performed using GeneMapper® IDX Software Version 1.2. 
2.3.8. Statistical Analysis 
Genotype and allele frequencies as well as the deviation from the Hardy-Weinberg 
Equilibrium were calculated using GenAlEx 6.5 software (Peakall and Smouse, 
2012, Wigginton et al., 2005). Allele and genotype frequencies are given with 
binomial proportion 95% confidence intervals (CI) calculated according to the 
method of Wilson. The SHEsis analysis platform was used to infer the haplotype 
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frequencies (Yong and Lin, 2005, Li et al., 2009). Statistical significance was 
defined as p<0.05. 
 
2.4. Results 
The population studied consisted of 130 Cape Admixed individuals between the ages 
of 18 and 61 years. There were 46 (35%) female and 84 (65%) male participants. 
The mean age of female participants was 25.3±9.0 years, whereas male participants 
had a mean age of 24.8±7.7 years. 
OCT1 
The genotype and allele frequencies of the 20 OCT1 gene SNPs investigated in the 
130 Cape Admixed subjects are summarized in Table 2.4.1. The allelic frequency of 
each SNP was in HWE (p>0.05), except for rs622342. Twelve of the nineteen 
investigated nonsynonymous SNPs were monomorphic in the CA population. None 
of the participants were homozygous for the variant allele for S14F (rs34447885), 
P341L (rs2282143), and V519F (rs78899680). The S14F variant genotype 
frequencies for homozygote wildtype (CC), heterozygote (CT) and homozygote (TT) 
were 98%, 2% and 0.0%, respectively. The MAF observed for S14F was 1%. The 
P341L variant genotype frequencies, on the other hand, for homozygote wildtype 
(CC), heterozygote (CT) and homozygote (TT) were 96%, 1% and 0.0%, 
respectively. The S189L and G220V variants displayed the same genotype 
frequencies for their respective genotypes; 98%, 2% and 0.0%, respectively. 
Additionally, the M440I and G465R variants displayed the same genotype 
frequencies for homozygote wildtype (GG), heterozygote (GA) and homozygote 
(AA); 99%, 1% and 0.0%, respectively for each. Whereas the genotype frequencies 
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for variant V519F were 97% (homozygote wildtype (GG)) and 3% (heterozygote 
(GT)). Variants R61C (rs12208357), C88R (rs55918055), P283L (rs4646277) and 
G401S (rs34130495) were not observed in the Cape Admixed nor the Native 
American/Hispanic Admixed populations. The S14F variant was observed in the 
Cape Admixed and other Sub-Saharan populations, but not in all other populations. 
The S189L and G220V variants were only observed in the Cape Admixed 
population at a frequency of 1%. 
The inferred haplotypes for investigated population are listed in Table 2.4.3. The 
most frequently observed haplotypes were CCTCGGCGCGCTAGAGCTGA (80%), 
CCTCGGCGCGCTAGCGCTGA (9.9%) and CCTCGGCGCGCGAGCGCTGA 
(3.5%).  
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Table 2.4.1 Genotype and allele frequencies of OCT1 (SLC22A1) gene SNPs in 130 
healthy CA individuals. 
Amino Acid 
Substitution 
dbSNP ID 
 
Observed Genotype 
Frequency 
 Allele Frequency  
Genotyp
e 
% 95% CI Allele % 95% CI 
HWE 
(P) 
         
S14F rs34447885 
CC 97.8 92.6 – 100.0 C 98.3 92.9 – 99.8 
0.920 CT 2.2 0.4 – 6.2 T 1.7 0.2 – 7.04 
TT 0.0 0.0 – 3.1    
         
R61C rs12208357 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
C88R rs55918055 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
S189L rs34104736 
CC 98.1 92.6 – 100.0 C 98.1 92.3 – 99.9 
0.920 CT 1.9 0.4 – 6.2 T 1.9 0.2 7.0 
TT 0.0 0.0 – 1.3    
         
G220V rs36103319 
GG 98.1 92.6 – 100.0 G 98.1 92.3 – 99.9 
0.920 GT 1.9 0.4 – 6.2 T 1.9 0.2 7.0 
TT 0.0 0.0 – 1.3    
         
P283L rs4646277 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3  0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
P341L rs2282143 
CC 96.2 92.6 – 98.9 C 98.6 92.3 – 99.9 
0.998 
CT 3.8 0.4 – 6.2 T 1.4 0.2 7.0 
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TT 0.0 0.0 – 3.1    
         
G401S rs34130495 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 1.6 
AA 0.0 0.0 – 1.3    
         
M440I rs35956182 
GG 99.0 92.6 – 100.0 G 99.0 92.3 – 99.9 
0.999 GA 1.0 0.4 – 6.2 A 1.0 0.2 7.0 
AA 0.0 0.0 – 1.3    
         
G465R rs34059508 
GG 99.0 92.6 – 100.0 G 99.0 92.3 – 99.9 
0.999 GA 1.0 0.4 – 6.2 A 1.0 0.2 7.0 
AA 0.0 0.0 – 1.3    
         
V519F rs78899680 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
Intronic SNP rs622342 
AA 67.9 59.9 – 75.1 A 96.9 91.5 – 99.4 
0.871 AC 30.1 21.2 – 39.9 C 3.1 0.6 – 8.5 
CC 2.4 0.4 – 6.2    
         
R287G rs4646278 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
I542V rs137928512 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
  AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
 
  GG 0.0 0.0 – 1.3     
         
M420V rs142448543 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
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AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
A413V rs144322387 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
I421F rs151333280 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
C436F rs139512541 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
V501E rs143175763 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
A306T COSM164365 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
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Table 2.4.2 Comparison of MAF of SLC22A1 gene SNPs of the CA population to other ethnic groups. 
dbSNP ID 
Amino acid 
change 
Minor 
Allele 
Minor Allele Frequency (%) 
CAa Luhyab Yorubab African-Americanc Japanesed Chinese-Hanb Caucasian-Finishb Caucasian-Americane 
rs34447885 S14F T 1.0 2.6 1.7 3.1 0.0 0.0 0.0 0.0 
rs12208357 R61C T 0.0 0.0 0.0 0.0 0.0 0.0 5.4 7.2 
rs55918055 C88R A 0.0 0.0 0.0 ND ND 0.0 0.0 0.6 
rs34104736 S189L T 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 
rs36103319 G220V T 1.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 
rs4646277 P283L T 0.0 0.0 0.0 ND ND 0.5 1.3 ND 
rs2282143 P341L T 0.5 8.0 9.0 8.2 16.8 12.4 16.7 0.0 
rs34130495 G401S A 0.0 0.0 0.0 0.7 0.0 0.0 1.6 1.1 
rs35956182 M440I A 0.5 0.0 0.0 0.5 0.0 0.0 2.7 0.0 
rs34059508 G465R A 0.5 0.0 0.0 0.0 0.0 0.0 1.1 4.0 
rs78899680 V519F T 1.5 2.0 6.0 ND ND 0.0 0.0 ND 
rs622342 Intronic C 18.0 22.0 15.0 ND ND 13.2 37.1 ND 
This study; b. Data from 1000Genomes; c. Data from (Shu et al., 2003); d. Data from (Itoda et al., 2004) 
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Figure 2.4.1. Allele frequencies of selected SLC22A1 SNPs in the CA population compared to other African and world populations. 
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Table 2.4.3 Haplotype structure defined by 20 SNPs in the SLC22A1 gene in the CA 
population. 
Haplotype No. Haplotype 
a
 Frequency % 
1 CCTCGGCGCGCTAGAGCTGA 80.0 
2 CCTCGGCGCGCTAGCGCTGA 9.9 
3 CCTCGGCGCGCGAGCGCTGA 3.5 
4 CCTCGGCGGGCTAGAGCTGA 1.5 
5 CCTCGGCGCGCTAGCGCTTA 1.1 
6 TCTTTGCGCGCTAGCGCTGA 1.0 
7 CCTCGGCGCGCTAGCGTTGA 0.6 
8 CCTCGGAGCGCTAGAGCTGA 0.5 
9 CCTCGGCGCGCGAGCACTGA 0.5 
10 CCTCGGCGCGCTAGCGATGA 0.5 
11 CCTCGGCGTGCTAGCGCTGA 0.5 
12 CCTCGGCGCGCTAGCGTTTA 0.4 
 TOTAL 100 
a) Haplotype sequences are based on the position of SNPs on chromosome 6. 
 
OCT2 
The genotype and allele frequencies of the 20 investigated SNPs of the OCT2 gene 
within a group of 130 Cape Admixed subjects are summarized in Table 2.4.4. The 
allelic frequency of each SNP was in HWE (p>0.05). Sixteen of the eighteen 
investigated non-synonymous SNPs were monomorphic in the Cape Admixed 
population. Heterozygosity was only observed for the non-synonymous SNP variants 
R176H (rs57371881) and S270A (rs316019). The R176H variant genotype 
frequencies for homozygote wildtype (CC), heterozygote (CT) and homozygote (TT) 
were 91%, 9% and 0.0%. The MAF observed for R176H was 4.5%. Variant S270A 
displayed a genotype frequency of 90% homozygous (CC), 6% heterozygous (CA) 
and 4% homozygous (AA) for the Cape admixed population.  
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The MAF of a selected number of the investigated OCT2 gene SNPs in different 
ethnic groups are summarized in Table 8. Inferred haplotypes for each population are 
listed in Table 2.4.5. The most frequently observed haplotypes were 
CATAATGCGTACGCGCGACG (~85%), CATAATGATTACGCGCGACG (~7%) and 
CATAATGAGTACGCGCGACG (~4.5%).  
 
 
 
Figure 2.4.2. Typical electropherogram of SLC22A2 multiplex 1 mini-sequencing 
fragments. Black represents C, green A, blue G, and red T. 
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Table 2.4.4 Genotype and allele frequencies of 20 known SLC22A2 coding SNPs in 
130 healthy Cape Admixed individuals. 
Amino Acid 
Substitution 
dbSNP ID 
Observed Genotype Frequency Allele Frequency 
Genotype % 95% CI Allele % 95% CI 
HWE 
(P) 
         
M1V rs141582772 CC 100.0 96.9 – 100.0 C 98.3 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3 T 1.7 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
        
 
M165V rs8177508 TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 
TC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
        
 
R176H rs57371881 TT 91.3 85.4 – 96.6 T 92.2 86.7 – 97.3 
0.637 
TA 8.7 3.4 – 14.6 A 3.8 0.2 – 7.8 
AA 0.0 0.0 – 1.3    
        
 
T199I rs201919874 CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3 T 0.0 0.0 1.6 
TT 0.0 0.0 – 1.3    
        
 
T201M rs145450955 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 
GT 0.0 0.0 – 1.3 T 0.0 0.0 1.6 
TT 0.0 0.0 – 1.3    
        
 
R207H rs199783132 CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3  0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3  
  
      
   
S270A rs316019 CC 89.3 82.5 – 95.1 C 91.3 86.7 – 97.3 
0.655 
CA 6.7 2.0 – 12.0 T 7.4 2.7 13.3 
AA 4.0 0.2 – 7.8     
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C282G rs144729356 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 
GA 0.0 0.0 – 1.3 A 0.0 0.0 1.6 
AA 0.0 0.0 – 1.3    
        
 
L351W rs45599131 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 
GA 0.0 0.0 – 1.3 A 0.0 0.0 1.6 
AA 0.0 0.0 – 1.3    
         
T357M rs184227446 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0  
  GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6  
  AA 0.0 0.0 – 1.3     
         
M393T rs141205337 GG 100.0 88.6 – 96.9 G 100.0 98.4 – 100.0  
GT 0.0 0.0 – 1.3 T 3.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R400C rs8177516 CC 100.0 88.6 – 96.9 G 100.0 98.4 – 100.0  
CT 0.0 0.0 – 1.3 T 3.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R404C rs137885730 CC 100.0 87.8– 96.4 C 100.0 98.4 – 100.0  
CG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
K432Q rs8177517 AA 100.0 88.6 – 96.9 G 100.0 98.4 – 100.0  
AC 0.0 0.0 – 1.3 T 3.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
G439E rs141405449 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
R463K rs3907239 CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0  
CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R487Q rs151282335 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R487W rs140829992 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0  
GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
V502E/G rs17853948 TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0  
TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
V502M rs140033522 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0  
GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
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Table 2.4.5 Comparison of MAF of selected SLC22A2 SNPs in the local populations 
to other ethnic groups. 
dbSNP ID 
Amino 
acid 
change 
Minor 
Allele 
Minor Allele Frequency (%) 
Cape 
Admixeda 
Luhyab Yorubab 
African-
Americanb 
Japaneseb 
Chinese-
Hanb 
Caucasian-
Finishb 
Caucasian-
Americanb 
           
rs8177508 M165V C 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 
rs201919874 T199I G 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 
rs145450955 T201M A 0.0 0.0 0.0 0.0 2.2 0.5 0.0 0.0 
rs199783132 R207H T 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 
rs316019 S270A A 7.1 16.0 15.9 14.8 0.0 14.7 5.9 8.8 
rs8177516 R400C T 0.0 0.0 2.3 1.6 0.0 0.0 0.0 0.0 
rs8177517 K432Q G 0.0 5.2 6.2 1.6 0.0 0.0 0.0 0.0 
rs57371881 R176H T 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
a. This study; b. Data from 1000 Genomes 
 
Table 2.4.6 Haplotype structure of SLC22A2 gene in the Cape Admixed population 
as defined by the 20 selected loci. 
Haplotype Id Haplotype Frequency 
Haplotype *1 C A T A A T G C G T A C G C G C G A C G 83.4% 
Haplotype *2 C A T A A T G A G T A C G C G C G A C G 6.8% 
Haplotype *3 C A T A A T G C G T A C G C G C G A C T 5.3% 
Haplotype *4 T A T A A T G C G T A C G C G C G A C G 4.1% 
Haplotype *5 T A T A A T G C G T A C G C G C G A C T 0.2% 
Haplotype *6 T AT A A T G A G T A C G C G C G A C G 0.2% 
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 Figure 2.4.3. Allele frequencies of selected SLC22A2 SNPs in the CA population compared to other African and world populations.
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OCT3 
In this study we have developed two SNaPshot™ multiplex assays for genotyping 18 
known nonsynonymous coding SNPs in the SLC22A3 gene. The genotype and allele 
frequencies of the 18 SLC22A3 gene SNPs investigated in the 130 CA subjects are 
summarized in Table 2.4.7. All 18 coding SNPs genotyped in this study were 
monomorphic in the CA population. 
Table 2.4.7 Genotype and allele frequencies of the OCT3 (SLC22A3) gene SNPs in 
130 healthy Cape Admixed individuals. 
Amino Acid 
Substitution 
dbSNP ID 
Observed Genotype Frequency Allele Frequency 
Genotype % 95% CI Allele % 95% CI 
HWE 
(P) 
         
N162I rs139266499 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 
AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
A169T rs150004342 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
R212H rs199688797 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
M248V rs149101094 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 1.6 
GG 0.0 0.0 – 1.3    
         
G269E rs147863404 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 1.6 
AA 0.0 0.0 – 1.3    
         
R293C rs142228053 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R310C rs183669984 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
S337F rs141104413 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3 T 0.0 0.0 1.6 
  TT 0.0 0.0 – 1.3     
         
R348W rs145328121 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 1.6 
TT 0.0 0.0 – 1.3    
         
M370I rs137958808 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
I381T rs187750009 TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
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  TC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
 
  CC 0.0 0.0 – 1.3     
         
V388M rs189883656 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 
GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
T400I rs8187725 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R403H rs200478210 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
R407H rs145082363 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
A439V rs12212246 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3     
         
I431K rs149424049 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 
TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3     
         
R490Q rs144856002 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
 
2.5. Discussion 
2.5.1. OCT1 
Single nucleotide polymorphisms in OCT1 gene have been recognized as a possible 
mechanism explaining inter-individual variation in drug response (Leabman et al., 
2002b). In this study, we determined the genotypic and allelic frequencies of 20 
SNPs in the OCT1 gene from 100 healthy individuals in the Cape Admixed 
population, and the data was compared to other population data available in literature 
and relevant databases.  
In a study conducted by Leabman et al. (2002) numerous polymorphisms within the 
SLC22A1 gene were identified, and have constituted the focus of many subsequent 
studies. Furthermore, it was determined that these variant might predict functional 
changes of the transporter protein (Leabman et al., 2002b). Several SNPs were found 
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to be protein-altering variants. This became important as these inherited differences 
may contribute to the inter-individual variability in drug response (Leabman et al., 
2002b, Shu et al., 2008). Fifteen of these protein-altering SNPs were also 
characterized and evaluated with respect to MPP
+
 uptake (Shu et al., 2008). It was 
determined that the variant S14F increased function of the transporter protein, 
whereas variants S189L, M420V and M440I were shown to exhibit the same 
functionality as the reference transporter. Furthermore, R61C and P341L were 
identified as reduced function variants, whereas variants G220V, G401S and G465R 
exhibited a loss of function compared to the reference sequence (Leabman et al., 
2002b). In subsequent studies, by Shu et al (2008) and Tzvetkov et al (2009), 
evaluating the effect OCT1 variants have on metformin uptake, it was shown that the 
R61C, G401S, M420V and G465R variants all exhibited a reduction in transporter 
function. In a prior study by Kerb et al (2002), the uptake of 0.1 [3H]-1methy-l4-
phenylpyridinium-([3H]MPP) by R61C, C88R and G401S were reduced to 30, 1.4 
and 0.9% compared to wildtype, respectively. The transport of 1 µM [3H] serotonin 
by C88R and G401S, on the other hand, was reduced to only 13 and 12% of 
wildtype respectively (Kerb et al., 2002). From the data obtained, Kerb et al (2002) 
suggested that mutants R61C, C88R and G401S could affect the disposition of 
hOCT1 substrates in terms of affinity and selectivity. This has led them to conclude 
that the duration and intensity of effects of drugs and neurotransmitters may be 
altered for these substrates (Leabman et al., 2002b). In the present study, 19 protein-
altering SNPs were evaluated within the Cape Admixed population. The intronic 
SNP (rs622342) was also included in the study because it was previously suggested 
to be associated with the blood glucose-lowering effect of metformin (Fujita et al., 
2006). 
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Variant S14F was observed in the Cape Admixed, Luhya and Yoruba populations at 
a MAF of 1%, 2.5% and 1.5% respectively. This variant was not observed in any of 
the other populations included in the analysis (Table 2.4.2). Therefore, it may be 
suggested that OCT1 substrate drugs might have different response profiles in the 
Cape Admixed and African populations compared to Caucasian and Asian 
populations. 
The G220V variant was observed in the Cape Admixed population with MAF of 1%, 
whereas, the other reduced-function variants G401S and G465R were not observed 
in the population. This may suggest an increased therapeutic response to metformin 
for our population (Becker et al., 2009a). The G401S and G465R variants were only 
observed in the Caucasian population at a MAF of 2.3% and 3.4% respectively. 
These variants were not observed in the African and Asian populations (Table 
2.4.2). 
The MAF of P341L observed in the Cape Admixed population (0.5%) was lower 
than that of other Sub-Saharan African, Asian and Caucasian populations (Table 
2.4.2). Functional in vitro transport assays have shown that the P341L variant results 
in a decrease rate of MPP+ transport, and has no effect on the transport of the 
antidiabetic drug metformin (Becker et al., 2009a, Crawford and Nickerson, 2005) 
The observed MAF at loci S189L, M440I and M420V was 1%, 0.5% and 4% 
respectively. However, S189L was only observed in the Cape Admixed population 
whereas M440I was observed in the Cape Admixed and Native American/Hispanic 
Admixed populations at a similar frequency (Table 2.4.2). Although at low 
frequencies, these variants are suggested to have a reduced transporter function with 
respect to metformin (Fujita et al., 2006). 
 
 
 
 
CHAPTER 2 
 84 
The observed MAF for variant V519P in our population was 1.5%. This value was 
lower than that of the Luhya and Yoruba, with respective values of 2% and 6% 
(Table 2.4.2). However, this variant was not observed in any of the other 
populations, indicating that it might be specific to African populations. The impact 
of this variant on transport function or drug efficacy has not yet been determined and 
requires further investigation. 
The intronic SNP (rs622342) was observed in the Cape Admixed population at lower 
MAF (18%) compared to previously reported frequencies for the European 
population (table 2.4.2). This includes the Dutch diabetic patients cohort where the 
variant was initially reported (Becker et al., 2009a). In this population-based cohort 
study, Becker et al (2009) concluded that an association existed between genetic 
variation in the gene encoding for the OCT1 transporter protein and the glucose 
lowering effect of metformin in diabetes mellitus patients, and that metformin 
therapy was less effective in patients carrying the minor C allele. 
Twelve out of the nineteen investigated non-synonymous SNPs were monomorphic 
in the study population. No polymorphisms were observed for these SNPs and they 
were all homozygous for the ancestral allele. This includes variants R61C, C88S, 
P283L, R287G, A306T, G401S, A413V, M420V, I421F, C436F, V501E and I542V. 
The population data available in the databases and the literature for variants R61C, 
C88S, P283L and G401S is limited, and low MAFs are usually reported for these 
SNPs. To our knowledge, this study is the first to report population data for A306T; 
A413V; M420V, C436F; I421F: V501E, V519F and I542V. Further investigations 
are needed to explore the genetic variations among these SNPs in world populations. 
The haplotype structure defined by 20 SNPs in the SLC22A1 gene was also inferred 
for the Cape Admixed population. A total of 12 haplotypes were observed in the 
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study population (Table 2.4.3). Haplotype structure could provide a more complete 
picture of genetic variations at multiple loci important in drug response at the 
individual and population level (Crawford and Nickerson, 2005).  
In our study population, it could be interesting to investigate the overall effect of the 
observed rare haplotype on the transport efficiency of the OCT1 protein, as well as 
possible clinical implications related to therapeutic drugs including metformin. This 
rare haplotype includes variants S14F, S189L, G220V and the intronic SNP 
rs622342, where further investigations are required to determine the cumulative 
effect of these variants on substrate transport efficiency and glucose-lowering effect 
of metformin.  
2.5.2. OCT2 
Drug transporters modulate the absorption, distribution, and elimination of drugs by 
controlling the influx and efflux of drugs in cells. Increasing evidence indicates 
genetic polymorphisms of transporters can have profound impact on drug 
disposition, drug efficacy, and drug safety (Ma and Lu, 2011). Single nucleotide 
polymorphisms in OCT2 gene have been recognized as a possible mechanism 
explaining inter-individual variation in drug response (Leabman et al., 2003b). In 
this study we compared the genotypic and allelic frequencies of 20 SNPs in the 
OCT2 gene from 140 healthy individuals in the Cape Admixed population. 
In cellular studies, the variant S270A has been shown to variably alter the transport 
function of OCT2. (Leabman et al., 2002b) showed that the S270A variant had a Km 
value for MPP
+ 
uptake which was not significantly different from that of the OCT2 
reference in oocytes. (Kang et al., 2007b) reported that the uptakes of MPP
+
 and 
TEA were about 40% lower in MDCK cells transiently transfected with 
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OCT2A270S variant than that in MDCK cells transiently transfected with reference 
OCT2. (Choi et al., 2012) determined that this variant decreased uptake of MPP
+
, 
TEA and Lamivudine in oocytes when compared with the wild type. Furthermore, it 
has been shown to decrease metformin transport activity and renal (tubular) 
clearance (Song et al., 2008b, Wang et al., 2008b). (Li et al., 2010) determined that 
individuals carrying the AA-genotype were not able to effectively bind metformin 
and excrete it via urine, thereby increasing the blood concentration of metformin and 
decreasing renal uptake of the drug. The S270A variant was observed in the CA 
population with a MAF of 7%which is lower than the average MAF of 12% for 
global populations (Table 2.4.5).  
Interestingly, no data exists in the public domain on variant R176H. It should be 
noted that further investigation into the effect this variant has on protein regulation 
and expression is required and, therefore, should be included in future transport and 
efficacy assays. 
In this study the 20 investigated nonsynonymous SLC22A2 SNPs showed a low level 
of heterozygosity, with roughly 95% of the loci displaying monomorphism (Table 
2.4.4). This study once again highlighted the fact that the distribution of SNPs and 
the MAFs thereof differ between the Cape Admixed and other populations, and even 
amongst African populations themselves. These differences in allele frequencies, 
although not fully understood, might provide us with the insight into interethnic and 
inter-individual variability in drug response for substrate drugs of hOCT2. 
Moreover, the single SNPs identified and haplotypes inferred for these populations 
may be important in future pharmacogenomic in identifying association between 
causative variants and altered drug response.  
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2.5.3 OCT3 
In the current study we genotyped 18 known SNPs in the SLC22A3 gene of 130 CA 
individuals residing in the Cape Town metropolitan area, South Africa. We observed 
no genetic variation for the 18 noncoding SNPs genotyped in the investigated 
population (Table 2.4.7). However, this lack of genetic variation in the coding 
region of SLC22A3 in the CA population is not a unique situation and has also been 
observed in other populations (Kang et al., 2007a, Lazar et al., 2003). Moreover, 
according to Lazar et al. (2008), this high degree of genetic preservation and lack of 
protein sequence variation may reflect the crucial physiological role hOCT3 plays in 
maintaining homeostasis (Lazar et al., 2008). 
Unlike its paralogues hOCT3 has a broad distribution in the human body and 
because of its localization in the CNS and its affinity for monoamines is believed to 
play a significant role in neuropsychiatric disorders. Methamphetamine (MAP) is a 
powerful highly addictive psychostimulant that affects the CNS. The illicit us of 
MAP has become a growing problem in a number of countries over the last two 
decades, and has recently emerged as a significant problem in South Africa 
(Plüddemann et al., 2010). Smoking crystalline MAP has been associated with high 
levels of harm. The most salient harms associated with MAP use are mental health 
problems, including psychosis, depression, anxiety, and violent behaviour. Ayoma et 
al. (2006), in a study with Japanese MAP users, found that SLC22A3 polymorphisms 
may be related to the development of polysubstance use in patients with MAP 
dependence (Aoyama et al., 2006). The polymorphisms used in the Aoyama study 
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were not included in the present study and as such no inferences can be drawn. 
However, given the health problems associated with, and the current prevalence of 
MAP use in South Africa, the role of genetic polymorphisms of SLC22A3 in the 
development of polysubstance use in individuals with MAP dependence in 
indigenous African populations need further investigation. 
The role of hOCT3 in monoamine transport in vivo is well established. Because of its 
role in monoamine transport and its localization in the CNS, hOCT3 has also been 
implicated in non-neuronal termination of noradrenergic signalling in the CNS and 
as a candidate gene for a variety of neuropsychiatric disorders (Lazar et al., 2008, 
Wultsch et al., 2009). Moreover, Lazar et al. (2008) identified two SNPs, 
106/107delAG and Met370Ile in a group of Caucasian patients diagnosed with 
obsessive compulsive disorder (OCD), which lead to a decrease in promoter activity 
and transport of norepinephrine, respectively, in assays performed in vitro (Lazar et 
al., 2008). Haenisch et al. (2012) showed that two psychoactive drugs nefazodone 
and clozapine had the potential to inhibit hOCT3 activity. However, their study was 
unable to demonstrate whether this direct inhibition of hOCT3 plays a role in the 
clinical effects of these drugs (Haenisch et al., 2012). 
The ubiquitously expressed hOCT3 has not only been implicated in the transport of 
anticancer drugs, but more recently also as a biomarker for cancer pathogenesis. For 
example, in colorectal cancers hOCT3 together with its paralogues, hOCT1 and 
hOCT2, have been shown to be determinants of oxaliplatin cytotoxicity (Yokoo et 
al., 2008, Zhang et al., 2006). Moreover, SLC22A3 expression in renal cell 
carcinoma cell lines enhances the sensitivity of these cell lines towards the 
chemotherapeutic agents melphalan, irinotecan, and vincristine (Shnitsar et al., 
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2009). Cui et al. (2011) recently identified the SLC22A3 SNP rs7758229 as a risk 
locus for distal colon cancer in an Asian population (Cui et al., 2011). In addition, a 
study by Grisanzio et al. (2012) showed that SLC22A3 is inversely correlated with 
prostate cancer progression, with markedly decreased expression in aggressive 
prostate cancers (Grisanzio et al., 2012). 
Metformin is a biguanide antidiabetic drug and is widely used as a first-line 
therapeutic in the treatment of type2 diabetes. Earlier studies have shown that 
metformin is transported by hOCT1 and hOCT2, and that genetic polymorphisms of 
these transporters affect the pharmacokinetic and therapeutic effect of the drug 
(Becker et al., 2009a, Becker et al., 2010, Kimura et al., 2009, Shu et al., 2007, Shu 
et al., 2008). Recent studies have now also implicated hMATEs and hOCT3 in 
metformin absorption, disposition, and pharmacological action (Becker et al., 2010, 
Chen et al., 2010a). Chen et al (2010) found that the hOCT3 variant T400I 
significantly reduced metformin uptake by the transporter (Chen et al., 2010a). 
Structural modelling suggested that this variant may be located in the pore lining of 
the TMHs, where it plays a critical role in substrate translocation. The T400I variant 
is a rare variant that has a low allele frequency and was not observed in the 
individuals that participated in this study. Given the prevalence of type2 diabetes in 
South Africa and the widespread use of metformin as a therapeutic, the distribution 
of this variant in the indigenous African populations require further investigation. 
The effect of this variant in vivo on metformin pharmacokinetics and efficacy has not 
been demonstrated yet, but should be assessed if the T400I variant is identified in the 
CA or any of the indigenous African populations. 
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Ideally a larger sample size and complete sequencing of the SLC22A3 gene would 
provide a more complete picture of the spectrum of genetic variation within this gene 
for the Cape Admixed population. In addition, a number of SNPs in the proximal 
promoter region had been associated with altered expression of the SLC22A3 gene 
previously, however the current approach of genotyping coding SNPs only, excluded 
these variants from being assayed. Furthermore, although medical research has 
primarily focused on protein-coding variants, this picture has changed with advances 
in the systematic annotation of functional noncoding elements (Ward and Kellis, 
2012). However, the genotyping strategy adopted in this study have excluded the 
typing of noncoding SNPs, which could be useful when performing linkage 
disequilibrium analysis or extracting information about disease association. 
2.6. Conclusions 
To our knowledge, this is the first study that investigated the allele and genotype 
frequency distributions of SNPs in the SLC22A1-3 genes of the CA population. This 
study also reports the observed haplotypes in the investigated population. It has also 
been shown that reduced-function nonsynonymous SNPs in the SLC22A1-3 genes 
found in Caucasian and Asian populations are absent from the CA population. We 
have shown that, although MAF observed for the CA population is largely similar to 
other African populations, differences exist that may translate into differences in 
organic cationic drug transport between these ethnic groups. These variations may 
translate into differences in the transport and efficacy of organic cationic drugs 
commonly used for the treatment of diseases prevalent in Africa. However, it should 
be noted that this was only a descriptive study and that no associations are made 
between any diseases or treatment outcomes. Although, it is well known that 
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individual variation in drug response can be attributed to specific genetic variants. 
Moreover, it is believed that the incorporation of haplotypes in pharmacogenomic 
studies will provide a more complete picture of loci that are relevant in the practice 
of ―genetic medicine‖ both at an individual or population level (Crawford and 
Nickerson, 2005). This study contributes towards filling the gap that exists with 
regards to genetic information about important variations in organic cation 
transporter genes, such as SLC22A1-3, for the indigenous populations of South 
Africa given that organic cationic drugs are used in the treatment of diseases such as 
type-2 diabetes mellitus, various cancers, and HIV, these variants may impact 
profoundly on healthcare provided over the African continent. Therefore, given the 
aforementioned reasons studies such as this is valuable in the generation of useful 
pharmacogenomic information specific for Admixed populations. 
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CHAPTER 3 
Assessment of Genetic Variations within the SLCO1B1 Gene of the Cape 
Admixed Population 
 
3.1. Abstract 
Human organic anion transporter OATP1B1 plays an important role in the transport 
of a wide variety of substrates. It includes bile salts, steroid conjugates cyclic 
peptides, drugs such as benzylpenicillin, methotrexate, pravastatin and rifampicin, 
and natural toxins microcystin and phalloidin. Numerous polymorphisms have been 
discovered in the SLCO1B1 gene. This includes RS4149056 and RS2306283, two of 
the most characterized SNPs in this gene. A SNaPshot® mini-sequencing panel was 
designed and optimized to investigate genetic variants in admixed and indigenous 
populations. The minor allele frequencies (MAF) of genetic variants observed were 
compared between the local populations and world populations. Possible clinical 
implications were determined. The observed MAFs for the coding region SLCO1B1 
variants V174A (rs4149056), L191L (rs4149057), P155T (rs11045819), and F199F 
(rs2291075) were 60.0%, 47.5%, 21.5%, 16%, respectively, for the CA population. 
The observed MAFs in the CA population for the intronic variants Rs4149032 and 
Rs4149081 were 36% and 8.3%, respectively. The most frequently observed 
haplotypes were TATCGACGACCCGATGTGAT (10.8%), 
CATCGACGACCCGATGTGAT (9.1%), TACCGACGACCCGATGTGAT (7.9%). 
The mixed ancestry can potentially provide the intrinsic variability needed to unravel 
intricate gene-environment interactions, which may help explain the population 
differences in the epidemiology of complex disease.  
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3.2. Introduction 
OATP1B1 is encoded by the SLCO1B1 gene, located on chromosome 12 (12p12). 
OATPs are sodium-independent uptake transporters that mediate the influx of a 
variety of amphipathic compounds. Their transport mechanism is electroneutral 
exchange, coupling the cellular uptake of organic compounds with the efflux of 
neutralizing anions such as bicarbonate, glutathione and glutathione-S-conjugates (Li 
et al., 1998, Satlin et al., 1997). The majority of OATPs transport a wide assortment 
of amphipathic organic compounds (Bossuyt et al., 1996). OATP1B1 is expressed at 
the basolateral plasma membrane of hepatocytes (Abe et al., 2001) and has a total 
mass of 84kDa, which is reduced to 54kDa after de-glycosylation (Konig et al., 
2000). Since it is primarily expressed in the human liver it is suggested that 
OATP1B1 plays a critical role in the hepatic clearance of albumin-bound 
amphipathic compounds (Hagenbuch and Meier, 2004). This includes bile salts, 
conjugated and unconjugated bilirubin, BSP, steroid conjugates, thyroid hormones 
T4 and T3, eicosanoids, cyclic peptides, drugs including benzylpenicillin, 
methotrexate, pravastatin and rifampicin as well as natural toxins such as mircosystin 
and phalloidin  (Hagenbuch and Meier, 2003).  
Numerous synonymous and nonsynonymous SNPs have been discovered on the 
SLCO1B1 gene. Many of these variants have been shown to affect transport function, 
both in vitro and in vivo (Iwai et al., 2004, Tirona et al., 2001). Furthermore, it is 
recognized that the majority of these SNPs span the transmembrane domain or 
extracellular loop 5 of OATP1B1 (Iwai et al., 2004, Tirona et al., 2001). This 
includes RS4149056 and RS2306283, the most well characterized SNPs in this gene, 
which produce amino acid changes Val174Ala and Asn130Asp respectively. 
However, when the effects of particular SNPs are evaluated it is important to take 
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into account the underlying haplotype these SNPs are found in (Mwinyi et al., 2008). 
For example, the abovementioned SNPs are in linkage equilibrium and exist in 
varying haplotypes together. However, when the nucleotide Adenine (A) is present 
at RS2306283 and Thymine (T) is present at RS4149056 it is referred to as 
haplotype *1A or the reference haplotype. Furthermore, SNPs in the promoter region 
of this gene can further sub-classify its haplotype into two distinct functional 
haplotypes (Niemi et al., 2004). Although, it is important to note that the effects of 
certain SLCO1B1 SNPs on transport function are substrate-specific (Tirona et al., 
2001). 
Haplotypes *5 and *15 have been associated with a strikingly reduced uptake of 
multiple OATP1B1 substrates including oestrone3sulphate, oestradiol17βD-
glucuronide, atorvastatin, cerivastatin, pravastatin and rifampicin (Iwai et al., 2004, 
Kameyama et al., 2005, Nozawa et al., 2005, Tirona and Kim, 2005, Tirona et al., 
2001). Additionally, RS4149056>C has been associated with increased plasma 
concentrations of many statins as well as fexofenadine and repaglinide (Chung et al., 
2005, Lee et al., 2005, Mwinyi et al., 2008, Niemi et al., 2005a, Niemi et al., 2005b, 
Niemi et al., 2004, Nishizato et al., 2003).  It is important to note that these 
haplotype designations only refer to the SNPs in linkage disequilibrium. Other, less 
studied SNPs also occur in the SLCO1B1 gene which are potentially functional 
variants.  
Sub-Saharan Africa, and for that matter South Africa, has a significant disease 
burden of both communicable and non-communicable diseases (Coovadia et al., 
2009, Mayosi et al., 2012). The current belief is that even developing nations, such 
as those in sub-Saharan Africa, can benefit from pharmacogenomics in order to 
inform public health policies, designing and interpreting clinical trials, and possibly 
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to help guide clinicians to prospectively evaluate those patients with the greatest 
probability of expressing a variant genotype (Daar and Singer, 2005b, Suarez-Kurtz, 
2008a). 
 Although African populations harbour more genetic diversity than Caucasians, for 
example, this genetic diversity is however understudied (Hardy et al., 2008). This 
lack of genetic information with robust allele frequencies currently serves as a 
significant hurdle to designing biomedical research and medical implications (May et 
al., 2013). South Africa is home to several indigenous African populations for which 
there is limited or no genomic information. The Cape Admixed (CA) population, 
historically indigenous to the Western Cape Province, is the second largest ethnic 
group in South Africa, and comprises approximately 9% (~4 million) of the total 
population (Drögemöller et al., 2010). Previous studies have shown that these 
populations harbour unique genotype and allele frequencies for 
pharmacogenomically relevant drug metabolizing enzymes (Ikediobi et al., 2011). 
However, to our knowledge only a limited number of studies have to date been 
undertaken to establish baseline genotype and allele frequency distributions of 
genetic polymorphisms in membrane transporter genes of admixed South African 
populations. Therefore, the aim of this study was to determine the baseline genotype 
and allele frequency distributions of 20 known SLCO1B1 coding SNPs in 130 CA 
individuals residing in Cape Town, South Africa 
3.3. Materials and Methods 
3.3.1. Subjects 
Subjects were as described in Chapter 2. 
3.3.2. DNA extraction and SNP selection 
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A standard salt lysis method was used for the isolation of genomic DNA was 
isolated from buccal swab samples as described in Chapter 2 and stored frozen at 
20°C until the time of genotyping (Leat et al., 2004). A total of 20 SLCO1B1 coding 
SNPs were selected for this study. SNPs were selected from the literature and the 
Ensembl database (http://www.ensebl.org) (Flicek et al., 2012). Variants, were 
included in this study based on predicted effect on function, using the SIFT (Sorting 
Intolerant From Tolerant) program (Flanagan et al., 2010, Kumar et al., 2009, Ng 
and Henikoff, 2003). To our knowledge no population data exist in the public 
domain for these variants. 
3.3.3. Primer design 
Multiplex PCR primers for the amplification of all SLCO1B1 exons and flanking 
regions were designed using Primer3 software 
(www.genome.wi.mit.edu/cgibin/primer/primer3) and are listed in Table 3.3.1. To 
test for possible nonspecific amplification, primers were aligned with the NCBI 
sequence databases using Basic Local Alignment Search Tool 
(www.ncbi.nlm.nih.gov/blast/blastcgi). Two SNaPshot™ Multiplex systems were 
specifically designed for the study, successfully optimized and used for genotyping. 
The single base extension primer sets for multiplex 1 and 2 are listed in Tables 3.3.2 
and 3.3.3. 
3.3.4. Multiplex PCR 
All the required SLCO1B1 exons and their flanking regions were simultaneously 
amplified using the primers listed in Table 3.3.1. The PCR reactions were performed 
in a 20 µl volume, containing 20 – 50 ng of genomic DNA, 1 x Qiagen multiplex 
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PCR master mix (Qiagen, Courtaboeuf, France) and 0.2 µM of each primer. Cycling 
parameters used and PCR product purification were as described in Chapter 2. 
 
 
 
3.3.5. SNaPshot™ genotyping reactions 
Multiplex mini-sequencing was performed in a 10 µl reaction volume using 3 µl of a 
1/10 dilution of purified PCR products, 0.10.2 µM of primers, and 5 µl of 
SNaPshot™ ready reaction mix (Also observed in the promoter region within the 
Xhosa population (Jacobs et al., 2015)). Sequence cycling was performed according 
to the instructions of the manufacturer. Post-extension treatment was done as 
described in Chapter 2. 
3.3.6. Electrophoresis of the mini-sequencing products 
The fluorescently labelled fragments were treated and separated on an ABI Prism 
3500 Genetic Analyzer (Also observed in the promoter region within the Xhosa 
population (Jacobs et al., 2015)) as described in Chapter 2. Data analyses were 
performed using GeneMapper® IDX Software Version 1.2. 
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Table 3.3.1  SLCO1B1 multiplex PCR primers for the amplification of exons and flanking regions. 
Location (Forward primer 5ʹ to 3ʹ) Reverse primer (5ʹ to 3ʹ) Amplicon size (bp) 
Exon 5 GGGGAAGATAATGGTGCAAA TGTTGTTAATGGGCGAACTG 403 
Exon 67 TCCTTTATAAATTACCCAGTCTCAGG GATCCCAGGGTAAAGCCAAT 618 
Exon 9 GCTGTGAACAGCCTGTGGTA TGCAACTTCAAATGCAGAGC 516 
Exon 10 TGATAGGTGCAGCAAACCAC TTGCTTCTCTTTAGTGGAGGAAT 598 
Exon 11 AAAAACTTTGCCATTTCGTCA TTTGTTTATACATCACACCCATCA 501 
Exon 13 TAATGGGGCCATTCAACTGT GGTCCATCACTCAATTTTACTCTG 417 
Exon 15 TCGTTATGCCCCAATAAAAA TGGAATGTCTTTATTTCTTCCACA 962 
Intron 1 TAGGGGCTTTTCATGTGCTT GGCAGGTACAGAGGAACAGG 304 
Intron 2 CATTTTGCTGCAACCATATCA ACCTTGGACATTAAGCTCTCTTC 321 
Intron 3 CTGACTTTGCATGCAGTATGG GAGAAGTCAGAGGCAATCGAA 300 
Intron 4 AGGGATATTGGCCTGTTGGT CCATCCAAAATGAACCATCC 328 
Promoter AAGCCATTCCCAAAAGTAAGG AAGCGTGTGGAAGACACAGA 371 
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Table 3.3.2  Multiplex 1 of SLCO1B1 single-base extension primers for SNaPshot™ mini-sequencing reactions. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
change 
Nucleotide sequence 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer length 
(bp) 
Poly-GACT tail 
rs4149056 V174A C/T aggaatctgggtcatacatgtggatatatg 14093965 30 0 
rs2306283 N130D A/G ataaggtcgatgttgaattttctgatgaat 14092154 35 5 
rs4149057 L191L C/T tagcgaaatcatcaatgtaagaaagcccca 14094015 40 10 
rs57040246 Y362Y C/T agatgaaggctgaccatactgttgctctac 14115973 45 15 
rs59502379 G488A C/G gaataacttacatctcaccctgtctagcag 14121349 50 20 
rs34671512 L643F A/C agtctcatcacttgttttatatattatatt 14154392 55 25 
rs11045819 P155T A/C aatcaaattttatcactcaatagagcatca 14092229 60 30 
rs11045818 S137S A/G aatttgattaattaaacaagtggataaggt 14092177 65 35 
rs79135870 I222V A/G tagaaaacagagatcccagggtaaagccaa 14094307 70 40 
rs2291075 F199F C/T accattggggctttcttacattgatgattt 14094041 75 45 
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Table 3.3.3 Multiplex 2 of SLO1B1 single-base extension primers for SNaPshot™ mini-sequencing reactions. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
change 
Nucleotide sequence 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer length 
(bp) 
Poly-GACT tail 
rs61760243 T345M C/T atcccctgtatgttatgtttgtgcttttga 
14115921 30 0 
rs59113707 F400L C/G gaatttggcaattccaacggtgttcagttt 
14117905 35 5 
rs11045859 V416V A/G aattgccaaattctcatgttttactgctgt 
14117953 40 10 
rs74700754 H575L A/T ctgaattgaaatcacttgcactgggtttcc 
14137691 45 15 
rs4149032 Intron C/T gtccctttttcctatctgcacataacatta 
14080207 50 20 
rs4149081 Intron A/G tagccattttctattatctctgatttttg 
14140437 55 25 
rs4363657 Intron C/T tttttcagaataatttagtacagtgggtac 
14131138 60 30 
rs4149015 Intron A/G cacatatatatatgtgcatatgtgtataca 
14045738 65 35 
rs59710386 Intron A/C aacctagttagttttaagagttcactccag 
14046426 70 40 
rs4149087 Intron G/T caaacaaacacagagtttgaactataatac 
14154978 75 45 
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3.4. Results  
Our study population consisted of a 130 healthy, unrelated CA individuals residing in the 
Cape Town Metropolitan area, South Africa. The age of the participants ranged from 18 to 60 
years with the mean age of female participants being 25.3±9.0 years, while male participants 
had a mean age of 24.8±7.7 years. There were 80 (54%) female and 68 (46%) male 
participants. 
In this study we have developed two SNaPshot™ multiplex assays for genotyping 20 known 
nonsynonymous coding SNPs in the SLCO1B1 gene. The genotype and allele frequencies of 
the 20 SLCO1B1 gene SNPs investigated in the 130 Cape Admixed subjects are summarized 
in Table 3.4.1. The allelic frequency of each SNP was in HWE (p>0.05). Fourteen of the 
nineteen investigated nonsynonymous SNPs were monomorphic in the CA population. 
The observed MAFs for the coding region SLCO1B1 variants V174A (rs4149056), L191L 
(rs4149057), P155T (rs11045819), and F199F (rs2291075) were 60.0%, 47.5%, 21.5%, 16%, 
respectively, for the CA population. The observed MAFs in the CA population for the 
intronic variants Rs4149032 and Rs4149081 were 36% and 8.3%, respectively. Inferred 
haplotypes for each population are listed in Table 3.4.2. The most frequently observed 
haplotypes were TATCGACGACCCGATGTGAT (10.8%), CATCGACGACCCGATGTGAT 
(9.1%), TACCGACGACCCGATGTGAT (7.9%), and CACCGACGACCCGATGTGAT (7.7%).  
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Table 3.4.1 Genotype and allele frequencies of OATP1B1 (SLCO1B1) gene SNPs in 130 
healthy CA individuals. 
Amino Acid 
Substitution 
dbSNP ID 
 
Observed Genotype 
Frequency 
 Allele Frequency  
Genotype % 95% CI Allele % 95% CI 
HWE 
(P) 
         
V174A rs4149056 
TT 25.0 16.5 –33.5 T 40.0 30.4 – 49.6 
14.063 TC 30.0 21.0 – 39.0 C 60.0 0.2 – 7.04 
CC 45.0 25.7 – 44.3    
         
N130D rs2306283 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
L191L rs4149057 
TT 52.0 42.2 – 61.8 T 52.4 42.2 – 61.8 
96.030 TC 0.8 0.01 – 3.0 C 47.6 37.2 – 56.8 
CC 47.2 37.2 – 56.8    
         
Y362Y rs57040246 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
G488A rs59502379 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
L643F rs34671512 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
P155T rs11045819 CC 96.2 92.2 – 99.8 C 78.5 71.0 – 87.0 
 
4.005 
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CA 3.8 0.2 – 7.8 A 21.5 13.0 29.0 
AA 0.0 0.0 – 3.1    
         
S137S rs11045818 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 1.6 
AA 0.0 0.0 – 1.3    
         
I222V rs79135870 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 1.6 
GG 0.0 0.0 – 1.3    
         
F199F rs2291075 
TT 3.0 0.3 – 6.3 T 16.0 8.8 – 23.2 
0.107 TC 26.0 17.4 – 34.6 C 84.0 76.8 91.2 
CC 71.0 62.1 – 79.9    
         
T345M rs61760243 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
F400L rs59113707 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 
CG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
V416V 
rs11045859 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
H575L rs74700754 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
  AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
 
  TT 0.0 0.0 – 1.3     
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Intronic SNP 
rs4149032 
TT 52.0 42.2 – 61.8 T 64.0 56.4 – 73.4 
 
22.960 
TC 24.0 15.6 – 32.4 C 36.0 26.6 – 45.4 
CC 24.0 15.6 – 32.4    
         
Intronic SNP rs4149081 
GG 90.7 85.4 – 96.6 G 90.7 85.4 – 96.6 
100.00 GA 0.0 0.0 – 1.3 C 9.3 3.4 – 14.6 
AA 9.3 3.4 – 14.6    
         
Intronic SNP rs4363657 
TT 75.0 66.5 – 83.5 T 85.5 79.2 – 92.8 
 TC 21.0 13.0 – 29.0 C 14.5 7.2 – 20.8 
CC 4.0 0.2 – 7.8    
         
Intronic SNP rs4149015 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
Intronic SNP rs59710386 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
Intronic SNP rs4149087 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
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Table 3.4.2 Comparison of MAF of SLC22A1 gene SNPs of the CA population to other ethnic groups 
dbSNP ID 
Amino acid 
change 
Minor 
Allele 
Minor Allele Frequency (%) 
CAa Luhyab Yorubab Peurto Ricanb Japaneseb Chinese-Hanb Caucasian-Britishb 
rs4149056 V174A C 60.0 2.0 1.0 12.0 12.0 12.0 14.0 
rs2306283 N130D A 0 16.0 19.0 47.0 34.0 20.0 64.0 
rs4149057 L191L C 47.5 5.0 15.0 50.0 34.0 21.0 64.0 
rs57040246 Y362Y T 0 3.0 7.0 1.0 0 0 0 
rs59502379 G488A C 0 5.0 5.0 0 0 0 0 
rs34671512 L643F C 0 7.0 6.0 8.0 0 0 4.0 
rs11045819 P155T A 21.5 3.0 5.0 14.0 0 0 15.0 
rs11045818 S137S A 0 0 0 12.0 0 0 15.0 
rs79135870 I222V G 0 1.0 3.0 0 0 0 0 
rs2291075 F199F T 16.0 55.0 60.0 41.0 38.0 51.0 35.0 
rs59113707 F400L G 0 3.0 7.0 1.0 0 0 0 
rs11045859 V416V A 0 3.0 12.0 1.0 0 0 0 
rs4149032 Intron C 36.0 28.0 28.0 56.0 49.0 39.0 66.0 
rs4149081 Intron A 9.0 19.0 16.0 18.0 38.0 45.0 15.0 
rs4363657 Intron C 14.5 17.0 13.0 18.0 38.0 45.0 15.0 
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rs4149015 Intron A 0 3.0 0
 
4.0 12.0 12.0 2.0 
rs59710386 Intron C 0 0 0 2.0 0 0 3.0 
rs4149087 Intron G 0 31.0 27.0 39.0 71.0 79.0 38.0 
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 Figure 3.4.1. Allele frequencies of selected SLCO1B1 SNPs in the CA population compared to other African and world populations. 
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 Table 3.4.3 Haplotype structure defined by 20 SNPs in the SLCO1B1 gene in the 
CA population. 
Haplotype No. Haplotype 
a
 Frequency % 
1 TATCGACGACCCGATGTGAT 10.8 
2 CATCGACGACCCGATGTGAT 9.1 
3 TACCGACGACCCGATGTGAT 7.9 
4 CACCGACGACCCGATGTGAT 7.7 
5 CATCGACGACCCGACGTGAT 5.7 
6 CATCGACGATCCGATGTGAT 5.3 
7 CACCGACGACCCGACATGAT 4.6 
8 CACCGACGACCCGACGTGAT 3.9 
9 TATCGAAGACCCGATGTGAT 3.6 
10 CACCGACGACCCGATGCGAT 2.9 
11 TATCGACGACCCGATGCGAT 2.8 
12 CACCGAAGACCCGACGTGAT 2.5 
13 TACCGACGACCCGACGTGAT 2.5 
14 TATCGAAGACCCGACGTGAT 2.5 
15 CACCGACGACCCGACACGAT 2.4 
16 CATCGAAGACCCGATGTGAT 2.2 
17 TACCGACGATCCGATGTGAT 2.1 
18 TATCGACGACCCGACGTGAT 1.7 
19 CACCGACGATCCGACGTGAT 1.5 
20 TACCGAAGACCCGACGTGAT 1.5 
21 CATCGAAGATCCGATGTGAT 1.4 
22 CACCGAAGACCCGATGTGAT 1.3 
23 TACCGAAGACCCGATGTGAT 1.2 
24 CACCGACGACCCGACGCGAT 1.1 
25 CACCGACGATCCGATGTGAT 1.1 
26 CATCGACGACCCGATGCGAT 1.1 
27 TATCGAAGATCCGATGTGAT 1.1 
28 TATCGACGATCCGACGTGAT 1.1 
29 CATCGAAGACCCGATGCGAT 1.0 
30 CATCGAAGATCCGACGTGAT 1.0 
31 CACCGAAGACCCGACATGAT 0.9 
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32 TACCGACGACCCGACGCGAT 0.9 
33 CATCGACGACCCGACGCGAT 0.6 
34 CATCGACGATCCGACGTGAT 0.6 
35 CACCGAAGACCCGATACGAT 0.5 
36 CACCGACGACCCGATATGAT 0.5 
37 CATCGAAGACCCGACGCGAT 0.5 
38 CATCGACGATCCGACGCGAT 0.4 
39 TACCGAAGATCCGATGTGAT 0.2 
40 CACCGAAGACCCGACACGAT 0.1 
41 CACCGACGATCCGATGCGAT 0.1 
42 CATCGACGATCCGATGCGAT 0.1 
43 TACCGAAGATCCGACGTGAT 0.0 
 TOTAL 100 
a) Haplotype sequences are based on the position of SNPs on chromosome 12. 
 
 
3.5. Discussion 
This study is the first study to report on the allele and genotype frequencies for 
fourteen nonsynonymous and six intronic SNPs of SLCO1B1 in the Cape Admixed 
population of South Africa. A total of 43 haplotypes were identified for the CA 
population. This study provides important data for ethnic populations of South 
Africa which could be further investigated within an in vitro, in vivo and clinical 
setting. 
Recently, much attention has been focused on the genetic variation of drug 
transporters. This is a result of the roles these transporters play in gastrointestinal 
absorption, biliary and renal elimination and distribution to target sites of their 
specific substrates (Choi and Song, 2008b). Moreover, emerging pharmacogenomic 
evidence suggests that membrane transporters are subject to both genotypic and 
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phenotypic variation (Collins et al., 1998). Additionally, it is also suggested that 
variation in drug transporters may be the underlying cause of inter-individual 
variability in pharmacokinetic disposition, efficacy and toxicity of drug transporter 
substrates (Choi and Song, 2008b).  
SLCO1B1 is thought to directly influence the meglitinide class of oral antidiabetic 
drugs. Repaglinide is a short-acting meglitinide analogue that enhances glucose-
stimulated insulin secretion from pancreatic beta cells, thereby reducing blood 
glucose concentrations (Dornhorst, 2001). Its mechanism of action is binding and 
closing the ATP-sensitive K
+
 channels. Binding and closing the K
+
 channel serves to 
depolarize the beta cell, allowing for the opening of voltage-gated Ca
++
 channels 
(Hatorp, 2002). This results in the influx of Ca
++
 ions which triggers the release of 
insulin by exocytosis. However, insulin release is dependent on the beta cell 
secretory capacity (Hatorp, 2002). The V174A variant has been shown to directly 
affect repaglinide plasma levels (Kajosaari et al., 2005). Additionally, V174A is 
associated with a weaker lipid response to statin therapy. In a study by (Rodrigues et 
al., 2011) it was concluded that this polymorphism causes significant increase in 
atorvastatin response and may be an important marker for predicting efficacy of 
lipid-lowering therapy. This is particularly evident when atorvastatin is used in 
combination with repaglinide. It is suggested that the atorvastatin acts as an 
inhibitor, thus inhibiting OATP1B1mediated hepatic repaglinide uptake (Chung et 
al., 2005, Lee et al., 2005, Mwinyi et al., 2008, Niemi et al., 2004, Nishizato et al., 
2003). 
Furthermore, SLCO1B1 has been shown to transport methotrexate in vitro (Abe et al., 
2001, Tirona et al., 2001). Previous studies have confirmed the functional 
consequences of nonsynonymous polymorphisms in SLCO1B1 (Kameyama et al., 
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2005, Tirona et al., 2001).  (Trevino et al., 2009) concluded that for this variant, as 
well as other less studied SNPs, a lower methotrexate clearance was observed. This is 
consistent with numerous preceding studies which demonstrated greater plasma 
exposure to several SLCO1B1 substrates in those carrying the V174A polymorphism 
(Ho et al., 2007, Niemi, 2007, Pasanen et al., 2007). 
Several pharmacogenetic studies have focused on the potential contribution of 
SLCO1B1 genetic variations to statin response. The N130D variant has been 
associated with elevated activity of OATP1B1 and lower statin concentration in 
plasma (Mwinyi et al., 2008, Romaine et al., 2010). In addition, the SLCO1B1*15 
haplotype, formed by both N130D and V174A variants, has been associated with 
decreased activity of the OATP1B1 transporter (Kalliokoski et al., 2010). However, 
this variant was not observed in the study population, which is curious as it is 
observed with a high MAF in highly admixed populations, such as the Brazilian 
population, as well as in homogenous populations such as the British Caucasian 
population. Furthermore, this may be result of the genetic contributions from 
Caucasian (Dutch, German and British) and indigenous South African populations 
present in the study population. Supplementary investigation into the genetic lineage 
of the study participants and the origin of this variant is suggested. 
Studies have determined that he synonymous L191L variant, despite its high 
prevalence, has no effect on the overall function of the OATP1B1 protein, and 
additionally, no effect on hepatic expression of SLCO1B1 (Prasad et al., 2014, Lee et 
al., 2011). No significant observable effects have been characterised when this SNP 
exist singly or as part of a haplotype (Lee et al., 2011).    
 
 
 
 
CHAPTER 3 
 112 
Remarkably, the P155T variant has been shown to enhance the proportional lipid 
reduction in fluvastatin therapy (Hopewell et al., 2013, Couvert et al., 2008). The 
observed MAF for the CA population was relatively high at 21.5%.  This, in 
conjunction with the V174A variant, may suggest an increased efficacy of the statin 
class of lipid-lowering drugs. However, it is suggested that further in vivo 
investigation is required to determine the overall effect of the haplotypes observed 
within the CA population. Additionally, in vivo studies conducted by (Kwara et al., 
2014) have suggested that the mechanism for the increased rifampin clearance and 
lower plasma exposure in subjects with the SLCO1B1 P155T variant genotype could 
be due to gain in transporter activity associated with this SNP. They further 
concluded that males with the P155T variant are at increased risk of lower rifampin 
plasma exposure (Kwara et al., 2014). The observed MAF in the study population 
was significantly higher than those it was compared with.  
Epidemiological studies often summarize the pattern of arsenic metabolites in urine 
as proportions of the 3 main inorganic arsenic metabolites, namely; inorganic arsenic 
(iAs), mono-methylarsonate (MMA), and di-methylarsinate (DMA) (Gribble et al., 
2013). A recent study evaluated the association of variants in SLCO1B1 with arsenic 
metabolite patterns in urine of participants from the Strong Heart Study, a cohort 
recruited from rural communities of the Southwestern and Midwestern United States 
exposed to low-to-moderate arsenic levels in drinking water (Gribble et al., 2013). 
Their results showed that the minor allele of F199F were significantly associated 
with variability in %MMA and %DMA accounting for 5% of the residual variance 
for %DMA arsenic species (Gribble et al., 2013). Interestingly, the observed MAF in 
the CA population (16%) was considerably lower than all other populations (Table 
3.4.2).   
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 The SLCO1B1 rs4149032 polymorphism is associated with low-level rifampin 
exposure (Chigutsa et al., 2011b). Interestingly, the SLCO1B1 rs4149032 
polymorphism was noted to occur at an uncannily high rate among South Africans. 
Recent studies have reported lower rifampin concentrations in a high proportion of 
patients suffering from tuberculosis, consistent with reports from other African 
populations. Moreover, it has been determined that the lower rifampin concentration 
observed in African populations, and the study population, may be accounted for by 
the rs4149032 variant allele (Chigutsa et al., 2011a). The observed MAF was 36% 
for the CA population, compared to 28% Yoruba (Nigeria) and 66% Caucasian 
(Britain). Since a large proportion of the CA population are carriers of the rs4149032 
polymorphism, it may be suggested that increasing the rifampin dose across the 
board would be beneficial to not only individuals carrying the variant allele, but also 
individuals without the variant as higher doses are more likely to be effective and 
appear to be safe (Chigutsa et al., 2011b).  
The intronic SNP rs4149081 in SLCO1B1 was associated with the LDLC response 
to statins in Chinese patients, with a MAF of 45% (Hu et al., 2012). Furthermore, 
gastro intestinal toxicity of methotrexate was associated with this SNP, as shown in a 
study conducted by (Trevino et al., 2009). Although the MAF for this variant was 
relatively low at 9%. 
3.6. Conclusions 
Numerous sequence variations have been characterized in the SLCO1B1 gene, many 
associated with altered transporter activity in vitro and in vivo. However, given the 
understudied genomic diversity harboured within sub-Saharan Admixed and 
indigenous African populations, the potential exist that novel and rare low frequency 
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variations could be identified and systematically investigated in the CA population. 
Admixed ancestry can potentially provide the intrinsic variability needed to unravel 
intricate gene-environment interactions, which may help explain the population 
differences in the epidemiology of complex disease. It is thus proposed that 
investigation of the SLCO1B1 polymorphisms present in the indigenous African and 
Admixed populations be initiated, and the effects thereof on statin, repaglinide and 
methotrexate pharmacokinetics and pharmacodynamics be identified and examined. 
Moreover, it is suggested that the interaction between these, and other, combinations 
of drugs also be investigated. This study also lays the foundation for future 
association studies between SLCO1B1 variations and treatment outcomes in the CA 
population. Therefore, Chapter 4 will prioritize the investigation of promoter 
variants of the SLC genes in the CA participants.
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CHAPTER 4 
Identification of Genetic Variations within Pharmaco-gene Promoters in the 
Cape Admixed Population 
4.1. Abstract 
The solute carrier transporter (SLC) superfamily is a large family of membrane-
bound proteins that share 20-25% of sequence homology. Furthermore, it is 
recognized that members of the SLC family are involved in the facilitated transport 
of a variety of substances including drugs, environmental toxins, xenobiotics, and 
endogenous metabolites across plasma membranes. Additionally, it is estimated that 
genetic factors account for at least 15-30% of variations in drug disposition and 
responses. Moreover, genetic polymorphisms in drug transporters are increasingly 
being recognized as a possible mechanism explaining this variation in drug 
disposition and response. However, to date only a few studies have explored the 
genetic diversity harboured in the pharmacogenomically relevant SLC genes of 
indigenous and admixed southern African populations. Therefore, the aim of this 
study was to determine whether the studied SLC genes of the CA participants 
harbours any novel SNPs using direct sequencing of the promoter regions in 96 of 
the participants. Of the six gene promoters studied, eighteen known variable sites 
were identified in this study. The number of variants observed in SLCO1B1, 
SLCO1B3, and MATE1 were four, six and eight respectively. The haplotypes 
inferred for the Cape Admixed population in this study is an important step in filling 
the gap with regards to genetic information on the pharmacogenomically relevant 
genes in indigenous southern African populations. The information generated in this 
study can potentially lay the foundation for future pharmacogenomic study design 
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and for the identification of association between the rare SNPs and drug response 
and toxicity. 
 
4.2. Introduction 
The solute carrier transporter (SLC) superfamily is a large family of membrane-
bound proteins that share 20-25% of sequence homology (Hediger et al., 2004). 
SLCs are expressed in most tissues. However, these proteins are expressed most 
abundantly in the liver, kidney, and intestine where they are either located at the 
basolateral or apical plasma membranes of polarized cells (Wojtal et al., 2009). 
Today it is acknowledged that members of the SLC family are involved in the 
facilitated transport of a variety of substances including drugs, environmental toxins, 
xenobiotics, and endogenous metabolites across plasma membranes (Hediger et al., 
2004, Koepsell et al., 2007b). Moreover, these SLC transporters play a critical role in 
the absorption and excretion of drugs in the kidneys, liver, and intestine, thus, 
influencing the pharmacodynamic and pharmacokinetic characteristics of these drugs 
(Meier et al., 2007b). 
Previous studies have shown that human SLCs are highly polymorphic in ethnically 
diverse populations (Sakata et al., 2004, Shu et al., 2003, Kang et al., 2007a). 
Functional characterization have revealed that several of these SNPs affect the 
transport function of these genes in vitro (Leabman et al., 2002a). Although in vivo 
evidence for the involvement of these SNPs in clinical phenotype is limited, for 
example, recent studies have shown that homozygous carriers of the hOCT2 variant 
A270S (rs316019) have a lower renal clearance of metformin compared to those 
carrying the homozygous wildtype (Song et al., 2008a, Wang et al., 2008a). 
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However, these pharmacogenomic association studies have primarily been 
conducted in non-African populations, usually Western European and North 
American Caucasians, and have focused on genetic variants which are common to 
these populations (Urban, 2010). The results of these studies are often extrapolated 
for use and interpretation in other populations. This is in spite of the fact that variant 
allele frequencies in pharmacogenomic genes can differ significantly between 
populations and even within populations (Drögemöller et al., 2010, Yen-Revollo et 
al., 2009). Additionally, population-specific variants exist in non-Caucasians which 
may more likely be of greater relevance to treatment/study outcomes then those 
found in Caucasians. 
Although it is widely accepted that African populations harbour more genomic 
diversity than non-African populations, this genetic diversity is however 
understudied (Frazer et al., 2009, Hardy et al., 2008, Tishkoff et al., 2009). However, 
in recent years African populations have started to attract research interest, with 
especially northern and central African countries being increasingly incorporated 
into studies assessing population structure (Ramsay, 2012, Tishkoff et al., 2009). 
The Hap-Map and 1000 Genomes projects currently include information on the 
Luhya and Maasai of Kenya, Yoruba and Esan of Nigeria, Gambian of The Gambia, 
and the Mende of Sierra Leone. However, the current opinion is that the population 
genetics of these groups cannot represent the total genomic diversity of the 
remaining populations in West and East Africa, nor the populations residing in 
southern Africa (Ikediobi et al., 2011, May et al., 2013). Moreover, the role of this 
genetic diversity in disease pathogenesis and treatment is currently not fully 
understood.  
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The potential importance of gene regulation in disease susceptibility and other 
inherited phenotypes has been underlined by the observation that the human genome 
contains fewer protein coding genes than expected (Hoogendoorn et al., 2003).  
Promoters are involved in initiating transcription and are therefore among the many 
important cis-acting elements that regulate gene expression that might harbour 
functionally relevant polymorphisms (Hoogendoorn et al., 2003). However, they 
differ from most regulatory elements in that their locations are fixed relative to the 
positions of their respective genes (Hoogendoorn et al., 2003).  
Therefore, the aim of this study was to determine whether the SLC genes of the CA 
participants harbours any novel SNPs, using direct sequencing of the promoter 
regions of these genes in 96 healthy individuals. Secondly, to determine the 
promoter haplotype structure of the SLC genes based on the genetic information 
acquired by sequencing, and finally, to compare the minor allele frequencies 
obtained for the Cape Admixed participants to the Hap-Map estimates for other 
African, American, European and Asian populations.  
4.3. Materials and Methods 
4.3.1. Subjects 
The DNA from 96 of the 130 unrelated healthy CA subjects (As described in 
Chapter 2) was used to screen for novel promoter SNPs by direct sequencing. 
4.3.2. DNA extraction and direct sequencing 
Genomic DNA samples were collected in the form of buccal swabs and were 
extracted using a standard salt lysis method as described in Chapter 1 (Leat et al., 
2004). The proximal promoter region of the selected SLC genes were generated 
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using self-designed primer sequences. These primers were designed using Primer3 
software (www.genome.wi.mit.edu/cgibin/primer/primer3) and obtained from 
Integrated DNA Technologies (San Diego, California, USA). The PCR reactions 
were performed in a 50 µl volume, containing 20 – 50 ng of genomic DNA, 1 x 
Qiagen multiplex TopTaq master mix (Qiagen, Courtaboeuf, France) and 0.2 µM of 
each forward and reverse primer. The PCR conditions included an initial 
denaturation at 95°C for 15 minutes, followed by 35 cycles of denaturation at 95°C 
for 1 minute, annealing for 1 minute, and extension at 72°C for 1minute, and then a 
final extension at 72°C for 10 minutes. The sequences and details of all the primers 
used in this study are listed in Table 4.4.1. The fragments were sequenced at Inqaba 
Biotec (Johannesburg, South Africa). 
4.4. Results 
4.4.1. Variant Screening 
To identify variants, the proximal promoter region of each gene in 96 Cape Admixed 
participants was screened using direct sequencing. Out of the six gene promoters 
studied, eighteen known variable sites were identified in this study (Table 4.2). Four 
variants were observed in SLCO1B1, six were detected in SLCO1B3, and eight were 
identified in MATE1. No variant SNPs were observed in the OCT1, OCT2, OCT3, 
and MATE2-K promoter regions. Novel variant sites in the six promoter regions were 
not observed.
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Table 4.4.1 PCR primer sequences for promoter region amplicon generation. 
Gene Forward Primer (5′ to 3′) Reverse Primer (5′ to 3′) 
Amplicon length 
(bp) 
    
SLC22A1 GCCCTACCAAACTGCAAAGC ACATCTGGAAGGCAACCAAG 
818 
SLC22A3 GAAGTTCTGATCGCGCTCTG CTCTCTTTACTCCGCCGCCT 
879 
SLC47A1 TTGGGAGGTGACGGTTAAGA CAGGAGCAGCAGAGACTCTC 
765 
SLC47A2 GTAGCCATGTTTTCACTTTCATAGC CGGAACCTGAGATACTTTGAGC 
698 
SLCO1B1 AGGGTCTGTACTTTATTTCAGAAGA AAACAAGTCCAGTGATGATTAACCA 
682 
SLCO1B3 ACAGCCATGTGCCTGAGATA CAAGTCCATCCTTTTTCTGATG 
728 
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Table 4.4.2 Summary of SNPs identified with direct sequencing of the promoter regions of pharmaco-genes in the CA population. 
dbSNP ID Gene 
Nucleotide 
Position 
Accession 
number 
(NC_000006.
12) 
Position 
from the 
translationa
l initiation 
site or the 
nearest 
exon 
Nucleotide 
change and 
flanking 
sequence  
(5′ to 3′) 
MAF HWE 
       
rs73598368 SLCO1B1 21130586 712 G>A 0.016 0.876 
rs372930030 SLCO1B1 21130664 634 T>A 0.010 0.011 
rs11835045 SLCO1B1 21130885 413 T>C 0.057 0.355 
rs71581973 SLCO1B1 21131013 285 C>G 0.005 0.003 
rs745982712 SLCO1B3 20810139 691 A>G 0.005 0.003 
rs769039801 SLCO1B3 20810268 562 C>T 0.016 0.024 
rs770749398 SLCO1B3 20810281 549 C>T 0.010 0.011 
rs776382139 SLCO1B3 20810289 541 T>G 0.010 0.011 
rs763010829 SLCO1B3 20810424 406 G>A 0.005 0.003 
rs60103218 SLCO1B3 20810466 364 C>A 0.026 0.069 
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rs763522289 MATE1 1494757 1543 G>A 0.005 0.003 
rs115229514 MATE1 1494774 1560 C>T 0.005 0.003 
rs374132895 MATE1 1494782 1568 A>G 0.005 0.003 
rs191898031 MATE1 1494810 1596 C>T 0.010 0.011 
rs7225894 MATE1 1494825 1611 C>G 0.005 0.003 
rs570369352 MATE1 1494838 1624 T>A 0.005 0.003 
rs553276075 MATE1 1494990 1776 T>A 0.005 0.003 
rs555153997 MATE1 1495183 1969 C>G 0.005 0.003 
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Figure 4.4.1. Minor allele frequencies of selected promoter SNPs in the CA population compared to other African and world populations. 
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Table 4.4.3 Comparison of MAF of selected promoter SNPs identified by direct sequencing in the CA population to other ethnic groups. 
dbSNP ID 
Minor 
Allele 
Minor Allele Frequency (%) 
Cape 
Admixed
a
 
Luhya
b
 Yoruba
b
 
African-
American
b
 
Japanese
b
 
Puerto 
Rican
b
 
Caucasian-
Finish
b
 
Caucasian-
American
b
 
          
rs73598368 A 1.6 1.0 0.0 0.0 9.0 0.0 0.0 0.0 
rs372930030 A 1.0 * * * * * * * 
rs11835045 C 5.7 18.0 31.0 25.0 9.0 4.0 0.0 0.0 
rs71581973 G 0.5 * * * * * * * 
rs745982712 G 0.5 * * * * * * * 
rs769039801 T 1.6 * * * * * * * 
rs770749398 T 1.1 * * * * * * * 
rs776382139 G 1.1 * * * * * * * 
rs763010829 A 0.5 * * * * * * * 
rs60103218 A 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
rs763522289 A 0.5 * * * * * * * 
rs115229514 T 0.5 3.0 0.0 4.0 0.0 0.0 0.0 0.0 
rs374132895 G 0.5 * * * * * * * 
rs191898031 T 1.0 1.0 0.0 0.0 0.0 2.0 0.0 0.0 
rs7225894 G 0.5 1.0 4.0 1.0 0.0 0.0 0.0 0.0 
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rs570369352 A 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
rs553276075 A 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
rs555153997 G 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
a. This study; b. Data from 1000 Genomes; *. No Data 
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4.4.2. Haplotype Analysis 
Haplotypes were calculated using an inferential procedure (Yong and Lin, 2005). 
This method identified 13 distinct haplotypes across the three gene promoters. The 
thirteen major haplotypes are listed in Table 4.4.4. 
4.5. Discussion 
This study is the first study to report on the allele and haplotype frequencies for the 
eighteen selected promoter SNP sites in the Cape Admixed population of South 
Africa. A total of 13 haplotypes were identified for the CA population. This study 
provides important data for ethnic populations of South Africa which could be 
further investigated within an in vitro, in vivo and clinical setting. 
Poly-specific solute carrier transporters (SLCs) are involved in the sodium-
independent electrogenic transport of small organic cations/anions (OCs/OAs) with 
different molecular structures (Koepsell et al., 2007b). These organic cations include 
clinically important drugs (metformin, cimetidine, procainamide), endogenous 
compounds (dopamine, norepinephrine, and toxic substrates (tetraethylammonium, 
haloperidol-derived pyridinium metabolite, 1methyl4phenylpyridinium) (Gorboulev 
et al., 1997a). Based on their substrate properties and tissue distributions, human 
SLC-transporters are thought to play important roles in the biliary and renal excretion 
of their substrates and the distribution of organic cationic drugs in the liver, kidney, 
heart, and brain (Jonker and Schinkel, 2004). 
In a study by (Endo et al., 2012), the association of SLCO1B1, SLCO1B3 and 
ABCC2 polymorphisms with the pharmacokinetics of olmesartan was investigated. 
Their study reports that rs73598368 was observed at 1.4% in the African-American 
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population and 0% in the Hispanic and Caucasian populations, respectively. 
However, there was no remarkable difference in any pharmacokinetic parameters of 
olmesartan between subjects with and without any major haplotypes in the three 
transporter genes they tested (Endo et al., 2012). This variant was observed at a 
MAF of 1.6% in the CA population. In the Luhya and Asian populations, it was 
observed at 1.0% and 9.0%, respectively (Table 4.4.3). This may suggest that this 
variant is specific to African and Asian populations as it is not observed in any 
Caucasian, European or South American (admixed) populations. 
(Kim et al., 2012) sought to determine whether polymorphisms in three drug 
transporter genes (ABCB1, SLCO1B1 and ABCC2) were risk markers for hepatitis 
induced by the unusual accumulation of antituberculosis drugs (ATDs). Their study 
revealed a MAF of 7.1% for the rs11835045 variant in the Korean population, 
compared to 5.7% in the CA population. Furthermore, the 1000genomes project has 
observed this variant across multiple populations where MAFs may be as high as 
31% (Table 4.4.3). However, their study suggests that these drug transporters do not 
play important roles in the pathogenesis of ATD-induced hepatitis in Korean 
patients, but reccommend that this negative association be reexamined in other 
ethnic groups as genetic assocciations may be ethnicityspecific (Kim et al., 2010). 
 Interestingly, no variants (known or novel) were observed for the OCTs and 
MATE2. However, the lack of amino acid and genetic diversity observed in hOCT1 
and SLC22A1 and is not unique, as it was also observed within hOCT2and SLC22A2, 
and hOCT3 and SLC22A3 in other populations (Lazar et al., 2003, Lazar et al., 
2008). This absence of genetic diversity merely demonstrates the critical role these 
transporter performs in the elimination of xenobiotics and the maintenance of 
cellular and organismal homeostasis (Leabman et al., 2003b, Lazar et al., 2003).  
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Table 4.4.4 Major haplotypes inferred from 18 promoter SNPs identified with direct 
sequencing. 
Haplotype ID Haplotype Frequency (%) 
SLCO1B1   
Haplotype *1 GTTC 94.3 
Haplotype *2 GTCC 4.2 
Haplotype *3 ATCC 0.5 
Haplotype *4 AACC 0.5 
Haplotype*5 AACG 0.5 
SLCO1B3   
Haplotype*1 ACCTGC 97.4 
Haplotype*2 ACCTGA 1.0 
Haplotype*3 ATCTGA 0.5 
Haplotype*4 ATTGGA 0.5 
Haplotype*5 GTTGAA 0.5 
MATE1   
Haplotype *1 GCACCTTC 99.0 
Haplotype *2 GCATCTTC 0.5 
Haplotype*3 ATGTGAAG 0.5 
 
Therefore, in a study by Jacobs et al (2015) a novel promoter SNP at position -156, 
which can potentially alter transcription of the SLC22A2 gene was discovered. 
Additionally, two promoter SNPs (rs59695691 and rs150063153) that are found only 
in African population groups were observed. The effect of these African-specific 
variations on basal promoter regulation has not yet been determined and will be 
further investigated in Chapter 5. 
4.6. Conclusions 
For the reason that the power to detect rare haplotypes is low, there are likely to be 
many more functional haplotypes of low frequency than have observed in this study. 
Like the common variants, the cumulative effects of a large number of rare 
functional variants can result in common phenotypes. Consequently, it may be 
concluded that this data offers empirical credibility to the notion that polymorphisms 
within promoters may be a common source of phenotypic variation and possibly a 
source of susceptibility to common disease, particularly since our estimate of the 
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frequency of functional variation is likely to be somewhat conservative. As a 
consequence, Chapter 5 will focus on the effect haplotypes, derived from known 
and novel variants identified in the hOCT2 promoter in the Xhosa population, might 
have on gene expression.  
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CHAPTER 5 
Cloning of the Polymorphic SLC22A2 Promoter Region and Development of 
Promoter Expression Assay   
 
5.1. Abstract 
The characterisation of variation in gene expression is complicated by the potentially 
minute differences associated with alterations in single alleles, as well as by potential 
variation between individuals arising from environmental or physiological rather 
than genetic factors. Promoters are involved in transcription initiation and are thus 
among the multitude of cis-acting elements that, by regulating gene expression, 
might harbour functionally relevant polymorphisms. However, contrary to most 
regulatory elements, the promoter location is fixed relative to their respective genes. 
Therefore, promoters are ideal for largescale analysis and functional annotation. 
Moreover, the frequencies for SNPs in regulatory elements is largely understudied in 
African, Sub-Saharan, populations. The aim of the present study was firstly, cloning 
the polymorphic promoter regions representative of 2 of the haplotypes, and 
secondly to develop a gene expression assay for the polymorphic promoters 
observed. In this study, we have observed the relative effect of the abovementioned 
regulatory SNPs on gene expression using a GFP reporter vector. It was 
demonstrated that a minor difference existed between expression levels of the two 
representative haplotypes, when compared to the positive control. Nevertheless, it 
was confirmed that no significant difference existed in relative expression between 
the two haplotypes. Furthermore, the effect of different tissue types seems to have 
little effect on promoter regulation. Thus, it may be concluded that our data lends 
some empirical credibility to the notion that polymorphisms within promoter regions 
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may be a common source of phenotypic variation, and a likely source of 
susceptibility to common disease. The capacity to assess the relative mRNA 
production should be included in future work as it would deliver a more accurate 
depiction of the inherent regulatory elements in single haplotype promoter 
expression.   
 
5.2. Introduction 
Biomedical research has the vital goal of understanding the genetic basis of human 
variation. Differences in the level of expression of certain genes account for a major 
part of the variation within and among other species, as suggested by previous 
studies in other organisms (Johnson and Porter, 2000, Levine, 2002). The 
characterisation of variation in gene expression is complicated by the potentially 
minute differences associated with alterations in single alleles, as well as by potential 
variation between individuals arising from environmental or physiological rather 
than genetic factors (Yan et al., 2002).   
Attributed to the unpredictably low number of protein coding genes (Peltonen and 
McKusick, 2001), it has been suggested that a different spectrum of sequence 
variants may be responsible for the genetic susceptibility to complex diseases 
(Mackay, 2001, Toma et al., 2002) compared to missense and nonsense mutations 
(Hoogendoorn et al., 2003). Included in this spectrum are polymorphisms that alter 
gene expression. These variants are thought to play a significant role in the inter-
individual variation in gene expression, attributed to cis-acting genetic mechanisms 
(Hoogendoorn et al., 2003). Since functional polymorphisms in regulatory regions in 
the human genome cannot yet be reliably distinguished from those with no 
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consequential effect by their sequence context, it is imperative that the effect these 
variants may confer be characterised (Hoogendoorn et al., 2003).  
Promoters are involved in transcription initiation and are thus among the multitude 
of cis-acting elements that, by regulating gene expression, might harbour 
functionally relevant polymorphisms (Hoogendoorn et al., 2003).  
However, contrary to most regulatory elements, the promoter location is fixed 
relative to their respective genes. Therefore, promoters are ideal for largescale 
analysis and functional annotation (Hoogendoorn et al., 2003). Moreover, the 
frequencies for SNPs in regulatory elements is largely understudied in African, Sub-
Saharan, populations. In a previous study by (Jacobs et al., 2015) this issue was 
addressed, where the main goal was to provide an estimate of the frequency with 
which functional sequence variation occurs in not only the proximal promoter, but 
also the coding regions of the SLC22A2 gene. The results revealed a rare novel SNP 
(0.52%) (rs572296424) observed in the promoter region in the Xhosa population at 
position -156 (Figure 5.2.1), relative to the start of the first exon. Furthermore, basal 
promoter activity is an important determinant of SLCA22A2 expression in vivo, and 
may influence the transport function of hOCT2, which in turn may affect the uptake, 
disposition, and elimination of its substrates. A deletion analysis of the hOCT2 
proximal promoter region by Asaka et al. (2007) suggested that the region spanning 
-91 to -58 base pairs (bp) was essential for basal transcriptional activity of the 
SLC22A2 gene (Asaka et al., 2007). This region lacks a canonical TATA-box, but 
does contain a CCAAT box and an E-box. The electrophoretic mobility assays 
revealed that the SLC22A2 E-box binds upstream stimulating factor 1 (USF1) which 
functions as a basal transcriptional regulator of the gene. Jacobs et al (2015) also 
observed a common SNP (1.6%) (rs150063153) at position -95 relative to the start of 
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the first exon. Given the proximity of this SNP to the above-mentioned regulatory 
region, DNA polymerases, USFs and enhancer element may suffer altered binding 
efficiencies. For these reasons, the rare novel variant (rs572296424) at position -156 
(-156 Haplotype) and more common known SNP variant (rs150063153) at position -
95 (-95 Haplotype) will serve as the areas of interest for the purpose of this study. 
 
Figure 5.2.1. Electropherograms of novel SNPs observed in the proximal promoter 
region of the SLC22A2 gene. MBPG_OCT2001 (wildtype -156 G/G and variant -156 
G/A) a novel SNP detected in the proximal promoter region by (Jacobs et al, 2015).  
 
The SLC22A2 gene, located on chromosome 6q26, encodes the hOCT2 solute carrier 
transporter (Gorboulev et al., 1997b, Koepsell et al., 2007a, Koehler et al., 1997b). 
Clinical studies, in vivo animal experiments, and meta-analyses have demonstrated 
that variations in the level of expression of SLC22A2 may be accountable for the 
observed inter-individual variation in pharmacokinetics (Jacobs et al., 2015). 
Furthermore, genetic polymorphisms in SLC22A2 have been implicated in the 
altered function of hOCT2, leading to a divergence in the disposition and response to 
substrate drugs, such as metformin (Jacobs et al., 2015). Thus the aim of the present 
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study was firstly, cloning the polymorphic promoter regions representative of two of 
the haplotypes generated by (Jacobs et al., 2015), and secondly to develop a gene 
expression assay for the polymorphic promoters observed by (Jacobs et al., 2015).  
5.3. Materials and Methods 
5.3.1. Promoter selection and variant identification 
The hOCT2 promoters used, representative of the haplotype associated with the 
novel SNPs, were identified by (Jacobs et al., 2015).  
5.3.2. Primer Design 
Primers, Table 5.5.1, were designed using Primer3 software 
(www.genome.wi.mit.edu/cgibin/primer/primer3) and obtained from Integrated 
DNA Technologies (San Diego, California, USA).  
5.3.3. Cloning Reaction 
DNA from the samples used by (Jacobs et al., 2015) was amplified using TopTaq 
(Qiagen, Courtaboeuf, France) according to manufacturer‘s protocols. TopTaq 
contains a high-fidelity DNA polymerase to minimize mis-incorporation of 
nucleotides. The PCR reactions were performed in a 50 µl volume, containing 20 – 
50 ng of genomic DNA, 1 x Qiagen multiplex TopTaq master mix and 0.2 µM of 
each forward and reverse primer. The PCR conditions included an initial 
denaturation at 95°C for 15 minutes, followed by 35 cycles of denaturation at 95°C 
for 1 minute, annealing for 1 minute, and extension at 72°C for 1minute, and then a 
final extension at 72°C for 10 minutes. The sequences and details of all the primers 
used in this study are listed in Table 4.4.1. PCR products were modified to have T/A 
overhangs and were ligated into a pGLOW vector (Invitrogen, California, USA), 
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which contains a green fluorescent protein gene (GFP), and cloned into Top10 super-
competent cells by T/A cloning as outlined by the manufacturer (Invitrogen, 
California, USA). Plasmid DNA was purified using standard protocols and 
sequenced using Big Dye terminator v3.1 (ThermoFisher Scientific, California, 
USA) in both directions to confirm the haplotype present.   
5.3.4. Cell Culture  
The ability of each sequence to promote transcription of the GFP gene was tested 
transiently in human cell lines HEK293 (Human embryonic kidney cells) (Cellonex, 
Randburg, South Africa) and LnCAP (human prostate adenocarcinoma cells) 
(ATCC, Manassas, USA). Cell lines were transfected using ScreenFect A (InCella, 
Eggenstein-Leopoldshafen, Germany) in a 6well format (two replicates per clone), 
and cultured according to standard protocol at 37°C and 5% CO2. GFP expression 
was confirmed by fluorescent microscopy.  
5.3.5. Flow Cytometry 
Quantification of GFP expression was carried out using the BD Accuri C6 flow 
cytometer. Cell suspensions of each cell line were passed through a 488 nm laser for 
excitation, and fluorescence emissions were collected at 530 nm (+/ 15 nm) for GFP. 
Plots were gated against side scatter to exclude cell debris. Samples were analysed 
using fluidics set to Slow (core size = 16µm, flow rate = 34µl/min), and at least 
50,000 events were collected per sample. 
Table 5.3.1 PCR primer sequences for cloning the promoter region in-frame. 
 Primer sequence (5’3’) 
Amplicon 
length 
(bp) 
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F Primer  GGGGTACCATCCTAAGGCTCACGGCCAAC 
1025 
R Primer  CGACGCGTTCACAGCCCAGTAATCTTCCC 
  
5.4. Results 
All cloned haplotypes were examined for their ability to drive transcription of the 
GFP reporter gene in two human cell lines, HEK293 and LNCaP, using a 6well 
culture format. For the measurement of fluorescence using flow cytometry, gating 
was determined by measuring untransfected cells. This allowed for the size and 
location, on a scatter plot, to be isolated and excluded from the measurement of 
representative haplotype fluorescence. Cell debris, untransfected cells and crystals in 
the tissue culture media, and fluorescence of the media itself, was observed to occur 
between the ranges of 10
1
 and 10
3
. Correspondingly, fluorescent emission was 
observed to occur in the ranges 10
3
 to 10
6
. This range, according to the 
manufacturers specifications, is the ideal area for GFP detection. Therefore, all 
samples were gated for this range. Furthermore, GFP expressing cell counts in the 
LNCaP cell line were noted to be lower than those in the HEK293 cell line. This is 
expected as SLC22A2 is primarily expressed by the kidneys. 
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Figure 5.4.1. Confirmation of GFP expression by fluorescent microscopy. A) 
HEK293 cells expressing GFP with cloned -95 haplotype. B) LNCaP cell expressing 
GFP with -95 haplotype. 
5.5. Discussion 
The principle of this study was to determine whether SNPs in the proximal promoter 
region of the SLC22A2 gene would have any adverse effect on expression. It is well 
documented that variations near or within consensus sequences, such as the TATA-
box or GC-box and other cis-elements, are responsible for variations in expression 
levels of their associated genes (Ogasawara et al., 2008).    
In this study we examined two distinct regulatory SNPs (rSNPs), a novel rare variant 
identified in the Xhosa population at -156bp and a known variant at -95bp. It is 
expected that the proximity of these rSNPs to regulatory sites (cis-elements) could 
alter the binding efficiency of transcription factors, polymerases and enhancers (Saji 
et al., 2008). Furthermore, clinical studies, in vivo animal experiments, and meta-
analyses have demonstrated that variations in the level of expression of SLC22A2 
may be accountable for the observed inter-individual variation in pharmacokinetics 
(Jacobs et al., 2015, Sakurai et al., 2004).  
 
 
Figure 5.5.1 – Relative fluorescence detected by flow cytometry. A) Untransfected 
HEK293 cells. B) HEK 293 cells transfected with the positive control, expressing 
GFP. Where M11 indicates cell debris and M13 indicates fluorescence. 
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In this study, we have observed the relative effect of the abovementioned rSNPs on 
gene expression using a GFP reporter vector. The results obtained within the present 
work are a double-edged.  
Initially, it was demonstrated that a minor difference existed between expression 
levels of the two representative haplotypes, when compared to the positive control 
(Figure 5.5.2). This may be due to fluctuations in the number of surviving cells 
which were able to express GFP. However, it was also confirmed that no significant 
difference existed in relative expression between the two haplotypes. Furthermore, a 
second method of fluorescent measurement, luminometric, was used to corroborate 
these findings (Table 5.5.1). The GloMax Multi detection System (Promega 
Corporation, Madison, USA), set to excitation at 525nm and emission detection at 
580-640nm, was used.  
Table 5.5.1 – Mean fluorescence measured in 23 replicates on green filter using a 
luminometer. 
Untransfected cells +ve control 
_
95 Haplotype 
_
156 Haplotype 
0 1 0,96 0,93 
0 1 0,94 0,94 
0 1 0,92 0,92 
0 1 0,95 0,93 
0 1 0,97 0,94 
0 1 1,50 1,35 
0 1 1,23 1,28 
0 1 1,03 1,11 
0 1 1,31 1,22 
0 1 0,77 0,78 
0 1 0,74 0,73 
0 1 0,72 0,72 
0 1 0,80 0,78 
0 1 0,97 0,92 
0 1 0,97 0,94 
0 1 0,93 0,93 
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0 1 0,95 0,90 
0 1 0,90 0,92 
0 1 0,92 0,93 
0 1 0,93 0,86 
0 1 0,96 0,86 
0 1 0,98 0,90 
0 1 0,89 0,94 
Standard error: -95 haplotype = 0.04, -156 haplotype = 0.03 
Once more the minor difference between the positive control and representative 
haplotypes was observed. In addition, the same lack of significant difference in 
fluorescence was observed between the two representative haplotypes. The average 
fluorescence detected between the single haplotypes existed between 0.95 – 0.97, 
after correcting for fluctuations is cell density, with a 95% CI of 0,8908 to 1,0429 for 
the   -95 haplotype and 0,8775 to 1,0134 for -156 haplotype. 
 
 Figure 5.5.2 – Fluorescent measurement of transfected HEK293 cells, where M11 
indicates cell debris and untransfected cells, and M13 is indicative of fluorescence. 
A) positive control expressing GFP. B) 95 Haplotype, transfected cells expressing 
GFP. C) 156 Haplotype, transfected cells expressing GFP.  
 
Furthermore, the effect of different tissue types seems to have little effect on 
promoter regulation (Figure 5.5.3). This may be due to qualitative differences in the 
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response of the cell lines to individual promoter haplotypes and demonstrates the 
importance of using multiple cell lines in these analyses (Hoogendoorn et al., 2003).  
 
 
Figure 5.5.3 - Fluorescent measurement of transfected LNCaP cells, where M11 
indicates cell debris and M13 is indicative of fluorescence. A) -95 Haplotype, 
transfected cells expressing GFP. B) -156 Haplotype, transfected cells expressing 
GFP. 
 
However, it must be noted that the results discussed above are measured at P>0.05. 
At P>0.01 the significance of the result increases theoretically, as the scale of 
measurement is smaller and can resolve minor differences more effectively. 
Nevertheless, since these variations have only been observed in understudied African 
populations thus far, the effect they may produce has yet to be determined. Thorough 
supplementary investigation will be required to elucidate the phenotypic effects. 
It should also be noted that a number of limitations exist within our study. Firstly, 
estimates of the occurrence of functional variations in regulatory regions are poor. 
Effects of polymorphisms in the proximal promoter region, studied herein, have not 
been measured under dynamic states, such as during development or in response to 
hormonal changes. Secondly, the relative amount of mRNA produced had not been 
determined. However, the magnitude of mRNA changes in vivo is largely unknown 
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as regulation of gene expression in living tissue, in their natural genomic 
frameworks, is likely to be more sophisticated than a reporter assay. 
Correspondingly, it is possible that changes in mRNA may not result in changes in 
protein abundance or activity as a result of translational and posttranslational 
regulatory process (Hoogendoorn et al., 2003). It may be suggested that the 
cumulative effects of a large number of rare, or novel, functional regulatory variants 
may result in common phenotypes. Moreover, single rSNP haplotypes are 
tremendously rare, and thus, the cumulative effect of observed SNPs should be 
extensively studied in order to make accurate predictions promoter activity, and 
ultimately drug response.  
5.6. Conclusions 
We may, therefore, conclude that our data lends some empirical credibility to the 
notion that polymorphisms within promoter regions may be a common source of 
phenotypic variation, and a likely source of susceptibility to common disease. It 
should also be noted that this is a descriptive study with the intention of developing 
and optimizing methods for future expression, and more importantly, drug transport 
assays. The capacity to assess the relative mRNA production should be included in 
future work as it would deliver a more accurate depiction of the inherent regulatory 
elements in single haplotype promoter expression.  
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 CHAPTER 6 
Summary and Future Perspectives 
It is well documented that genetic variations in drug metabolizing enzymes underlie 
the inter-individual differences in drug response. A great deal of inter-individual 
variability exists in drug disposition, therapeutic efficacy, and adverse drug 
reactions. Although numerous factors can contribute to this variation, it is estimated 
that genetic factors account for between 15-30% of inter-individual variations in 
drug disposition, efficacy and adverse responses, and for certain drugs this estimate 
can even be as high as 95%. However, polymorphisms in solute carrier transporters 
have been recognized as a contributing factor to inter-individual variation in drug 
response and being involved in the toxicity of drug treatment or predisposition to 
adverse drug reactions. These polymorphisms have attracted interest as SLCs are 
widely distributed in the epithelial membrane of the liver, kidney, and intestine and 
play an important role in the gastrointestinal absorption, biliary and renal uptake and 
excretion, and distribution to target sites of their substrate drugs. 
Membrane transporters of the SLC superfamily, particularly OCTs and OATs, play a 
critical role in maintaining organismal and cellular homeostasis. They perform this 
important function by being involved in the absorption of nutrients essential for 
cellular metabolism and the elimination of metabolic waste products and toxic 
xenobiotics. Approximately 40% of therapeutic drugs are organic cations or weak 
bases at physiological pH and are substrates of organic cation transporters and 
multidrug and toxin extrusion transporters. The transport of organic cations is 
mediated by OCTs in an electrogenic manner, independent of a sodium-gradient, and 
by MATEs through an oppositely directed proton gradient. Examples of clinically 
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important drugs transported by OCTs and MATEs include the antidiabetic drugs 
metformin and phenformin, the antineoplastic drugs cisplatin and oxaliplatin, the 
anti-HIV drugs lamivudine and zalcitabine, and the histamine receptor antagonist 
cimetidine. 
Moreover, the current data suggest that these transporters also play an important part 
in vivo drug disposition, therapeutic efficacy, and adverse drug reactions. Genetic 
polymorphisms in SLC22A1-3 and SLCO1B1 have been associated with reduced 
transport and efficacy of clinically important drugs such as, for example, the 
biguanide antidiabetic metformin and the HMG-CoA reductase inhibitor simvastatin. 
However, these studies with reduced-function variants have primarily focused on 
genetic polymorphisms that are prevalent within Caucasian and Asian populations. 
This is in spite of numerous studies which have shown that the genomic diversity 
found within African populations is greater than the genetic variation found within 
other populations. However, this genomic diversity, especially in the southern 
African context, is currently relatively understudied. Given the enormous health 
burden that sub-Saharan Africa, and for that matter South Africa, faces, this lack of 
local genetic information with robust allele frequency distribution currently serves as 
a significant hurdle to designing biomedical research, and may have important 
medical implications.  
Our investigation into the allele and genotype frequency distributions of previously 
reported nonsynonymous SNPs revealed that SLC22A1 reduced-function variants 
found in Caucasians (R61C, C88R, S189L, G401S, and M440I) and Asians (P283L 
and R287G) were not only absent in the Cape Admixed subjects genotyped in this 
study, but are also absent from other African populations that are included in the 
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Hap-Map and 1000 Genomes projects. Given that these variants have been 
implicated in reduced transport of the antidiabetic metformin, screening for them in 
the Cape Admixed and African populations still remains clinically relevant. 
The high frequency, reduced-function nonsynonymous variants which are common 
amongst populations such as P341L in SLC22A1 and A270S in SLC22A2 have 
different frequency distributions for African populations when compared to other 
populations. For example, the average reported MAF for P341L is higher for Asians 
(14.6%) and Africans (8.5%) compared to that observed for American Caucasians 
(<1.0%). Conversely, the average reported MAF for A270S is higher for Africans 
(15.9%) than that recorded for Asians (14.7%), European-Caucasians (5.9%) and 
American-Caucasians (8.8%). 
Furthermore, ethnic-specific nonsynonymous genetic variants that have been 
observed at allele frequencies >1% within the Xhosa and other African populations, 
such as S14F, G220V, and V519F (SLC22A1) and R176H (SLC22A2) have to date 
not been reported for Asian or Caucasian populations or are very rare in these 
populations with MAF of <5%. Additionally, the in vitro and in vivo consequences 
of these variants have not yet been established. The effect in vivo of these Africa-
specific nonsynonymous variants on drug disposition, efficacy, and adverse reactions 
in African patients has not yet been determined, and requires further investigation. 
The M420del deletion variant of hOCT1 had been implicated in the reduced 
transport and efficacy of the antidiabetic drug metformin. In addition, this variant is 
also associated with increased failure rate of imatinib, an antineoplastic TKI, 
treatment in CML patients. Although the M420del variant was not observed in the 
 
 
 
 
CHAPTER 6 
 146 
current study, screening for it in the Cape Admixed and indigenous African 
populations still remain a priority. 
Genotyping of the SLC22A3 gene, which encode hOCT3, revealed that none of the 
nonsynonymous SNPs assayed were present in the Cape Admixed subjects screened. 
However, these polymorphisms are rare variants that occur at very low frequency in 
a population and therefore the results are consistent with studies conducted in other 
populations. This lack of protein sequence and mutational variability was ascribed to 
selective pressures that act at the SLC22A3 loci and pointed at the important 
physiological roles the hOCT3 transporter perform in vivo. Furthermore, the SNPs 
typed in this study were previously identified in other populations and therefore we 
cannot rule out the presence of novel SNPs in the SLC22A3 gene of Cape Admixed 
individuals. 
Similar to common variants, the cumulative effects of a large number of rare 
functional variants can result in common phenotypes. As a result, it may be 
concluded that the data generated herein offers empirical credibility to the notion that 
polymorphisms within promoters may be a common source of phenotypic variation 
and possibly a source of susceptibility to common disease, particularly since our 
estimate of the frequency of functional variation is likely to be somewhat 
conservative. 
In the current study, we have examined the effect of a novel SNP in the SLC22A2 
gene of the Xhosa population in the 5′-untrnaslated region -156 bp from the initiation 
codon. Our data lends some empirical credibility to the notion that polymorphisms 
within promoter regions may be a common source of phenotypic variation, and a 
likely source of susceptibility to common disease. However, since this is a 
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descriptive study with the intention of developing and optimizing methods for future 
expression, and more importantly, drug transport assays, the capacity to assess the 
relative mRNA production should be included in future work. This would deliver a 
more accurate depiction of the inherent regulatory elements in single haplotype 
promoter expression.   
The sample size of this study compared well to that of the Hap-Map and 1000 
Genomes Projects, which have more than demonstrated their value as reference 
panels for specific populations, but a larger sample size and complete individual 
gene/genome sequences would give a more accurate account of the full spectrum of 
genetic diversity within the Cape Admixed population. However, sequencing whole 
genomes/exomes remains an expensive exercise. 
To our knowledge, this is the first study that investigated the allele and genotype 
frequency distributions of SNPs in the SLC genes of the Cape Admixed population. 
This study also reports the observed haplotypes in the investigated population. It has 
also been shown that reduced-function nonsynonymous SNPs in the SLC genes 
found in Caucasian and Asian populations are absent from the Cape Admixed 
population. We have shown that, although MAF observed for the Cape Admixed 
population is largely similar to other African populations, differences exist that may 
translate into differences in organic cationic drug transport between these ethnic 
groups. These variations may translate into differences in the transport and efficacy 
of organic cationic drugs commonly used for the treatment of diseases prevalent in 
Africa. However, it should be noted that this was only a descriptive study and that no 
associations are made between any diseases or treatment outcomes. Although, it is 
well known that individual variation in drug response can be attributed to specific 
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genetic variants. Moreover, it is believed that the incorporation of haplotypes in 
pharmacogenomic studies will provide a more complete picture of loci that are 
relevant in the practice of ―genetic medicine‖ both at an individual or population 
level. This study contributes towards filling the gap that exists with regards to 
genetic information about important variations in organic cation transporter genes, 
such as SLC22A1-3, for the indigenous populations of South Africa given that 
organic cationic drugs are used in the treatment of diseases such as type-2 diabetes 
mellitus, various cancers, and HIV, these variants may impact profoundly on 
healthcare provided over the African continent. Therefore, given the aforementioned 
reasons studies such as this is valuable in the generation of useful pharmacogenomic 
information specific for Admixed populations. 
These systems have since been routinely used to genotype additional indigenous and 
admixed populations. The variants included deleterious SNPs which have been 
implicated in altered pharmacokinetics and pharmacodynamics of the widely-
prescribed antidiabetic drug metformin and as a predictor of treatment outcome for 
the antineoplastic imatinib. Firstly, these genotyping systems can now potentially be 
used to screen routinely for these reduced-function variants in responders and non-
responders to metformin therapy. Secondly, it can also be used to determine whether 
CML patients carry the M420del allele which is a predictor of imatinib treatment 
outcome. Thirdly, the genotyping systems for SLC22A1, SLC22A2 and SLCO1B1 
can potentially be used to determine whether certain individuals have a genetic 
predisposition for drug-drug interactions. Lastly, the genotyping systems developed 
for the screening of SLC22A3 SNPs can be used to screen patients with psychiatric 
disorders in order to determine whether they carry any of the variant alleles included 
in these systems.  
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Future studies require a more comprehensive sequencing of the SLC22A1-3 and 
SLCO1B1-3 genes and to expand this to more individuals or, where such sequencing 
information becomes available from other largescale sequencing projects, use it to 
determine correlation between genotypes and clinical phenotypes. Furthermore, the 
effect of the newly identified and the other African-specific promoter SNPs on the 
expression on SLC22A2 and on hOCT2 transport function needs to be further 
assessed in future work. However, it must be noted that these results were observed 
at 95% confidence interval, and that a 99% confidence interval the significance may 
increase theoretically. In addition, the cumulative effects of observed SNPs/rSNPs 
haplotypes on transport kinetics, protein turnover, and plasma membrane localization 
of the SLC‘s also requires further investigation in the Cape Admixed and other 
indigenous African populations, and should also be prioritized in future studies.  
Therefore, further translational work is also suggested to develop associations 
between the SLC superfamily and drug response in a clinical setting. Optimization of 
choice, dose, and method of treatment, need to be developed and prioritised in future 
studies, particularly in understudied sub-Saharan African populations.
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